CA2219486A1 - Human antibodies derived from immunized xenomice - Google Patents
Human antibodies derived from immunized xenomice Download PDFInfo
- Publication number
- CA2219486A1 CA2219486A1 CA002219486A CA2219486A CA2219486A1 CA 2219486 A1 CA2219486 A1 CA 2219486A1 CA 002219486 A CA002219486 A CA 002219486A CA 2219486 A CA2219486 A CA 2219486A CA 2219486 A1 CA2219486 A1 CA 2219486A1
- Authority
- CA
- Canada
- Prior art keywords
- analog
- immunoglobulin
- antigen
- human
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Antibodies with fully human variable regions against a specific antigen can be prepared by administering the antigen to a transgenic animal which has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled. Various subsequent manipulations can be performed to obtain either antibodies per se or analogs thereof.
Description
W O96/3409G PCTnUS95/05500 H~MAN ANTIBODIES DERIVED FROM IMMUNIZED XENOMICE
Technical Field The invention relates to the ~ield of immunology, and in particular to the production o~ antibodies. More speci~ically, it concerns producing such antibodies by a process which includes the step of ;mmlln;zing a transgenic ~n~m~l with an antigen to which antibodies are desired. The transgenic ;m~l has been modi~ied so as to produce human, as opposed to endogenous antibodies.
Backqround Art PCT application WO 94/02602, published 3 February 1994 and incorporated herein by reference, describes in detail the production of transgenic no~hllm~n ~n;m~ls which are modified so as to produce antibodies with fully ~hllmAn variable regions rather than endogenous antibodies in response to antigenic challenge. Briefly, the endogenous loci encoding the light and heavy immunoglobulin t~h~; n~ are incapacitated in the transgenic hosts and loci encoding hnm~n heavy and light chain proteins are inserted into the genome. In general, the ~n;m~l which provides all the desired modi~ications is obtained by cross-breeding int~rm~ te ~n;m~ls cont~;n;ng fewer than the full complement of modifications. The preferred embodiment o~ the nonh~lm~n ~n;m~l described in the specification is a mouse. Thus, mice, specifically, are described which, when a~m;n;~tered immunogens, produce antibodies with hnm~n variable regions, including ~ully hl~m~n antibodies, rather than murine antibodies that are ;mmllnospecific for these antigens.
The availability of such transgenic An;m~ls makes possible new approaches to the production o~ fully htlm~n antibodies. Antibodies with various ;mmllnospecificities are desirable for therapeutic and diagnostic use. Those antibodies intended ~or hnm~n therapeutic and in vivo diagnostic use, in particular, have been problematic because prior art sources ~or such antibodies resulted in ;mmllnoglobulins bearing the characteristic structures of antibodies produced by no~hllm~n W 096/34096 PCTrUS95/05500 hosts. Such antibodies tend to be ;mmllnogenic when used in hnm~ n ~:, The availability o~ the no~hnm~n, ;mmnnogen-responsive c transgenic ~n;m~l 8 described in the above-re~erenced WO 94/02602 make possible convenient production o~ hnm~n antibodies without the necessity o~ employing hnm~n hosts.
Disclosure o~ the Invention The invention is directed to methods to produce human antibodies by a process wherein at least one step o~ the process includes ;mmlln;zing a transgenic nonhllm~n ~n;m~l with the desired antigen. The modi~ied ~n;m~l ~ails to produce endogenous antibodies, but instead produces B-cells which secrete immunoglobulins with ~ully hnm~n variable regions. The antibodies produced include fully human antibodies and can be obtained ~rom the ~n;m~l directly, or ~rom immortalized B-cells derived ~rom the ~n;m~l Alternatively, the genes encoding the ;mmllnoglobulins with hllm~n variable regions can be recovered and expressed to obtain the antibodies directly or modi~ied to obtain analogs o~ antibodies such as, ~or example, single chain Fv molecules.
Thus, in one aspect, the invention is directed to a method to produce an ;mmllnoglobulin with a ~ully human variable region to a speci~ic antigen or to produce an analog o~ said ;mmnnoglobulin by a process which comprises ;mmlln;zing a nonhllm~n ;:~n;m~l with the antigen under conditions that stimulate an ;mmllne response. Fully hllm~n ;mmllnoglobulins are included in this group and are pre~erred. The nonhllm~n ~n;m~l is characterized by being substantially incapable o~ producing endogenous heavy or light ;mmllnoglobulin chain, but capable of producing ;mmllnoglobulins either with both human variable regions and constant regions or with ~ully human variable regions or both. In the resulting ;mmlln~ response, the ~n;m~l produces B cells which secrete ;mmllnoglobulins, with at least variable regions that are ~ully human, speci~ic ~or the antigen.
The human ;mmllnQglobulin o~ desired specif~icity can be directly recovered ~rom the ~n;m~ or example, ~rom the serum, or primary B cells can be obt~;n~ ~rom the ~n;m~l and W 096/34096 PCT~US95/05500 -- 3 im.mortalized. The immortalized B cells can be used directly as the source o~ hl~mAn antibodies or, alternatively, the genes encoding the antibodies can be prepared from the immortalized B
cells or from primary B cells of the blood or lymphoid tissue (spleen, tonsils, lymph nodes, bone marrow) o~ the ;mmlln;zed ~n;m~l and expressed in recombinant hosts, with or without modification, to produce the ;mmllnoglobulin or its analogs. In addition, the genes encoding the repertoire o~ ;mmllnoglobulins produced by the ;mmlln;zed ~n;m~l can be used to generate a library of ;mmnnoglobulins to permit screening for those variable regions which provide the desired af~inity. Clones from the library which have the desired characteristics can then be used as a source of nucleotide sequences encoding the desired variable regions ~or ~urther manipulation to generate antibodies or analogs with these characteristics using st~n~d recombinant techniques.
In another aspect, the invention relates to an immortalized nonhuman B cell line derived from the above described ~n;m~l In still another aspect, the invention is directed to a recombinant host cell which is modified to contain the gene encoding either the human ;mmnnoglobulin with the desired speci~icity, or an analog thereo~ which exhibits the same speci~icity.
In still other aspects, the invention is directed to antibodies or antibody analogs prepared by the above described methods and to recom.binant materials ~or their production.
In still other aspects, the invention is directed to antibodies with ~ully hllm~n variable regions, including ~ully hnm~n antibodies which are ;mmllnospeci~ic with respect to particular antigens set ~orth herein and to analogs which are s;m;l~ly ;mmllnospecific, as well as to the reco-m-binant materials use~ul in the production of the~e antibodies.
~ Brie~ Description o~ the Drawings Figure 1 shows the ~erum titers o~ anti-I~-6 antibodies from a X~nnmr~usen';mmlln;zed with hllm~n IL-6 and which antibodies cont~;n h~lm~n ~ light ch~;n~ and/or hllm~n ~ heavy ~h~;n~.
W 096/34096 PCTrUS95/05500 Figure 2 shows the serum titers o~ anti-Ih-8 antibodies ~rom a x~nnmouse~ ;mmlln;zed with human Ih-8 and which antibodies contain hllm~n K light ~h~;ns and/or human ~ heavy ~h~n~
Figure 3 shows the serum titers o~ anti-TNF~
antibodies ~rom a x~nOmOUse~ ;mmlln;zed with human TNF-~ and which antibodies contain hllm~n K light ch~;n~ and/or human heavy ~h~;n~
Figure 4 shows the serum titers o~ anti-CD4 antibodies ~rom a Xenomouse~ ;mmlln;zed with human CD4 and which antibodies contain human K light Ch~; n~ and/or human ,u heavy rh~;n~:.
Figure 5 shows the serum titers o~ a ~nom~use~
;mmlln;zed with 300.19 cells expressing h-selectin at their sur~ace. In the EhISA assay used, these antibodies are detectable only i~ they carry hllm~n ~ constant region heavy rh~; nc Figure 6 shows the serum titers o~ a X~nnmouse~
;mmlln;zed with 300.19 cells expressing h-selectin at their sur~ace. In the EhISA assay used, these antibodies are detectahle only i~ they carry human ~ light ch~;n~.
Figure 7 shows the serum titers o~ a ~nnmouse~
;mmlln;zed with 300.19 cells expressing h-selectin. In this EhISA, these antibodies are detectable i~ they carry human K
light chain and/or murine ~ constant regions.
Figure 8 shows a FACS analysis o~ human neutrophils coupled to sera ~rom a ~nom~use~ (A195-2) ;mmlln;zed with human h-selectin and labeled with an antibody ;mmllnoreactive with murine heavy chain ~ constant region.
Figure 9 shows a FACS analysis o~ human neutrophils ;ncllh~ted with serum ~rom a ~nnm~Use~ (A195-2) ;mmlln;zed with hllm~n h-selectin and labeled with an antibody ;mmllnoreactive with hnm~n light chain K region.
Figure 10 is a diagram o~ a plasmid used to trans~ect m~mm~lian cells to e~ect the production o~ the human protein gp39.
Figure 11 represents the serum titration curve o~ mice ;mmlln;zed with CH0 cells expressing human gp39. The antibodies detected in this EhISA must be ;mmllnoreactive with gp39 and _ W 096/34096 PCTrUS95/05500 -- 5 -- .
contain hllm~n heavy chain ~ constant regions or hnm~n K light ~:l ;n!:, Figure 12 shows the results of a FACS analysis of antibodies from a Xenomouse~ (labeled A247-4) ;mmlln;zed with hllm~n gp39 reacted with activated hllm~n T cells. Figure 12A
shows the separation of hllm~n activated T cells into CD4+ and CD4- populations. Panel B shows the results of a FACS analysis of the activated CD4+ T cells with antibodies from the XPnclm~use~ ;mmlln;zed with gp39 which contain murine heavy chain ~y constant regions; panel C shows the corresponding results with respect to CD4- populations.
Figure 13 is a titration curve with respect to monoclonal antibodies secreted by the hybridoma clone D5.1.
This clone is obtained from a x~nom~use~ ;mmlln;zed with tetanus toxin C (TTC) and contains hllm;~n K light chain and hnm~n constant region in the heavy chain.
Figure 14 is a titration curve with respect to the hybridoma supernatant from clone K4.1. This hybridoma clone is obt~;n~A from a x~nomousenl ;mmlln;zed with TTC and contains hllmAn K light chain and heavy chain having the murine ~y constant region.
Figure 15 shows binding curves for various concentrations of the K4.1 monoclonal antibody in a determ;n~tion of the affinity of the monoclonal with its antigen in a BIAcore instrument.
Figure 16 shows the complete nucleotide sequence of the heavy chain from the antibody secreted by K4.1.
Figure 17 shows the complete nucleotide sequence of the light chain from the antibody secreted by K4.1.
Figure 18 shows the complete nucleotide sequence of the heavy chain from the antibody secreted by D5.1.
Figure 19 shows the complete nucleotide sequence of the light chain from the antibody secreted by D5.1.
Modes of Carryinq Out the Invention In general, the methods of the invention include ~Am;n;F~tering an antigen for which hllmAn forms of ;mmllnospecific reagents are desired to a transgenic nonhllm;~n ~n;m~l which has -W 096/34096 PCT~US95/05500 -- 6 been modi~ied genetically so as to be capable o~ producing human, but not endogenous, antibodies. Typically, the ~n;m~l has been modi~ied to disable the endogenous heavy and/or light chain loci in its genome, so that these endogenous loci are incapable of the rearrangement required to generate genes encoding ;mmllnoglobulins in response to an antigen. In addition, the ~n;m~l will have been provided, stably, in its genome, at least one hllm~n heavy chain locus and at least one human light chain locus so that in response to an ~m;n;stered antigen, the human loci can rearrange to provide genes encoding hllm~n variable regions ;mmllnospeci~ic ~or the antigen.
The details for constructing such an ~n;m~l useful in the method of the invention are provided in the PCT application 2 referenced above.
For production o~ the desired antibodies, the first step is ~m;n;stration o~ the antigen. Techniques ~or such ;n;stration are conventional and involve suitable ;mmlln;zation protocols and formulations which will depend on the nature o~ the antigen per se. It may be necessary to provide the antigen with a carrier to ~nh~nce its ;mmllnogenicity and/or to include formulations which contain adjuvants and/or to ~m;n;ster multiple injections, and the like. Such techniques are st~n~d and optimization o~ them will depend on the characteristics o~ the particular antigen ~or which ;mmllnospeci~ic reagents are desired.
As used herein, the term ";mmllnospeci~ic reagents~
includes ;mmllnoglobulins and their analogs. The term "analogs"
has a specific m~n;ng in this context. It refers to moieties that contain the ~ully human portions of the ;mmllnoglobulin which account for its ;mmllnospecificity. In particular, variable regions including the complementarity det~rm;n;ng regions (CDRs) are required, along with sufficient portions of the ~ramework regions (FRs) to result in the appropriate three ~;m~n~ional con~ormation. Typical ;mmllnospeci~ic analogs o~
antibodies include F(ab~) 2' Fab,, and Fab regions. Modified îorms of the variable regions to obtain, ~or example, single chain Fv analogs with the appropriate ;mmllnospeci~icity are known. A
review o~ such Fv construction is ~ound, ~or example, in Tibtech CA 022l9486 l997-l0-27 W 096/34096 PCTrUS95/05500 (1991) 9: The construction o~ antibody analogs with multiple ;mml~nospecificities i8 also possible by coupling the human variable regions derived ~rom antibodies with varying speci~icities.
The variable regions with ~ully hllm~n characteristics can also be coupled to a variety o~ additional substances which can provide toxicity, biological functionality, alternative binding speci~icities and the like. The moieties including the ~ully human variable regions produced by the methods o~ the invention include single-chain ~usion proteins, molecules coupled by covalent methods other than those involving peptide linkages, and aggregated molecules. Examples o~ analogs which include variable regions coupled to additional molecules covalently or noncovalently include those in the ~ollowing nonlimiting illustrative list. Traunecker, A. et al. Int J
Cancer Supp (1992) SUPP 7:51-52 describe the bispecific reagent janusin in which the Fv region directed to CD3 is coupled to soluble CD4 or to other ligands such as OVCA and IL- 7.
Similarly, the ~ully hnm~n variable regions produced by the 20 method of the invention can be constructed into Fv molecules and coupled to alternative ligands such as those illustrated in the cited article. Higgins, P.J. et al. J In~ect Disease (1992) 166:198-202 describe a heteroconjugate antibody composed o~ OKT3 cross-linked to an antibody directed to a speci~ic sequence in 25 the V3 region or GP120. Such heteroconjugate antibodies can also be constructed using at least the hllm~n variable regions cont~;ne~ in the ;mmllnoglobulins produced by the invention methods. Additional examples o~ bispeci~ic antibodies include those described by Fanger, M.W. et al. Cancer Treat Res (1993) 30 68:181-194 and by Fanger, M.W. et al. Crit Rev TmmnnQl (1992) 12:101-124. Conjugates that are ;mmllnotoxins including conventional antibodies have been widely described in the art.
The toxins may be coupled to the antibodies by conventional r coupling techniques or ;mml1notoxins cont~;n;ng protein toxin 35 portions can be produced as ~usion proteins. The analogs o~ the present invention can be used in a corresponding way to obtain such ;mm~lnotoxins. Illustrative o~ such ;mmllnotoxins are those W 096/34096 PCTrUS95/OSSOO
described by Byrs, B.S. et al. S~m;n~Ars Cell Biol (1991) 2:59-70 and by Fanger, M.W. et al. TmmllnQl Today (1991) 12:51-54.
It will also be noted that some o$ the ;mmllnQglobulins and analogs o$ the invention will have agonist activity with respect to antigens for which they are ;mmllnospeci$ic in the cases wherein the antigens per$orm signal transducing ~unctions.
Thus, a subset o$ antibodies or analogs prepared according to the methods o$ the invention which are ;mmlln~speci$ic $or, $or example, a cell sur$ace receptor, will be capable o~ eliciting a response ~rom cells bearing this receptor corresponding to that elicited by the native ligand. Furth~rmnre~ antibodies or analogs which are immunospeci$ic ~or substances mimicking transition states o~ chemical reactions will have catalytic activity. Hence, a subset o$ the antibodies and analogs o~ the invention will $unction as catalytic antibodies.
In short, the genes encoding the immunoglobulins produced by the transgenic An;mAls of the invention can be retrieved and the nucleotide sequences encoding the ~ully human variable region can be manipulated according to known techniques to provide a variety o~ analogs such as those described above.
In addition, the immunoglobulins themselves contA;n;ng the human variable regions can be modi~ied using stAn~Ard coupling techniques to provide conjugates retA;n;ng ;mmllnospeci~icity and ~ully hllmAn characteristics in the ;mmllnospeci~ic region.
Thus, ;mmllnoglobulin "analogs" re~ers to moieties which contain those portions o$ the antibodies o$ the invention which retain their hllmAn characteristics and their immunospeci$icity. These will retain su$$icient h~lmAn variable region to provide the desired speci~icity.
As stated above, all o$ the methods o~ the invention include A~m; n; ~tering the appropriate antigen to the transgenic An;mAl The recovery or production o~ the antibodies themselves can be achieved in various ways.
First, and most straight~orward, the polyclonal antibodies produced by the An;mAl and secreted into the bloodstream can be recovered using known techniques. Puri~ied ~orms o$ these antibodies can, o~ course, be readily prepared by stAn~Ard puri$ication techniques, pre$erably including a$$inity W Og~/~lO~G PCTrUS95/05500 g chromatography with respect to the particular antigen, or even with respect to the particular epitope of the antigen for which speci~icity is desired. In any case, in order to monitor the success o~ ;mmlln;zation~ the antibody levels with respect to the antigen in serum will be monitored using stAn~Ard techniques such as ELISA, RIA and the like.
It will be noted, from the examples below, that a portion o~ the polyclonal antiserum obtained may include an endogenous heavy chain constant region derived from the host, even though the variable regions are fully hllmAn~ Under these circumstances, to the extent that an application requires fully h~lmAn antibodies, use of the polyclonal antiserum directly would be inappropriate. However, the presence of these ~h;m~as~
which is believed to result from in vivo isotype switching as described by Gerstein et al . Cell (1990) 63:537, is not problematic, in view of conventional purification and modification methods and in view of the availability of alternative methods to recover fully hnm~n antibodies, if desired, described in the following paragraphs.
First, and most simply, the polyclonal antiserum could be subjected to suitable separation techniques to provide compositions contA;n;ng only ~ully hnmAn immunoglobulins.
Portions of the serum which display characteristics o~ the host species can be removed, for example, using a~finity reagents with the appropriate anti species ;mmllnoglobulins or immunospeci~ic portions thereof. Furth~rmore, ~or applications where only the variable regions o~ the antibodies are required, treating the polyclonal antiserum with suitable reagents so as to generate Fab, Fab,, or F(ab,~ portions results in compositions contA;n;ng ~ully hllmAn characteristics. Such fragments are sufficient for use, for example, in ;mmllnodiagnostic procedures - involving coupling the ;mmllnospeci~ic portions of immunoglobulins to detecting reagents such as radioisotopes.
Thus, ~or some applications, the polyclonal antiserum can be treated to provide compositions with the desired characteristics including compositions consisting essentially o~ fully hllmAn antibodies and compositions including ;mmllnoglobulin analogs wherein the ;mmllnospeci~ic portion is ~ully hllmAn.
, W 096/34096 PCT~US95105500 Alternatively, ;mmllnoglobulins and analogs with desired characteristics can be generated from immortalized B
cells derived from the transgenic ~n;m~ls used in the method of the invention or from the rearranged genes provided by these 5 ~n;m~lS in response to ;mmlln;zation~ It will be apparent that hybridomas derived from the B cells of the ;mmlln;zed ~n;m~l can be screened so as to choose only those secreting fully hllm~n antibodies and that the genetic material can be recovered from the hybridomas or from lymphocytes in spleen, blood, or lymph nodes of the ;mmlln;zed ~n;m~l and manipulated using conventional techniques to replace any endogenous constant region with a hllm~n one or to produce a desired analog.
Thus, as an alternative to harvesting the antibodies directly from the ~n;m~l, the B cells can be obt~;ne~ typically from the spleen, but also, if desired, from the peripheral blood lymphocytes or lymph nodes and immortalized using any of a variety of techniques, most c~mmnnly using the fusion methods described by Kohler and Milstein. The resulting hybridomas (or otherwise immortalized B cells) can then be cultured as single colonies and screened for secretion of antibodies of the desired specificity. As described above, the screen can also include a dete~m;n~tion of the fully human character of the antibody. For example, as described in the examples below, a sandwich ELISA
wherein the monoclonal in the hybridoma supernatant is bound both to antigen and to an ant;hllm~n constant region can be employed. Conversely, hybridomas that secrete antibodies which are ;mmllnoreactive with antispecies antibodies directed to the species of the ;mmlln;zed ~n;m~l can be discarded. After the appropriate hybridomas are selected, the desired antibodies can be recovered, again using conventional techniques. They can be prepared in quantity by culturing the immortalized B cells using conventional methods, either in vitro, or in vivo to produce ascites fluid. Purification of the resulting monoclonal antibody preparations is less burdensome than in the case of serum since each immortalized colony will secrete only a single type of antibody. In any event, st~n~d purification techniques to isolate the antibody from other proteins in the culture medium can be employed.
W O 96/34096 PCTrUS95105500 As an alternative to obtA;n;ng hnm~n ;mmllnoglobulins directly from the culture of immortalized B cells derived from the An;m~l, the immortalized cells can be used as a source of rearranged heavy chain and light chain loci for subse~uent expression and/or genetic manipulation. Isolation of genes from such antibody-producing cells is straightforward since high levels of the appropriate m~RNAS are available for production of a cDNA library. The recovered rearranged loci can be manipulated as desired. For example, the constant region can be ~ch~nged for that of a different isotype or that of a hllm~n antibody, as described above, or eliminated altogether. The variable regions can be linked to encode single chain Fv regions. Multiple Fv regions can be linked to confer binding ability to more than one target or ch;m~ic heavy and light chain combinations can be employed. Once the genetic material is available, design of analogs as described above which retain their ability to bind the desired target, as well as their hllmAn characteristics, is straightforward.
Once the appropriate genetic material is obtA; n~A and, if desired, modified to encode an analog, the coding sequences including those that encode, at a m; n; mllm, the variable regions of the hllm~n heavy and light chain can be inserted into expression systems contA; n~ on vectors which can be transfected into stAn~d recombinant host cells. As described below, a variety of such host cells may be used; for efficient processing, however, mAmmAlian cells are preferred. Typical mAmmAlian cell lines useful for this purpose include CHO cells, 293 cells, or NSO-GS cells.
The production of the antibody or analog is then undertaken by culturing the modified recombinant host under culture conditions appropriate for the growth of the host cells - and the expression of the coding sequences. The antibodies are then recovered from the culture. The expression systems are preferably designed to include signal peptides so that the resulting antibodies are secreted into the medium; however, intracellular production is also possible.
In addition to deliberate design of modified forms of the immunoglobulin genes to produce analogs, advantage can be CA 022l9486 l997-l0-27 W 096/34096 ' PCTrUS9~/05500 taken of phage display techniques to provide libraries cont~;n;ng a repertoire o~ antibodies with varying a~inities ~or the desired antigen. For production o~ such repertoires, it is unnecessary to immortalize the B cells ~rom the ~mmlln;zed ~n;m~l; rather the primary B cells can be used directly as a source o~ DNA. The mixture o~ cDNAs obt~;ne~ ~rom B cells, e.g., derived ~rom spleens, is used to prepare an expression library, for example, a phage display library trans~ected into E. col i . The resulting cells are tested ~or immunoreactivity to the desired antigen. Techniques ~or the identi~ication o~ high a~inity hllm~n antibodies ~rom such libraries are described by Gri~iths, A.D., et al., EMBO J (1994) 13:3245-3260; by Nissim, A., et al. ibid, 692-698, and by Gri~fiths, A.D., et al., ibid, 725-734. Ultimately, clones ~rom the library are identi~ied which produce binding a~inities o~ a desired magnitude ~or the antigen, and the DNA encoding the product responsible ~or such binding is recovered and manipulated ~or st~n~rd recombinant expression. Phage display libraries may also be constructed using previously manipuiated nuclaoL~d~ se~u~l~s and screened in similar ~ashion. In general, the cDNAs encoding heavy and light chain are independently supplied or are linked to ~orm Fv analogs ~or production in the phage library.
The phage library is thus screened for the antibodies with highest a~inity ~or the antigen and the genetic material recovered ~rom the appropriate clone. Further rounds o~
screening can increase the a~inity o~ the original antibody isolated. The manipulations described above ~or recombinant production o~ the antibody or modi~ication to ~orm a desired analog can then be employed.
As above, the modi~ied or l~nmoA;~ied rearranged loci are manipulated using st~n~rd recombinant techniques by constructing expression systems operable in a desired host cell, such as, typically, a C'h;ne~e hamster ovary cell, and the desired ;mmllnoglobulin or analog is produced using st~n~rd recombinant expression techniques, and recovered and puri~ied using conventional methods.
The application o~ the ~oregoing processes to antibody production has enabled the preparation o~ human ;mmnnospeci~ic reagents with respect to antigens ~or which hnm~n antibodies have not hereto~ore been available. The ;mmllnoglobulins that result ~rom the above-described methods and the analogs m~de possible thereby, provide novel compositions ~or use in analysis, diagnosis, research, and therapy. The particular use will, of course, depend on the ;mmllnoglobulin or analog prepared. In general, the compositions o~ the invention will have utilities similar to those ascribable to no~hllmAn antibodies directed against the same antigen. Such utilities include, ~or example, use as a a~finity ligands ~or puri~ication, as reagents in immunoassays, as components of immunoconjugates, and as therapeutic agents for appropriate indications.
Particularly in the case o~ therapeutic agents or diagnostic agents for use in vivo, it is highly advantageous to employ antibodies or their analogs with ~ully h~lm~n characteristics. These reagents avoid the undesired ;mmlln~
responses engendered by antibodies or analogs which have characteristics marking them as originating ~rom non-h~lm~n species. Other attempts to "hllm~n;ze" antibodies do not result in reagents with ~ully hllm~n characteristics. For example, ~h;m~iC antibodies with murine variable regions and hl~m~n constant regions are easily prepared, but, o~ course, retain murine characteristics in the variable regions. Even the much more di~icult procedure o~ ~h~lm~n;zing" the variable regions by manipulating the genes encoding the amino acid sequences that form the ~ramework regions does not provide the desired result since the CDRs, typically of nonhllm~n origin, cannot be manipulated without destroying ;mmllnospeci~icity. Thus, the methods o~ the pre~ent invention provide, ~or the ~irst time, ;mm~lnoglobulins that are fully hnm~n or analogs which contain ;mmnnospecific regions with ~ully hllm~n characteristics.
There are large numbers of antigens for which hllm~n antibodies and their hllm~n analogs would be made available by the methods of the invention. These include the ~ollowing as a nonlimiting set:
leukocyte markers, such as CD2, CD3, CD4, CD5, CD6, CD7, CD8, CDlla,b,c, CD13, CD14, CD18, CDl9, CD20, CD22, CD23, CA 022l9486 l997-l0-27 W 096/34096 PCTrUS95/OSSOO
CD27 and its ligand, CD28 and its ligands B7.1, B7.2, B7.3, CD29 and its ligand, CD30 and its ligand, CD40 and its ligand gp39, CD44, CD45 and iso~orms, CDw52 (Campath antigen), CD56, CD58, CD69, CD72, CTLA-4, hFA-l and TCR
histocompatibility antigens, such as MHC class I or II, the Lewis Y antigens, SLex, Shey, SLea, and Sheb;
adhesion molecules, including the integrin~, such as VLA-l, VLA-2, VLA-3, VLA-4, VLA-5, VLA-6, LFA-l, Mac-l and pl50,95; and the selectins, such as L-selectin, E-selectin, and P-selectin and their counterreceptors VCAM-l, ICAM-l, ICAM-2, and LFA-3;
interleukins, such as IL-l, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, Ih-ll, IL-12, IL-13, IL-14, and~5 IL-15;
interleukin receptors, such as I~-lR, IL-2R, IL-3R, IL-4R, IL-5R, IL-6R, IL-7R, IL-8R, IL-9R, IL-lOR, IL-llR, IL-12R, IL-13R, IL-14R, and IL-15R;
ch~m~kines, such as PF4, RANTES, MIPl~, MCPl, NAP-2,~0 Gro~, Gro~, and IL-8;
growth ~actors, such as TNFalpha, TGFbeta, TSH, VEGF/VPF, PTHrP, EGF ~amily, FGF, PDGF ~amily, endothelin, and gastrin releasing peptide (GRP);
growth ~actor receptors, such as TNFalphaR, RGFbetaR,~5 TSHR, VEGFR/VPFR, FGFR, EGFR, PTHrPR, PDGFR ~amily, EPO-R, GCSF-R and other hematopoietic receptors;
inter~eron receptors, such as IFN~R, IFN~R, and IFN~R;
Igs and their receptors, such as IgE, FceRI, and FCeRII;
tumor antigens, such as her2-neu, mucin, CEA and endosialin;
allergens, such as house dust mite antigen, lol pl (grass) antigens, and urushiol;
viral proteins, such as CMV glycoproteins B, H, and gCIII, HIV-l envelope glycoproteins, RSV envelope glycoproteins, HSV envelope glycoproteins, EBV envelope glycoproteins, VZV
envelope glycoproteins, HPV envelope glycoproteins, Hepatitis ~amily sur~ace antigens;
-CA 022l9486 l997-l0-27 W 096/34096 PCTnUS95/05500 toxins, such as pseudnmo~ endotoxin and osteopontin/uropontin, snake venom, and bee venom;
blood ~actors, such as complement C3b, complement C5a, complement C5b-9, Rh factor, ~ibrinogen, ~ibrin, and myelin associated growth inhibitor;
enzymes, such as cholesterol ester transfer protein, membrane bound matrix metalloproteases, and glutamic acid decarboxylase (GAD); and miscellaneous antigens including ganglioside GD3, ganglioside GM2, hMP1, hMP2, eosinophil major basic protein, eosinophil cationic protein, pANCA, Amadori protein, Type IV
collagen, glycated lipids, ~-inter~eron, A7, P-glycoprotein and Fas (AFO-1) and oxidized-hDL.
Particularly preferred ;mmnnoglobulins and analogs are those ;mmllnospecific with respect to hnm~n Ih-6, hnm~n Ih-8, hllmAn TNF~, hllm~n CD4, hllm~n h-selectin, and hnm~n gp39. Human antibodies against Ih-8 are particularly useful in preventing tumor metastasis and inflammatory states such as asthma and reper~usion injury. Antibodies and analogs ;mmllnoreactive with hnm~n TNF~ and hllm~n Ih-6 are useful in treating cachexia and septic shock as well as auto;mmlln~ disease. Antibodies and analogs ;mmllnoreactive with gp39 or with h-selectin are also effective in treating or preventing auto;mmnne disease. In addition, anti-gp39 is helpful in treating gra~t versus host disease, in preventing organ transplant rejection, and in treating glomerulonephritis. Antibodies and analogs against h-selectin are useful in treating isch~m;~ associated with reper~usion injury.
Typical auto;mmlln~ diseases which can be treated using the above-mentioned antibodies and analogs include systemic lupus erythematosus, rheumatoid arthritis, psoriasis, Sjogren~s, ~ scleroderma, m;~e~ connective tissue disease, dermatomyositis, polymyositis, Reiter's syndrome, Behcet's disease, Type 1 - diabetes, ~h;mnto's thyroiditis, Grave's disease, multiple sclerosis, myasth~n;~ gravis and pemphigus.
The examples below are intended to illustrate but not to limit the invention.
CA 022l9486 l997-l0-27 In these examples, mice, designated ~xennm;ce", are used ~or initial ;mmlln;zations. A detailed description o~ such x~nnm;ce is ~ound in the above re~erenced PCT application WO
94/02602, Tmmnn; zation protocols appropriate to each antigen are described in the speci~ic examples below. The sera o~ the ;mmlln;zed x~nnm;ce (or the supernatants ~rom immortalized B
cells) were titrated ~or antigen speci~ic human antibodies in each case using a st~n~rd ELISA format. In this ~ormat, the antigen used ~or ;mmlln;zation was immobilized onto wells of microtiter plates. The plates were washed and blocked and the sera (or supernatants) were added as serial dilutions ~or 1- 2 hours o~ incubation. A~ter washing, bound antibody having human characteristics was detected by adding the appropriate antispecies Ig (typically ant; hnmAn K chain antibody or ant;hllmAn ~ chain antibody) conjugated to horseradish peroxidase (HRP) ~or one hour. In some cases, the bound antibodies were tested ~or murine characteristics using antimurine antibodies, typically antimurine ~ chain antibody. A~ter again w~h; n~, the chromogenic reagent o-phenylene ~; Am; n~ (OPD) substrate and 2 0 hydrogen peroxide were added and the plates were read 30 minutes later at 492 nm using a microplate reader.
Unless otherwise noted, the antigen was coated using plate coating buf~er (O.1 M carbonate bu~er, pH 9 . 6); the assay blocking bu~i~er used was 0. 5% BSA, 0.1~ Tween 20 and 0.01 Thimerosal in PBS; the substrate bu~er used in color development was citric acid 7.14 g/l: dibasic sodium phosphate 17.96 g/l; the developing solution (made ;mm~ tely be~ore use) was 10 ml substrate bui~i~er, 10 mg OPD, plus 5 ml hydrogen peroxide; the stop solution (used to stop color development) was 2 M suli~uric acid. The wash solution was 0. 05~ Tween 20 in PBS.
Example 1 ~llmAn Antibodies Against Human IL- 6 Three to 5 x~nom; ce aged 8-20 weeks were age-matched and ;mmnn;zed intraperiton~Ally with 50 ~g hnm~n IL-6 emulsi~ied in complete Freund~s adjuvant ~or primary ;mmlln;zation and in ;ncnmrlete Freund's adjuvant ~or subse~uent injections. The mice received 6 injections 2 - 3 weeks apart. Serum titers were CA 022l9486 l997-l0-27 WO 96/34096 PCTrUS95/05500 det~rm;ne~ after the second dose and following each dose thereafter. Bleeds were performed 6-7 days after injections from the retrobulbar plexus. The blood was allowed to clot at room temperature for about 2 hours and then incubated at 4~C for at least 2 hours before separating and collecting the sera.
ELISAs were conducted as described above by applying 100 ~l/well of recombinant hnm~n IL-6 at 2 mg/ml in coating buffer. Plates were then incubated at 4~C overnight or at 37~C
for 2 hours and then washed three times in washing buffer.
Addition of 100 ~l/well blocking buffer was followed by incubation at room temperature for 2 hours, and an additional 3 washes.
Then, 50 ~l/well of diluted serum samples (and positive and negative controls) were ~ to the plates.
Plates were then incubated at room temperature for 2 hours and again washed 3 times.
After washing, 100 ~l/well of either mouse antihuman chain antibody conjugated to HRP at 1/2,000 or mouse antihu-man K
chain antibody conjugated to HRP at 1/2,000, diluted in blocking buffer were ~e~. After a 1 hour incubation at room temperature, the plates were washed 3 times and developed with OPD substrate for 10-25 minutes. 50 ~l/well of stop solution were then added and the results read on an ELISA plate reader at 492 nm. The dilution curves resulting from the titration of serum from ~Cenomouse~y A40- 7 after 6 injections are shown in Figure 1. The data in Figure 1 show production of anti-IL- 6 ;mmllnoreactive with ant;hl~m~n ~ and ant;h-lm~n ~ detectable at ~erum dilutions above 1:1,000.
Example 2 3 o ~llm~n Antibodies Aqainst Human I~-8 - Tmmlln;zation and serum preparation were as described in Example 1 as except that hllm~n recombinant Ih-8 was used as - an ;mm~lnogen.
RrT~ assays were performed with respect to the recovered serurn, also exactly as described in R~C~mple 1, except that the ELISA plates were initially coated using 100 ~l/well of recombinant hllm~n IL-8 at 0.5 mg/ml in the coating buffer. The CA 022l9486 l997-l0-27 W 096/34096 PCT~US95/05500 results obt~;ne~ ~or various serum dilutions ~rom ~nomouse~
A260-5 a~ter 6 injections are shown in Figure 2. Human anti-IL-8 binding was again shown at serum dilutions having concentrations higher than that represented by a 1:1,000 dilution.
Example 3 Human Antibodies Aqainst Human TNF~
Tmmlln;zation and serum preparation were conducted as described in Example 1 except that hllm~n recombinant TNF~ was substituted ~or hllm~n IL-6. ELISAs were conducted as described in Example 1 except that the initial coating of the ELISA plate employed 100 ~l/well recombinant human TNFa at 1 mg/ml in coating bu~er.
The dilution curves ~or serum ~rom X~nnmouse~ A210-8 a~ter 6 injections obt~;n~ are shown in Figure 3. Again signi~icant titers of hllm~n anti-TNF~ binding were shown.
Example 4 Euman Antibodies Aqainst Human CD4 The human CD4 antigen was prepared as a sur~ace protein using human CD4 ~ on trans~ected recombinant cells as ~ollows. Human CD4 ~ consists o~ the extracellular ~nm~; n o~
CD4, the tr~n~m~mhrane ~nm~; n o~ CD4, and the cytoplasmic ~nm~;n of residues 31-142 o~ the mature ~ chain. Human CD4 zeta (F15 LTR) as described in Roberts, et al., Blood (1994) 84:2878 was introduced into the rat basophil leukemic cell line RBL-2H3, described by Callan, M., et al., Proc Natl Acad Sci USA (1993) 9Q:10454 using the kat high e~iciency transduction system described by Finer, et al., Blood (1994) 83:43. Brie~ly, RBL-2H3 cells at 106 cells per well were cultured in 750 ml DMEMl~W +
20~ FBS (Gibco) and 16 ~g/ml polybrene with an equal volume o~
proviral supernatant ~or 2 hours at 37~C, 5~ CO2. One ml o~
medium was removed and 750 ~l o~ in~ection medium and retroviral supernatant were added to each well and the cultures incubated overnight. The cells were washed and expanded in DMEMl~W + 10~
FBS until su~icient cells were available ~or sorting. The CD4-zeta transduced RBL-2H3 cells were sorted using the FACSTAR plus W 096/34096 PCTrUS9J/05SOO
(Becton Dickinson). The cells were st~; neA ~or hllm~n CD4 with a mouse ant;hllm~n CD4- PE antibody and the top 2-3~ expressing cells were selected.
T~mlln;zationS were conducted as described in Example 1 using 10 x 106 cells per mouse except that the primary injection was subcutaneous at the base o$ the neck. The mice received ~
injections 2-3 weeks apart. Serum was prepared and analyzed by ELISA as described in Example 1 except that the initial coating o~ the ELISA plate utilized 100 ~l per well o~ recombinant soluble CD4 at 2 mg/ml of coating bu~fer. The titration curve for serum ~rom Xenomouse~ A207-1 after 6 injections is shown in Figure 4. Titers o~ hllm~n anti-CD4 reactivity were shown at concentrations representing greater than those at 1:1,000 dilution.
Example 5 Human Antibodies Aqainst ~llm~n L-selectin The antigen was prepared as a surface displayed protein in C51 cells, a high expressing clone derived by transfecting the mouse pre-B cell 300.19 with LAM-1 cDNA (hAM-1 is the gene encoding L-selectin) (Tedder, et al., J Tmmllnol (1990) 144:532) or with similarly transfected CHO cells. The trans~ected cells were sorted using ~luorescent activated cell sorting using anti-Leu-8 antibody as label.
The C51 and the trans~ected CHO cells were grown in DME 4.5 g/l glucose with 10~ FCS and 1 mg/ml G418 in 100 mm ~;~hec. Negative control cells, 3T3-P317 (trans~ected with gag/pol/env genes o~ Moloney virus) were grown in the same medium without G418.
Primary ;mmlln;zation was done by injection subcutaneously at the base o~ the neck; subsequent injections - were intraperitoneal. 70-100 million C51 or trans~ected CHO
cells were used per injection ~or a total o~ ~ive injections 2-3 weeks apart.
Sera were collected as described in Example 1 and analyzed by ELISA in a protocol s;m; 1~ to that set ~orth in Example 1.
W 096/34096 PCTrUS9~/05500 For the ELISA, the trans~ected cells were plated into 96 well plates and cell monolayers grown ~or 1-2 days depending on cell number and used ~or ELISA when con~luent. The cells were ~ixed by ~irst washing with cold 1 x PBS and then ~ixing solution (5~ glacial acetic acid, 95~ ethanol) was added. The plates were incubated at -25~C ~or 5 minutes and can be stored at this temperature i~ sealed with plate sealers.
The EhISA is begun by bringing the plates to room temperature, ~licking to remove ~ixing solution and w~h;ng 5 times with DMEM medium cont~;n;ng 10~ FCS at 200 ~l per well.
The wells were treated with various serum dilutions or with positive or negative controls. Positive control wells cont~;n~ murine IgG1 monoclonal antibody to human L-selectin.
The wells were incubated ~or 45 minutes and monolayer integrity was checked under a microscope. The wells were then incubated with either antimouse IgG (1/1000) or with ant;hllm;1n K
chain antibody or ant;hllm~n ~ chain antibody conjugates with HRP
described in Example 1. The plates were then washed with 1~
BSA/PBS and again with PBS and monolayer integrity was checked.
The plates were developed, stopped, and read as described above.
The results ~or serum ~rom ~n~mouse~ A303-3 are shown in Figs.
5 and 6; human antibodies both to L-selectin and control 3T3 cells were obt~;n~. However, the serum titers are higher ~or the L-selectin-expressing cells as compared to parental 3T3 cells. These results show that ~nomouse~ A303-3 produces antibodies speci~ic ~or L-selectin with hllm~n ~ heavy chain regions and/or hllm~n ~ light ~h~3; nc, T~T.T.~ were also per~ormed using as the immobilized antigen a ~usion protein consisting o~ the extracellular ~om~;n o~ hllm~n h-selectin ~used to the constant ~om~;n o~ human IgG
(Guo, et al., Cell Immunol (1994) 154:202). The L-selectin ~usion protein was made by transient trans~ection o~ hllm~n 293 cells using calcium phosphate trans~ection (Wigler, M., Cell (1979) 16:777). Serum preparation was per~ormed as described in Example 1. ELISAs were conducted essentially as in Example 1, except that the initial coating o~ the ELISA plate employed 100 ~l trans~ected 293 cell culture supernatant co~t~;n~ng the CA 022l9486 l997-l0-27 W 096/34096 PCTrUS95tO5500 L-selectin-Ig ~usion protein. Detection employed HRP-mouse ant; htlm~n K and HRP-goat antimouse IgG.
Figure 7 shows the results from ~r~nomouse~ A195-2;
antibodies speciEic ~or h-selectin having hnm~n K light ~h~;nc:
and/or h~lm~n variable regions with murine heavy chain ~ regions are present in the serum.
The antisera obtained ~rom the ;mmlln;zed x~nnm;ce were also tested for St~; n;ng of hllmAn neutrophils which express L-selectin. ~llm~n neutrophils were prepared as follows:
peripheral blood was collected from normal volunteers with 100 units/ml heparin. About 3.5 ml blood was layered over an e~ual volume o~ One-step Polymorph Gradient (Accurate Chemical, Westbury, NY) and spun for 30 minutes at 450 x g at 20~C. The neutrophil fraction was removed and w~h~i twice in DPBS/2~ FBS.
The neutrophils were then StA; ne~l with either:
(1) antiserum from ~nnmouse~ A195-2 ;mmlln;zed with C51 cells (expressing L-selectin);
(2) as a positive control, mouse monoclonal antibody ~AM1-3 (against L-selectin); and (3) as negative control, antiserum from a X~nomouse ;mmlln;zed with cells expressing hllm~n gp39.
The st~;n~l, w~h~-l neutrophils were analyzed by FACS.
The results f~or antiserum from Xenomouse~ A195-2 are shown in Figures 8 and 9.
These results show the presence of antibodies in ;mmnn;zed ~nnmouse~ serum which contain f~ully hllm~n variable regions ;mmllnoreactive with L-selectin. The negative control antiserum from mice ;mmlln;zed with gp39 does not contain antibodies reactive against hllm~n neutrophils. Serum from A195-2 (;mmlln;zed with L-selectin-expressing cells) contains antibodies binding to hllm~n neutrophils detectable with a goat - antimouse IgG antibody (Figure 8), which binds with heavy chain protein composed o~ ~ully hnm~n variable regions and mouse y - constant regions. St~;n;ng with anti L-selectin X~nomousen' antisera detected with a mouse monoclonal antibody against hllm~3n K chain antibody is shown in Figure 9, showing the presence oE
~ully hllm~n K light chain.
W 096/34096 PCTrUS95/05500 As explained above, thege antibodies cont~;n;ng hllm~n variable regions are readily convertible to ~ully human antibodies. For example, using hybridomas secreting these antibodies, the cDNAs encoding them can be obt~;n~. By ampli~ying the genes encoding human V regions using primers cont~;n;ng restriction enzyme recognition sites and cloning them into plasmids cont~;n;ng the coding sequences ~or human constant regions as described by Queen, et al., Proc Natl Acad Sci (1989) 86:10029, genes encoding the ~ully human antibodies can be obt~;ne~ ~or recombinant production.
Example 6 Human Antibodies Against Human gp39 gp39 (the ligand ~or CD40) is expressed on activated hllm~n CD4+ T cells. The sera o~ ~n~m;ce ;mmlln;zed with recombinant gp39 according to this example cont~;n~ antibodies ;mmllnospeci~iC ~or gp39 with ~ully human variable regions; the sera contained ~ully hllm~n IgM antibodies and ~h;m~ic IgG
antibodies cont~;n;ng human variable regions and murine constant heavy chain ~ region.
The antigen consisted o~ stable trans~ectants o~
300.19 cells or o~ CHO cells expressing gp39 cDNA cloned into the m~mm~lian expression vector PlRl.HUgp39/IRES NEO as shown in Figure 10. CHO cells were split 1:10 prior to trans~ection in DMEM 4.5 g/l glucose, 10~ FBS, 2 mM glut~m;ne, MEM, NEAA
supplemented with additional glycine, hypoxanthine and thymidine. The cells were cotrans~ected with the gp39 vector at 9 ~g/10 cm plate (6 X 105 cells) and the DHFR expressing vector pSV2DHFRs (Subranani et al . Mol Cell Biol (1981) 9:854) at 1 ~g/10 cm plate using calcium phosphate trans~ection. 24 hours later the cells were split 1:10 into the original medium cont~;n;ng G418 at 0.6 mg/ml. Cells producing gp39 were sorted by FACS using an anti-gp39 antibody.
Mice grouped as described in Example 1 were ;mmlln;zed with 300.19 cells expressing gp39 using a primary ;mmlln;zation subcutaneously at the base o~ the neck and with secondary intraperitoneal injections every 2-3 weeks. Sera were harvested as described in Example 1 ~or the ELISA assay. The EhISA
CA 022l9486 l997-l0-27 W 096/34096 PCTnUS95/05500 procedure was conducted substantially as set forth in Example 1;
the microtiter plates were coated with CHO cells expressing gp39 grown in a 100 mm dish in DMEM, 4.5 g/l glucose, 10~ FCS, 4 mM
glut~m;ne, and nonessential amino acid (NEAA) solution ~or MEM
(lOOX). On the day preceding the EhISA assay, the cells were trypsinized and plated into 96-well filtration plates at 105 cells/200 ~l well and incubated at 37~C overnight. The positive controls were mouse ant;hllm~n gp39; negative controls were antisera from mice ;mmlln;zed with an antigen other than gp39.
50 ~l of sample were used for each assay. The r~m~;nA~r of the assay is as described in Example 1.
The dilution curves for the sera obt~;neA after 4 injections from mice ;mml~n;zed with gp39 expressed on CHO cells are shown in Figure 11. As shown, the sera cont~;neA ant;hllm~n gp39 ;mmnnospecificity which is detectable with hllm~n K and hnm~n ~ chain antibodies coupled to HRP.
In addition, the sera were tested for their ability to react with activated hllm~n T cells included in PBMC using FACS
analysis. To prepare the PBMC, hllm~n peripheral blood was collected from normal volunteers with the addition of 100 unit/ml heparin. PBMC were isolated over Ficoll gradient and activated with 3 ,ug/ml PHA, 1 ~Lg/ml PMA in IMDM plus 10~ FBS
plus 25 ~M 2-mercaptoethanol for 4 hours. A~ter washing, the PBMC were st~;n~A with mouse Mab against hnm~n CD4 labeled with FITC to permit separation of CD4+ and CD4- hnm~n T cells.
The activated CD4+ and CD4- T cells were then analyzed by FACS using st~;n;ng with either:
1) antiserum from a ~onnmouse~ ;mmlln;zed with 300.19 cells producing gp39;
2) a positive control mouse Mab directed against ~-CD40L (hllm~n gp39); and - 3) a negative control antiserum from a ~nomouse~
;mmnn;zed with TNF.
The detecting antibody in the FACS analysis was goat antimouse IgG (PE). The results are shown in Figure 12.
As shown in Figure 12A, CD4+ (R2) and CD4- (R3) cells were separated prior to FACS analysis. Panel B shows the results for CD4+ cells and shows that sera from mice ;mmlln;zed W 096/34096 PCTrUS95/05500 with gp39 (labeled A247-4 in the ~igure) reacted with these activated CD4+ T cells; panel C shows that these sera did not react with CD4- cells. These antibodies carried murine heavy chain ~ constant regions. The results o~ panels B and C also con~irm that the TNF-injected ~nomouse~ did not make antibodies against gp39.
Example 7 Preparation o~ Hiqh-A~inity Human Mabs Against Tetanus Toxin The antibodies prepared in this example were secreted by hybridomas obtained by immortalizing B cells ~rom x~nnm; ce ;mmlln;zed with tetanus toxin. The ;mmlln;zation protocol was similar to that set ~orth in Example 1 using 50 ~g tetanus toxin emulsi~ied in complete Freund's adjuvant ~or intraperitoneal primary ;mmlln;zation ~ollowed by subsequent intraperitoneal injections with antigen incorporated into incomplete Freund's adjuvant. The mice received a total o~ 4 injections 2-3 weeks apart.
A~ter acceptable serum titers o~ antitetanus toxinC
(anti-TTC) were obt~;ne~, a ~inal ;mmlln;zation dose o~ antigen in PBS was given 4 days before the ~n;m~l S were sacri~iced and the spleens were harvested ~or ~usion.
The spleen cells were ~used with myeloma cells P3X63-Ag8.653 as described by Gal~re, G. and Milstein, C. Methods in Enzymoloqy (1981) 73:3-46.
A~ter ~usion the cells were resuspended in DMEM, 15~
FCS, cont~;n;ng HAT supplemented with glut~m;n~, pen/strep ~or culture at 37~C and 10~ C02. The cells were plated in microtiter trays and maint~; n~ in HAT-supplemented medium ~or two weeks be~ore trans~er to HAT-supplemented medium.
Supernatants from wells cont~;n;ng hybridomas were collected ~or a primary screen using an Ti~T.T.C~
The ELISA was conducted as described in Example 1 wherein the antigen coating consisted o~ 100 ~l/well o~ tetanus toxin C (TTC) protein at 2 mg/ml in coating bu~er, ~ollowed by ;ncllh~tion at 4~C overnight or at 37~C ~or two hours. In the primary F~T-T-C~, HRP-conjugated goat antimouse IgG at 1/2000 was W 096/34096 PCTnUS9510~500 used in addition to HRP mouse ant;hllm~n IgM as described in Example 1. Two hybridomas that secreted anti-TTC according to the ELISA assay, clone D5.1 and clone K4.1 were used for further analysis.
As shown in Figure 13, clone D5.1 secretes fully hllm~n anti-TTC which is detectable using HRP-conjugated ant;hllm~n Ghain antibody and HRP-conjugated antihllm~n ~ Gha~n antibody.
This is confirmed in Figures 18 and 19. Figure 14 shows that clone K4.1 secretes anti-TTC which is ;mmllnoreactive with antimurine ~ and ant;hllm~n ~ HRP-conjugated antibodies. Thus, clone K4.1 provides anti-TTC fully with hllm~n variable region as confirmed in Figures 16 and 17 and a murine constant heavy chain region.
The antibodies secreted by D5.1 and K4.1 did not ;mmllnoreact in ELISAs using TNF~, IL-6, or IL-8 as immobilized antigen under conditions where positive controls (sera from xenom;ce ;mmlln;zed with TNF~, IL-6 and IL-8 respectively) showed positive ELISA results.
The affinity of the monoclonal antibodies secreted by K4.1 for TTC antigen was determ;ned using commercially available reagents and instrumentation. BIAcore Instrument, CM5 sensor chips, sur~actant P20 and the amine coupling kit were purchased from phA~m~cia Biosensor (Piscataway, NJ). TTC was immobilized at two levels of antigen density on the surface of the sensor chips according to the manufacturer's instructions. Briefly, after washing and equilibrating the instrument with buf~er contA;n;ng surfactant, the surfaces were activated and the TCC
was immobilized.
For high antigen density, the surface was activated with 35 ~1 of equal volumes 0.1 M NHS and 0.1 M EDC injected across the sur~ace followed by 30 ~1 of TTC fragment at 100 ~g/ml in 10 mM sodium acetate buffer pH 5Ø The sur~ace was blocked by injecting 35 ~l 1 M ethanol~m;n~ and washed to e~--~ve noncovalently bound TCC using 5 ~l 0.1 M HCl. The entire immobilization procedure was conducted with a continuous flow of buffer at 5 ~l/min. This results in about 7500-8500 response units (RU) of TTC per chip. (1000 RU corresponds to about 1 ng o~ protein per mm2.) CA 022l9486 l997-l0-27 W 096/34096 PCTrUS95/05500 For chips with low antigen density, the procedure utilizes 15 ~l rather than 30 ~l o~ TTC, resulting in chips cont~;n;ng 550-950 RU.
Chips could be regenerated a~ter use in single det~rm;n~tions by injecting 10 ~l ~ormal or MgC12.
The chips are used to det~rm; n~ binding a~inities by determ; n; ng ka and kb (the association and dissociation rate constants) ~or the antibody with respect to the immobilized TTC.
The association rate constant is measured over six minutes at a flow rate of 5 ~l/min. at di~erent concentrations o~ K4.1 Mab in the range o~ 2.16 nm-69.33 nm. The dissociation rate constant is measured at a constant bu~er ~low rate o~ 5 ~l/min after completion o~ the antibody injection. The raw data are graphed in Figure 15 and the calculated results are shown in Table 1.
W 096/34096 PCTrUS9S/05S00 ~ o o ,C X
X 'I 'I
~ X
a U ~ o N
~ ~ a o O
~,, ~y o O
-- ~ X
a m, ~o g V g _ N .1 ~ v m o g S~ _ N N
- ~ ~ ~
~ t7-~ .~
P ~ n 0 ~ 'm ~ ~I
a.~ ~ ~ o t~ a~
r~
O O
m O ~1 rr~
~! ~ ~I) I
- ,d ~J
_, p pP
' m ,i 0 H a~
W 096/34096 PCTrUS95/05500 As shown, the K4.1 antibody has a binding constant (Ka) ~or TTC somewhat larger than 10l~ M-1.
The complete nucleotide sequence o~ the cDNAs encoding the heavy and light t-h~; n~ o~ the K4.1 and D5.1 monoclonals were det~rm;ne~ as shown in Figures 16-19. PolyA mRNA was isolated ~rom about 106 hybridoma cells and used to generate cDNA using r~n~om h~m~rs as primers. Portions o~ the product were ampli~ied by PCR using the appropriate primers.
Both cell lines were known to provide human K light ch~l; n~; ~or PCR ampli~ication oi~ light chain encoding cDNA, the primers used were HKP1 (5'-CTCTGTGACACTCTCCTGGGAGTT-3') for priming ~rom the constant region term;nll~ and two oligos, used in equal amounts to prime ~rom the variable segments: B3 (5'-CCACCATCAACTGCAAGTCCAGCCA-3') and B2/B1 (5'-GAAACGACACTCACGCAGTCTCCAGC-3').
For ampli~ication o~ the heavy chain ~rom K4.1 (which contains the murine ~1 constant region), the primers were MG-24Vi ~or the human variable regions:
5'-CAGGTGCAGCTGGAGCAGTCiGG-3' which, with inosine as shown recognizes the hllm~n variable regions VH1_2~ VH1_3' VH4 and VH6' and ~rom the constant region MG-25 i.e., 5'-GCACACCGCTGGACAGGGATCCAiAGTTTC-3~, which, cont~;n;ng inosine as shown recognizes murine ~ 2A, ~2B, and ~3.
For ampli~ication o~ the heavy chain o~ the antibody derived ~rom D5.1 (which contains the human ~ constant region), MG-24VI was used to prime ~rom the variable and ~P1 (5'-TTTT~ll"l~l-lGCCGTTGGGGTGC-3') was used to prime from the constant region t~rm;nllc.
Turning ~irst to the results shown in Figure 16 representing the heavy chain o~ the Mab secreted by K4.1, the sequence shows the presence o~ the human variable segment VH6, the hllm~n diversity region DN1, and the human joining segment JH4 linked to the murine ~1 constant region. Nine base-pair mutations ~rom the published germline sequence were present in the variable region, two o~ them within CDR2. One mutation was observed in the D segment. Three nongermline nucleotide additions were present in the DH-JH junction.
W 096/34096 PCTrUS95/05500 Referring to Figure 17 which shows the light chain of the K4.1 antibody, analysis shows the presence of the hnmAn K
variable region B3 and joining region JK4. Eight nucleotides are missing from B3 at the VR-JK junction and four mutations were found in the variable region. Five nongermline nucleotide additions were present at the VK-JK junction.
Referring now to Figure 18 which sets forth the sequence for the heavy chain of the antibody secreted by clone D5.1, this shows the heavy chain is comprised of the hnmAn variable fragment VH6, the h~lmAn diversity region DN1 and the hnmAn joining segment JH4 linked to the hnmAn ~ constant region.
There were two base-pair mutations from the germline sequence in the variable region, neither within the CDRs. Two additional mutations were in the D segment and six nongermline nucleotide additions were present at the DH-JH junction.
Finally, referring to Figure 19 which presents the light chain of the antibody secreted by D5.1, the hllmAn K
variable region B3 and hllmAn K joining region JK3 are shown.
There are nine base-pair differences from the germline sequences, three falling within CDR1.
Example 8 Production of Human Antibodies to IgE
A. Tmmlln;zation of Mice Germline ~h;me~iC mice contA;n;ng integrated hllmAn DNA
from the ;mmllnoglobulin loci were ;mmlln;zed by injection of 15-20 ~g of hllmAn IgE/~ in adjuvant. The mice were boosted with 15-20 ~g of hllmAn IgE/~ every 14 days after the primary ;mmlln;zation~ A bleed was done on the ;mmun;zed An;mAls to test the titer of serum antibodies against hllmAn IgE/~. The mice with the highest titers were sacrificed and the spleen removed.
B. Fusion of Splenocytes Myeloma cells, line P3X63-Ag8.653, used as the fusion partner for the spleen cells, were thawed 6 days prior to the fusion and grown in tissue culture. One day before the fusion, cells were split into fresh medium contA;n;ng 10~ fetal calf serum (FCS) at a ratio of 1:3.
. --CA 022l9486 l997-l0-27 W 096134096 PCTrUS9S/05S00 After sacri~icing the mouse, the spleen was aseptically removed and placed in a culture dish with serum-~ree culture medium. A single cell suspension was created by gently grinding the spleen between two ~rosted microscope slides. The cells were washed in f~resh serum-~ree medium red blood cells were lysed and debris ~iltered away.
The splenocytes were ~urther washed twice by centri~ugation in serum-~ree medium. Myeloma cells were also washed in serum-~ree medium at this time. Each cell type was 10 counted and co-mbined at a ratio of~ 1:3 (myeloma to splenocyte), m;~ gently and centri~uged once together.
A solution o~ 40~ polyethylene glycol (PEG) was slowly added to the cell pellet while the cells were gently resuspended over a period o~ one minute. Cells were incubated at room 15 temperature for one minute in the PEG solution and then slowly diluted into 5 ml serum-i~ree medium over 5 minutes. Five ml more were added over the next 90 seconds. Cells were incubated at room temperature f~or 5 minutes. The cells were centrifuged at low speed and the supernatant removed. The cells were 20 resuspended slowly and very gently in 5 ml o~ hybridoma medium cont~;n;ng 10~ FCS, lX OPI, lX NE amino acids and 10 mM HEPES.
Cells were ~urther diluted to 100 ml ~inal volume in hybridoma medium with lX HAT solution (hypoxanthine, aminopterin and thymidine). The ~used cells were aliquoted 100 ~l/well o~ 96-25 2311 plates and cultured at 37~C and 10~ CO2. Cells were fed at 10 days post-~usion with 100 ~l/well o~ hybridoma medium with lX
HT (hypoxanthine and thym;~;n~) and allowed to grow close to confluence be~ore screening.
Supernatant was aseptically taken ~rom each growing 30 well and tested ~or the presence oE ~ully hnm~3n antibodies.
Positive wells were ~urther tested ~or human IgE/~ speci~icity.
When a positive well was identi~ied, the cells were trans~erred i~rom the 96-well plate to 0 .5 ml o~ hybridoma medium with lX HT
in a 48-well plate. At this stage the cells were subcloned by 35 limiting dilution into 96-well plates so that a single antibody producing cell was in culture. As the culture became con~luent, the cells were ~n~ l to 1 ml, 3 ml, 5 ml, etc. and frozen CA 022l9486 l997-l0-27 W 096/34096 PCTrUS95/05500 aliquots were stored in liquid nitrogen to preserve the cell stocks.
Using the ~oregoing procedures, antibodies speci~ic ~or the antigens described above are prepared.
In accordance with the above procedure, mouse hybridomas producing h~m~n antibody against hllm~n IgE/~ were obtained.
In accordance with the above procedures, a ~h;m~ric nonhllm~n host, particularly a murine host, may be produced which can be ;mmlln;zed to produce hllm~n antibodies or analogs speci~ic ~or an ;mmllnQgen. In this m~nner, the problems associated with obt~;n;ng hllm~n monoclonal antibodies are avoided, because the transgenic host can be ;mmnn;zed with ;mmnnogens which could not be used with a hnm~n host. Furthermore~ one can provide ~or booster injections and adjuvants which would not be permitted with a hllm~n host. The resulting B cells may then be used ~or immortalization for the continuous production o~ the desired antibody. The immortalized cells may be used ~or isolation o~
the genes encoding the ;mmllnoglobulin or analog and be subjected to i~urther molecular modi~ication by methods such as in YitrO
mutagenesis or other techniques to modify the properties of the antibodies. These modi~ied genes may then be returned to the immortalized cells by trans~ection to provide ~or a continuous m~mm~lian cellular source o~ the desired antibodies. The subject invention provides ~or a convenient source o~ human antibodies, where the hllm~n antibodies are produced in analogous m~nn~r to the production o~ antibodies in a hnm~n host. The ~n;m~l host cells conveniently provide for the activation and rearrangement o~ hllmAn DNA in the host cells ~or production of hllm~n antibodies.
In accordance with the subject invention, hllm~n antibodies can be produced to hllm~n ;mm~lnogens, e.g., proteins, by ;mmlln;zation o~ the subject host m~mm~l with hllm~n ;mmnnogens~ The resulting antisera will be speci~ic ~or the hllm~ ;mmllnogen and may be harvested ~rom the serum o~ the host.
The ;mmlln;zed host B cells may be used for im-m--ortalization~
e.g., myeloma cell ~usion, trans~ection, etc. to provide immortal cells, e.g., hybridomas, to produce monoclonal antibodies. The antibodies, antiserum and monoclonal antibodies will be glycosylated in accordance with the species o~ the cell producing the antibodies. Rare variable regions o~ the Ig locus may be recruited in producing the antibodies, so that antibodies having rare variable regions may be obt~;ne~.
All productions and patent applications cited in this speci~ication are herein incorporated by re~erence as i~ each individual publication or patent application were speci~ically and individually indicated to be incorporated by re~erence.
Technical Field The invention relates to the ~ield of immunology, and in particular to the production o~ antibodies. More speci~ically, it concerns producing such antibodies by a process which includes the step of ;mmlln;zing a transgenic ~n~m~l with an antigen to which antibodies are desired. The transgenic ;m~l has been modi~ied so as to produce human, as opposed to endogenous antibodies.
Backqround Art PCT application WO 94/02602, published 3 February 1994 and incorporated herein by reference, describes in detail the production of transgenic no~hllm~n ~n;m~ls which are modified so as to produce antibodies with fully ~hllmAn variable regions rather than endogenous antibodies in response to antigenic challenge. Briefly, the endogenous loci encoding the light and heavy immunoglobulin t~h~; n~ are incapacitated in the transgenic hosts and loci encoding hnm~n heavy and light chain proteins are inserted into the genome. In general, the ~n;m~l which provides all the desired modi~ications is obtained by cross-breeding int~rm~ te ~n;m~ls cont~;n;ng fewer than the full complement of modifications. The preferred embodiment o~ the nonh~lm~n ~n;m~l described in the specification is a mouse. Thus, mice, specifically, are described which, when a~m;n;~tered immunogens, produce antibodies with hnm~n variable regions, including ~ully hl~m~n antibodies, rather than murine antibodies that are ;mmllnospecific for these antigens.
The availability of such transgenic An;m~ls makes possible new approaches to the production o~ fully htlm~n antibodies. Antibodies with various ;mmllnospecificities are desirable for therapeutic and diagnostic use. Those antibodies intended ~or hnm~n therapeutic and in vivo diagnostic use, in particular, have been problematic because prior art sources ~or such antibodies resulted in ;mmllnoglobulins bearing the characteristic structures of antibodies produced by no~hllm~n W 096/34096 PCTrUS95/05500 hosts. Such antibodies tend to be ;mmllnogenic when used in hnm~ n ~:, The availability o~ the no~hnm~n, ;mmnnogen-responsive c transgenic ~n;m~l 8 described in the above-re~erenced WO 94/02602 make possible convenient production o~ hnm~n antibodies without the necessity o~ employing hnm~n hosts.
Disclosure o~ the Invention The invention is directed to methods to produce human antibodies by a process wherein at least one step o~ the process includes ;mmlln;zing a transgenic nonhllm~n ~n;m~l with the desired antigen. The modi~ied ~n;m~l ~ails to produce endogenous antibodies, but instead produces B-cells which secrete immunoglobulins with ~ully hnm~n variable regions. The antibodies produced include fully human antibodies and can be obtained ~rom the ~n;m~l directly, or ~rom immortalized B-cells derived ~rom the ~n;m~l Alternatively, the genes encoding the ;mmllnoglobulins with hllm~n variable regions can be recovered and expressed to obtain the antibodies directly or modi~ied to obtain analogs o~ antibodies such as, ~or example, single chain Fv molecules.
Thus, in one aspect, the invention is directed to a method to produce an ;mmllnoglobulin with a ~ully human variable region to a speci~ic antigen or to produce an analog o~ said ;mmnnoglobulin by a process which comprises ;mmlln;zing a nonhllm~n ;:~n;m~l with the antigen under conditions that stimulate an ;mmllne response. Fully hllm~n ;mmllnoglobulins are included in this group and are pre~erred. The nonhllm~n ~n;m~l is characterized by being substantially incapable o~ producing endogenous heavy or light ;mmllnoglobulin chain, but capable of producing ;mmllnoglobulins either with both human variable regions and constant regions or with ~ully human variable regions or both. In the resulting ;mmlln~ response, the ~n;m~l produces B cells which secrete ;mmllnoglobulins, with at least variable regions that are ~ully human, speci~ic ~or the antigen.
The human ;mmllnQglobulin o~ desired specif~icity can be directly recovered ~rom the ~n;m~ or example, ~rom the serum, or primary B cells can be obt~;n~ ~rom the ~n;m~l and W 096/34096 PCT~US95/05500 -- 3 im.mortalized. The immortalized B cells can be used directly as the source o~ hl~mAn antibodies or, alternatively, the genes encoding the antibodies can be prepared from the immortalized B
cells or from primary B cells of the blood or lymphoid tissue (spleen, tonsils, lymph nodes, bone marrow) o~ the ;mmlln;zed ~n;m~l and expressed in recombinant hosts, with or without modification, to produce the ;mmllnoglobulin or its analogs. In addition, the genes encoding the repertoire o~ ;mmllnoglobulins produced by the ;mmlln;zed ~n;m~l can be used to generate a library of ;mmnnoglobulins to permit screening for those variable regions which provide the desired af~inity. Clones from the library which have the desired characteristics can then be used as a source of nucleotide sequences encoding the desired variable regions ~or ~urther manipulation to generate antibodies or analogs with these characteristics using st~n~d recombinant techniques.
In another aspect, the invention relates to an immortalized nonhuman B cell line derived from the above described ~n;m~l In still another aspect, the invention is directed to a recombinant host cell which is modified to contain the gene encoding either the human ;mmnnoglobulin with the desired speci~icity, or an analog thereo~ which exhibits the same speci~icity.
In still other aspects, the invention is directed to antibodies or antibody analogs prepared by the above described methods and to recom.binant materials ~or their production.
In still other aspects, the invention is directed to antibodies with ~ully hllm~n variable regions, including ~ully hnm~n antibodies which are ;mmllnospeci~ic with respect to particular antigens set ~orth herein and to analogs which are s;m;l~ly ;mmllnospecific, as well as to the reco-m-binant materials use~ul in the production of the~e antibodies.
~ Brie~ Description o~ the Drawings Figure 1 shows the ~erum titers o~ anti-I~-6 antibodies from a X~nnmr~usen';mmlln;zed with hllm~n IL-6 and which antibodies cont~;n h~lm~n ~ light ch~;n~ and/or hllm~n ~ heavy ~h~;n~.
W 096/34096 PCTrUS95/05500 Figure 2 shows the serum titers o~ anti-Ih-8 antibodies ~rom a x~nnmouse~ ;mmlln;zed with human Ih-8 and which antibodies contain hllm~n K light ~h~;ns and/or human ~ heavy ~h~n~
Figure 3 shows the serum titers o~ anti-TNF~
antibodies ~rom a x~nOmOUse~ ;mmlln;zed with human TNF-~ and which antibodies contain hllm~n K light ch~;n~ and/or human heavy ~h~;n~
Figure 4 shows the serum titers o~ anti-CD4 antibodies ~rom a Xenomouse~ ;mmlln;zed with human CD4 and which antibodies contain human K light Ch~; n~ and/or human ,u heavy rh~;n~:.
Figure 5 shows the serum titers o~ a ~nom~use~
;mmlln;zed with 300.19 cells expressing h-selectin at their sur~ace. In the EhISA assay used, these antibodies are detectable only i~ they carry hllm~n ~ constant region heavy rh~; nc Figure 6 shows the serum titers o~ a X~nnmouse~
;mmlln;zed with 300.19 cells expressing h-selectin at their sur~ace. In the EhISA assay used, these antibodies are detectahle only i~ they carry human ~ light ch~;n~.
Figure 7 shows the serum titers o~ a ~nnmouse~
;mmlln;zed with 300.19 cells expressing h-selectin. In this EhISA, these antibodies are detectable i~ they carry human K
light chain and/or murine ~ constant regions.
Figure 8 shows a FACS analysis o~ human neutrophils coupled to sera ~rom a ~nom~use~ (A195-2) ;mmlln;zed with human h-selectin and labeled with an antibody ;mmllnoreactive with murine heavy chain ~ constant region.
Figure 9 shows a FACS analysis o~ human neutrophils ;ncllh~ted with serum ~rom a ~nnm~Use~ (A195-2) ;mmlln;zed with hllm~n h-selectin and labeled with an antibody ;mmllnoreactive with hnm~n light chain K region.
Figure 10 is a diagram o~ a plasmid used to trans~ect m~mm~lian cells to e~ect the production o~ the human protein gp39.
Figure 11 represents the serum titration curve o~ mice ;mmlln;zed with CH0 cells expressing human gp39. The antibodies detected in this EhISA must be ;mmllnoreactive with gp39 and _ W 096/34096 PCTrUS95/05500 -- 5 -- .
contain hllm~n heavy chain ~ constant regions or hnm~n K light ~:l ;n!:, Figure 12 shows the results of a FACS analysis of antibodies from a Xenomouse~ (labeled A247-4) ;mmlln;zed with hllm~n gp39 reacted with activated hllm~n T cells. Figure 12A
shows the separation of hllm~n activated T cells into CD4+ and CD4- populations. Panel B shows the results of a FACS analysis of the activated CD4+ T cells with antibodies from the XPnclm~use~ ;mmlln;zed with gp39 which contain murine heavy chain ~y constant regions; panel C shows the corresponding results with respect to CD4- populations.
Figure 13 is a titration curve with respect to monoclonal antibodies secreted by the hybridoma clone D5.1.
This clone is obtained from a x~nom~use~ ;mmlln;zed with tetanus toxin C (TTC) and contains hllm;~n K light chain and hnm~n constant region in the heavy chain.
Figure 14 is a titration curve with respect to the hybridoma supernatant from clone K4.1. This hybridoma clone is obt~;n~A from a x~nomousenl ;mmlln;zed with TTC and contains hllmAn K light chain and heavy chain having the murine ~y constant region.
Figure 15 shows binding curves for various concentrations of the K4.1 monoclonal antibody in a determ;n~tion of the affinity of the monoclonal with its antigen in a BIAcore instrument.
Figure 16 shows the complete nucleotide sequence of the heavy chain from the antibody secreted by K4.1.
Figure 17 shows the complete nucleotide sequence of the light chain from the antibody secreted by K4.1.
Figure 18 shows the complete nucleotide sequence of the heavy chain from the antibody secreted by D5.1.
Figure 19 shows the complete nucleotide sequence of the light chain from the antibody secreted by D5.1.
Modes of Carryinq Out the Invention In general, the methods of the invention include ~Am;n;F~tering an antigen for which hllmAn forms of ;mmllnospecific reagents are desired to a transgenic nonhllm;~n ~n;m~l which has -W 096/34096 PCT~US95/05500 -- 6 been modi~ied genetically so as to be capable o~ producing human, but not endogenous, antibodies. Typically, the ~n;m~l has been modi~ied to disable the endogenous heavy and/or light chain loci in its genome, so that these endogenous loci are incapable of the rearrangement required to generate genes encoding ;mmllnoglobulins in response to an antigen. In addition, the ~n;m~l will have been provided, stably, in its genome, at least one hllm~n heavy chain locus and at least one human light chain locus so that in response to an ~m;n;stered antigen, the human loci can rearrange to provide genes encoding hllm~n variable regions ;mmllnospeci~ic ~or the antigen.
The details for constructing such an ~n;m~l useful in the method of the invention are provided in the PCT application 2 referenced above.
For production o~ the desired antibodies, the first step is ~m;n;stration o~ the antigen. Techniques ~or such ;n;stration are conventional and involve suitable ;mmlln;zation protocols and formulations which will depend on the nature o~ the antigen per se. It may be necessary to provide the antigen with a carrier to ~nh~nce its ;mmllnogenicity and/or to include formulations which contain adjuvants and/or to ~m;n;ster multiple injections, and the like. Such techniques are st~n~d and optimization o~ them will depend on the characteristics o~ the particular antigen ~or which ;mmllnospeci~ic reagents are desired.
As used herein, the term ";mmllnospeci~ic reagents~
includes ;mmllnoglobulins and their analogs. The term "analogs"
has a specific m~n;ng in this context. It refers to moieties that contain the ~ully human portions of the ;mmllnoglobulin which account for its ;mmllnospecificity. In particular, variable regions including the complementarity det~rm;n;ng regions (CDRs) are required, along with sufficient portions of the ~ramework regions (FRs) to result in the appropriate three ~;m~n~ional con~ormation. Typical ;mmllnospeci~ic analogs o~
antibodies include F(ab~) 2' Fab,, and Fab regions. Modified îorms of the variable regions to obtain, ~or example, single chain Fv analogs with the appropriate ;mmllnospeci~icity are known. A
review o~ such Fv construction is ~ound, ~or example, in Tibtech CA 022l9486 l997-l0-27 W 096/34096 PCTrUS95/05500 (1991) 9: The construction o~ antibody analogs with multiple ;mml~nospecificities i8 also possible by coupling the human variable regions derived ~rom antibodies with varying speci~icities.
The variable regions with ~ully hllm~n characteristics can also be coupled to a variety o~ additional substances which can provide toxicity, biological functionality, alternative binding speci~icities and the like. The moieties including the ~ully human variable regions produced by the methods o~ the invention include single-chain ~usion proteins, molecules coupled by covalent methods other than those involving peptide linkages, and aggregated molecules. Examples o~ analogs which include variable regions coupled to additional molecules covalently or noncovalently include those in the ~ollowing nonlimiting illustrative list. Traunecker, A. et al. Int J
Cancer Supp (1992) SUPP 7:51-52 describe the bispecific reagent janusin in which the Fv region directed to CD3 is coupled to soluble CD4 or to other ligands such as OVCA and IL- 7.
Similarly, the ~ully hnm~n variable regions produced by the 20 method of the invention can be constructed into Fv molecules and coupled to alternative ligands such as those illustrated in the cited article. Higgins, P.J. et al. J In~ect Disease (1992) 166:198-202 describe a heteroconjugate antibody composed o~ OKT3 cross-linked to an antibody directed to a speci~ic sequence in 25 the V3 region or GP120. Such heteroconjugate antibodies can also be constructed using at least the hllm~n variable regions cont~;ne~ in the ;mmllnoglobulins produced by the invention methods. Additional examples o~ bispeci~ic antibodies include those described by Fanger, M.W. et al. Cancer Treat Res (1993) 30 68:181-194 and by Fanger, M.W. et al. Crit Rev TmmnnQl (1992) 12:101-124. Conjugates that are ;mmllnotoxins including conventional antibodies have been widely described in the art.
The toxins may be coupled to the antibodies by conventional r coupling techniques or ;mml1notoxins cont~;n;ng protein toxin 35 portions can be produced as ~usion proteins. The analogs o~ the present invention can be used in a corresponding way to obtain such ;mm~lnotoxins. Illustrative o~ such ;mmllnotoxins are those W 096/34096 PCTrUS95/OSSOO
described by Byrs, B.S. et al. S~m;n~Ars Cell Biol (1991) 2:59-70 and by Fanger, M.W. et al. TmmllnQl Today (1991) 12:51-54.
It will also be noted that some o$ the ;mmllnQglobulins and analogs o$ the invention will have agonist activity with respect to antigens for which they are ;mmllnospeci$ic in the cases wherein the antigens per$orm signal transducing ~unctions.
Thus, a subset o$ antibodies or analogs prepared according to the methods o$ the invention which are ;mmlln~speci$ic $or, $or example, a cell sur$ace receptor, will be capable o~ eliciting a response ~rom cells bearing this receptor corresponding to that elicited by the native ligand. Furth~rmnre~ antibodies or analogs which are immunospeci$ic ~or substances mimicking transition states o~ chemical reactions will have catalytic activity. Hence, a subset o$ the antibodies and analogs o~ the invention will $unction as catalytic antibodies.
In short, the genes encoding the immunoglobulins produced by the transgenic An;mAls of the invention can be retrieved and the nucleotide sequences encoding the ~ully human variable region can be manipulated according to known techniques to provide a variety o~ analogs such as those described above.
In addition, the immunoglobulins themselves contA;n;ng the human variable regions can be modi~ied using stAn~Ard coupling techniques to provide conjugates retA;n;ng ;mmllnospeci~icity and ~ully hllmAn characteristics in the ;mmllnospeci~ic region.
Thus, ;mmllnoglobulin "analogs" re~ers to moieties which contain those portions o$ the antibodies o$ the invention which retain their hllmAn characteristics and their immunospeci$icity. These will retain su$$icient h~lmAn variable region to provide the desired speci~icity.
As stated above, all o$ the methods o~ the invention include A~m; n; ~tering the appropriate antigen to the transgenic An;mAl The recovery or production o~ the antibodies themselves can be achieved in various ways.
First, and most straight~orward, the polyclonal antibodies produced by the An;mAl and secreted into the bloodstream can be recovered using known techniques. Puri~ied ~orms o$ these antibodies can, o~ course, be readily prepared by stAn~Ard puri$ication techniques, pre$erably including a$$inity W Og~/~lO~G PCTrUS95/05500 g chromatography with respect to the particular antigen, or even with respect to the particular epitope of the antigen for which speci~icity is desired. In any case, in order to monitor the success o~ ;mmlln;zation~ the antibody levels with respect to the antigen in serum will be monitored using stAn~Ard techniques such as ELISA, RIA and the like.
It will be noted, from the examples below, that a portion o~ the polyclonal antiserum obtained may include an endogenous heavy chain constant region derived from the host, even though the variable regions are fully hllmAn~ Under these circumstances, to the extent that an application requires fully h~lmAn antibodies, use of the polyclonal antiserum directly would be inappropriate. However, the presence of these ~h;m~as~
which is believed to result from in vivo isotype switching as described by Gerstein et al . Cell (1990) 63:537, is not problematic, in view of conventional purification and modification methods and in view of the availability of alternative methods to recover fully hnm~n antibodies, if desired, described in the following paragraphs.
First, and most simply, the polyclonal antiserum could be subjected to suitable separation techniques to provide compositions contA;n;ng only ~ully hnmAn immunoglobulins.
Portions of the serum which display characteristics o~ the host species can be removed, for example, using a~finity reagents with the appropriate anti species ;mmllnoglobulins or immunospeci~ic portions thereof. Furth~rmore, ~or applications where only the variable regions o~ the antibodies are required, treating the polyclonal antiserum with suitable reagents so as to generate Fab, Fab,, or F(ab,~ portions results in compositions contA;n;ng ~ully hllmAn characteristics. Such fragments are sufficient for use, for example, in ;mmllnodiagnostic procedures - involving coupling the ;mmllnospeci~ic portions of immunoglobulins to detecting reagents such as radioisotopes.
Thus, ~or some applications, the polyclonal antiserum can be treated to provide compositions with the desired characteristics including compositions consisting essentially o~ fully hllmAn antibodies and compositions including ;mmllnoglobulin analogs wherein the ;mmllnospeci~ic portion is ~ully hllmAn.
, W 096/34096 PCT~US95105500 Alternatively, ;mmllnoglobulins and analogs with desired characteristics can be generated from immortalized B
cells derived from the transgenic ~n;m~ls used in the method of the invention or from the rearranged genes provided by these 5 ~n;m~lS in response to ;mmlln;zation~ It will be apparent that hybridomas derived from the B cells of the ;mmlln;zed ~n;m~l can be screened so as to choose only those secreting fully hllm~n antibodies and that the genetic material can be recovered from the hybridomas or from lymphocytes in spleen, blood, or lymph nodes of the ;mmlln;zed ~n;m~l and manipulated using conventional techniques to replace any endogenous constant region with a hllm~n one or to produce a desired analog.
Thus, as an alternative to harvesting the antibodies directly from the ~n;m~l, the B cells can be obt~;ne~ typically from the spleen, but also, if desired, from the peripheral blood lymphocytes or lymph nodes and immortalized using any of a variety of techniques, most c~mmnnly using the fusion methods described by Kohler and Milstein. The resulting hybridomas (or otherwise immortalized B cells) can then be cultured as single colonies and screened for secretion of antibodies of the desired specificity. As described above, the screen can also include a dete~m;n~tion of the fully human character of the antibody. For example, as described in the examples below, a sandwich ELISA
wherein the monoclonal in the hybridoma supernatant is bound both to antigen and to an ant;hllm~n constant region can be employed. Conversely, hybridomas that secrete antibodies which are ;mmllnoreactive with antispecies antibodies directed to the species of the ;mmlln;zed ~n;m~l can be discarded. After the appropriate hybridomas are selected, the desired antibodies can be recovered, again using conventional techniques. They can be prepared in quantity by culturing the immortalized B cells using conventional methods, either in vitro, or in vivo to produce ascites fluid. Purification of the resulting monoclonal antibody preparations is less burdensome than in the case of serum since each immortalized colony will secrete only a single type of antibody. In any event, st~n~d purification techniques to isolate the antibody from other proteins in the culture medium can be employed.
W O 96/34096 PCTrUS95105500 As an alternative to obtA;n;ng hnm~n ;mmllnoglobulins directly from the culture of immortalized B cells derived from the An;m~l, the immortalized cells can be used as a source of rearranged heavy chain and light chain loci for subse~uent expression and/or genetic manipulation. Isolation of genes from such antibody-producing cells is straightforward since high levels of the appropriate m~RNAS are available for production of a cDNA library. The recovered rearranged loci can be manipulated as desired. For example, the constant region can be ~ch~nged for that of a different isotype or that of a hllm~n antibody, as described above, or eliminated altogether. The variable regions can be linked to encode single chain Fv regions. Multiple Fv regions can be linked to confer binding ability to more than one target or ch;m~ic heavy and light chain combinations can be employed. Once the genetic material is available, design of analogs as described above which retain their ability to bind the desired target, as well as their hllmAn characteristics, is straightforward.
Once the appropriate genetic material is obtA; n~A and, if desired, modified to encode an analog, the coding sequences including those that encode, at a m; n; mllm, the variable regions of the hllm~n heavy and light chain can be inserted into expression systems contA; n~ on vectors which can be transfected into stAn~d recombinant host cells. As described below, a variety of such host cells may be used; for efficient processing, however, mAmmAlian cells are preferred. Typical mAmmAlian cell lines useful for this purpose include CHO cells, 293 cells, or NSO-GS cells.
The production of the antibody or analog is then undertaken by culturing the modified recombinant host under culture conditions appropriate for the growth of the host cells - and the expression of the coding sequences. The antibodies are then recovered from the culture. The expression systems are preferably designed to include signal peptides so that the resulting antibodies are secreted into the medium; however, intracellular production is also possible.
In addition to deliberate design of modified forms of the immunoglobulin genes to produce analogs, advantage can be CA 022l9486 l997-l0-27 W 096/34096 ' PCTrUS9~/05500 taken of phage display techniques to provide libraries cont~;n;ng a repertoire o~ antibodies with varying a~inities ~or the desired antigen. For production o~ such repertoires, it is unnecessary to immortalize the B cells ~rom the ~mmlln;zed ~n;m~l; rather the primary B cells can be used directly as a source o~ DNA. The mixture o~ cDNAs obt~;ne~ ~rom B cells, e.g., derived ~rom spleens, is used to prepare an expression library, for example, a phage display library trans~ected into E. col i . The resulting cells are tested ~or immunoreactivity to the desired antigen. Techniques ~or the identi~ication o~ high a~inity hllm~n antibodies ~rom such libraries are described by Gri~iths, A.D., et al., EMBO J (1994) 13:3245-3260; by Nissim, A., et al. ibid, 692-698, and by Gri~fiths, A.D., et al., ibid, 725-734. Ultimately, clones ~rom the library are identi~ied which produce binding a~inities o~ a desired magnitude ~or the antigen, and the DNA encoding the product responsible ~or such binding is recovered and manipulated ~or st~n~rd recombinant expression. Phage display libraries may also be constructed using previously manipuiated nuclaoL~d~ se~u~l~s and screened in similar ~ashion. In general, the cDNAs encoding heavy and light chain are independently supplied or are linked to ~orm Fv analogs ~or production in the phage library.
The phage library is thus screened for the antibodies with highest a~inity ~or the antigen and the genetic material recovered ~rom the appropriate clone. Further rounds o~
screening can increase the a~inity o~ the original antibody isolated. The manipulations described above ~or recombinant production o~ the antibody or modi~ication to ~orm a desired analog can then be employed.
As above, the modi~ied or l~nmoA;~ied rearranged loci are manipulated using st~n~rd recombinant techniques by constructing expression systems operable in a desired host cell, such as, typically, a C'h;ne~e hamster ovary cell, and the desired ;mmllnoglobulin or analog is produced using st~n~rd recombinant expression techniques, and recovered and puri~ied using conventional methods.
The application o~ the ~oregoing processes to antibody production has enabled the preparation o~ human ;mmnnospeci~ic reagents with respect to antigens ~or which hnm~n antibodies have not hereto~ore been available. The ;mmllnoglobulins that result ~rom the above-described methods and the analogs m~de possible thereby, provide novel compositions ~or use in analysis, diagnosis, research, and therapy. The particular use will, of course, depend on the ;mmllnoglobulin or analog prepared. In general, the compositions o~ the invention will have utilities similar to those ascribable to no~hllmAn antibodies directed against the same antigen. Such utilities include, ~or example, use as a a~finity ligands ~or puri~ication, as reagents in immunoassays, as components of immunoconjugates, and as therapeutic agents for appropriate indications.
Particularly in the case o~ therapeutic agents or diagnostic agents for use in vivo, it is highly advantageous to employ antibodies or their analogs with ~ully h~lm~n characteristics. These reagents avoid the undesired ;mmlln~
responses engendered by antibodies or analogs which have characteristics marking them as originating ~rom non-h~lm~n species. Other attempts to "hllm~n;ze" antibodies do not result in reagents with ~ully hllm~n characteristics. For example, ~h;m~iC antibodies with murine variable regions and hl~m~n constant regions are easily prepared, but, o~ course, retain murine characteristics in the variable regions. Even the much more di~icult procedure o~ ~h~lm~n;zing" the variable regions by manipulating the genes encoding the amino acid sequences that form the ~ramework regions does not provide the desired result since the CDRs, typically of nonhllm~n origin, cannot be manipulated without destroying ;mmllnospeci~icity. Thus, the methods o~ the pre~ent invention provide, ~or the ~irst time, ;mm~lnoglobulins that are fully hnm~n or analogs which contain ;mmnnospecific regions with ~ully hllm~n characteristics.
There are large numbers of antigens for which hllm~n antibodies and their hllm~n analogs would be made available by the methods of the invention. These include the ~ollowing as a nonlimiting set:
leukocyte markers, such as CD2, CD3, CD4, CD5, CD6, CD7, CD8, CDlla,b,c, CD13, CD14, CD18, CDl9, CD20, CD22, CD23, CA 022l9486 l997-l0-27 W 096/34096 PCTrUS95/OSSOO
CD27 and its ligand, CD28 and its ligands B7.1, B7.2, B7.3, CD29 and its ligand, CD30 and its ligand, CD40 and its ligand gp39, CD44, CD45 and iso~orms, CDw52 (Campath antigen), CD56, CD58, CD69, CD72, CTLA-4, hFA-l and TCR
histocompatibility antigens, such as MHC class I or II, the Lewis Y antigens, SLex, Shey, SLea, and Sheb;
adhesion molecules, including the integrin~, such as VLA-l, VLA-2, VLA-3, VLA-4, VLA-5, VLA-6, LFA-l, Mac-l and pl50,95; and the selectins, such as L-selectin, E-selectin, and P-selectin and their counterreceptors VCAM-l, ICAM-l, ICAM-2, and LFA-3;
interleukins, such as IL-l, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, Ih-ll, IL-12, IL-13, IL-14, and~5 IL-15;
interleukin receptors, such as I~-lR, IL-2R, IL-3R, IL-4R, IL-5R, IL-6R, IL-7R, IL-8R, IL-9R, IL-lOR, IL-llR, IL-12R, IL-13R, IL-14R, and IL-15R;
ch~m~kines, such as PF4, RANTES, MIPl~, MCPl, NAP-2,~0 Gro~, Gro~, and IL-8;
growth ~actors, such as TNFalpha, TGFbeta, TSH, VEGF/VPF, PTHrP, EGF ~amily, FGF, PDGF ~amily, endothelin, and gastrin releasing peptide (GRP);
growth ~actor receptors, such as TNFalphaR, RGFbetaR,~5 TSHR, VEGFR/VPFR, FGFR, EGFR, PTHrPR, PDGFR ~amily, EPO-R, GCSF-R and other hematopoietic receptors;
inter~eron receptors, such as IFN~R, IFN~R, and IFN~R;
Igs and their receptors, such as IgE, FceRI, and FCeRII;
tumor antigens, such as her2-neu, mucin, CEA and endosialin;
allergens, such as house dust mite antigen, lol pl (grass) antigens, and urushiol;
viral proteins, such as CMV glycoproteins B, H, and gCIII, HIV-l envelope glycoproteins, RSV envelope glycoproteins, HSV envelope glycoproteins, EBV envelope glycoproteins, VZV
envelope glycoproteins, HPV envelope glycoproteins, Hepatitis ~amily sur~ace antigens;
-CA 022l9486 l997-l0-27 W 096/34096 PCTnUS95/05500 toxins, such as pseudnmo~ endotoxin and osteopontin/uropontin, snake venom, and bee venom;
blood ~actors, such as complement C3b, complement C5a, complement C5b-9, Rh factor, ~ibrinogen, ~ibrin, and myelin associated growth inhibitor;
enzymes, such as cholesterol ester transfer protein, membrane bound matrix metalloproteases, and glutamic acid decarboxylase (GAD); and miscellaneous antigens including ganglioside GD3, ganglioside GM2, hMP1, hMP2, eosinophil major basic protein, eosinophil cationic protein, pANCA, Amadori protein, Type IV
collagen, glycated lipids, ~-inter~eron, A7, P-glycoprotein and Fas (AFO-1) and oxidized-hDL.
Particularly preferred ;mmnnoglobulins and analogs are those ;mmllnospecific with respect to hnm~n Ih-6, hnm~n Ih-8, hllmAn TNF~, hllm~n CD4, hllm~n h-selectin, and hnm~n gp39. Human antibodies against Ih-8 are particularly useful in preventing tumor metastasis and inflammatory states such as asthma and reper~usion injury. Antibodies and analogs ;mmllnoreactive with hnm~n TNF~ and hllm~n Ih-6 are useful in treating cachexia and septic shock as well as auto;mmlln~ disease. Antibodies and analogs ;mmllnoreactive with gp39 or with h-selectin are also effective in treating or preventing auto;mmnne disease. In addition, anti-gp39 is helpful in treating gra~t versus host disease, in preventing organ transplant rejection, and in treating glomerulonephritis. Antibodies and analogs against h-selectin are useful in treating isch~m;~ associated with reper~usion injury.
Typical auto;mmlln~ diseases which can be treated using the above-mentioned antibodies and analogs include systemic lupus erythematosus, rheumatoid arthritis, psoriasis, Sjogren~s, ~ scleroderma, m;~e~ connective tissue disease, dermatomyositis, polymyositis, Reiter's syndrome, Behcet's disease, Type 1 - diabetes, ~h;mnto's thyroiditis, Grave's disease, multiple sclerosis, myasth~n;~ gravis and pemphigus.
The examples below are intended to illustrate but not to limit the invention.
CA 022l9486 l997-l0-27 In these examples, mice, designated ~xennm;ce", are used ~or initial ;mmlln;zations. A detailed description o~ such x~nnm;ce is ~ound in the above re~erenced PCT application WO
94/02602, Tmmnn; zation protocols appropriate to each antigen are described in the speci~ic examples below. The sera o~ the ;mmlln;zed x~nnm;ce (or the supernatants ~rom immortalized B
cells) were titrated ~or antigen speci~ic human antibodies in each case using a st~n~rd ELISA format. In this ~ormat, the antigen used ~or ;mmlln;zation was immobilized onto wells of microtiter plates. The plates were washed and blocked and the sera (or supernatants) were added as serial dilutions ~or 1- 2 hours o~ incubation. A~ter washing, bound antibody having human characteristics was detected by adding the appropriate antispecies Ig (typically ant; hnmAn K chain antibody or ant;hllmAn ~ chain antibody) conjugated to horseradish peroxidase (HRP) ~or one hour. In some cases, the bound antibodies were tested ~or murine characteristics using antimurine antibodies, typically antimurine ~ chain antibody. A~ter again w~h; n~, the chromogenic reagent o-phenylene ~; Am; n~ (OPD) substrate and 2 0 hydrogen peroxide were added and the plates were read 30 minutes later at 492 nm using a microplate reader.
Unless otherwise noted, the antigen was coated using plate coating buf~er (O.1 M carbonate bu~er, pH 9 . 6); the assay blocking bu~i~er used was 0. 5% BSA, 0.1~ Tween 20 and 0.01 Thimerosal in PBS; the substrate bu~er used in color development was citric acid 7.14 g/l: dibasic sodium phosphate 17.96 g/l; the developing solution (made ;mm~ tely be~ore use) was 10 ml substrate bui~i~er, 10 mg OPD, plus 5 ml hydrogen peroxide; the stop solution (used to stop color development) was 2 M suli~uric acid. The wash solution was 0. 05~ Tween 20 in PBS.
Example 1 ~llmAn Antibodies Against Human IL- 6 Three to 5 x~nom; ce aged 8-20 weeks were age-matched and ;mmnn;zed intraperiton~Ally with 50 ~g hnm~n IL-6 emulsi~ied in complete Freund~s adjuvant ~or primary ;mmlln;zation and in ;ncnmrlete Freund's adjuvant ~or subse~uent injections. The mice received 6 injections 2 - 3 weeks apart. Serum titers were CA 022l9486 l997-l0-27 WO 96/34096 PCTrUS95/05500 det~rm;ne~ after the second dose and following each dose thereafter. Bleeds were performed 6-7 days after injections from the retrobulbar plexus. The blood was allowed to clot at room temperature for about 2 hours and then incubated at 4~C for at least 2 hours before separating and collecting the sera.
ELISAs were conducted as described above by applying 100 ~l/well of recombinant hnm~n IL-6 at 2 mg/ml in coating buffer. Plates were then incubated at 4~C overnight or at 37~C
for 2 hours and then washed three times in washing buffer.
Addition of 100 ~l/well blocking buffer was followed by incubation at room temperature for 2 hours, and an additional 3 washes.
Then, 50 ~l/well of diluted serum samples (and positive and negative controls) were ~ to the plates.
Plates were then incubated at room temperature for 2 hours and again washed 3 times.
After washing, 100 ~l/well of either mouse antihuman chain antibody conjugated to HRP at 1/2,000 or mouse antihu-man K
chain antibody conjugated to HRP at 1/2,000, diluted in blocking buffer were ~e~. After a 1 hour incubation at room temperature, the plates were washed 3 times and developed with OPD substrate for 10-25 minutes. 50 ~l/well of stop solution were then added and the results read on an ELISA plate reader at 492 nm. The dilution curves resulting from the titration of serum from ~Cenomouse~y A40- 7 after 6 injections are shown in Figure 1. The data in Figure 1 show production of anti-IL- 6 ;mmllnoreactive with ant;hl~m~n ~ and ant;h-lm~n ~ detectable at ~erum dilutions above 1:1,000.
Example 2 3 o ~llm~n Antibodies Aqainst Human I~-8 - Tmmlln;zation and serum preparation were as described in Example 1 as except that hllm~n recombinant Ih-8 was used as - an ;mm~lnogen.
RrT~ assays were performed with respect to the recovered serurn, also exactly as described in R~C~mple 1, except that the ELISA plates were initially coated using 100 ~l/well of recombinant hllm~n IL-8 at 0.5 mg/ml in the coating buffer. The CA 022l9486 l997-l0-27 W 096/34096 PCT~US95/05500 results obt~;ne~ ~or various serum dilutions ~rom ~nomouse~
A260-5 a~ter 6 injections are shown in Figure 2. Human anti-IL-8 binding was again shown at serum dilutions having concentrations higher than that represented by a 1:1,000 dilution.
Example 3 Human Antibodies Aqainst Human TNF~
Tmmlln;zation and serum preparation were conducted as described in Example 1 except that hllm~n recombinant TNF~ was substituted ~or hllm~n IL-6. ELISAs were conducted as described in Example 1 except that the initial coating of the ELISA plate employed 100 ~l/well recombinant human TNFa at 1 mg/ml in coating bu~er.
The dilution curves ~or serum ~rom X~nnmouse~ A210-8 a~ter 6 injections obt~;n~ are shown in Figure 3. Again signi~icant titers of hllm~n anti-TNF~ binding were shown.
Example 4 Euman Antibodies Aqainst Human CD4 The human CD4 antigen was prepared as a sur~ace protein using human CD4 ~ on trans~ected recombinant cells as ~ollows. Human CD4 ~ consists o~ the extracellular ~nm~; n o~
CD4, the tr~n~m~mhrane ~nm~; n o~ CD4, and the cytoplasmic ~nm~;n of residues 31-142 o~ the mature ~ chain. Human CD4 zeta (F15 LTR) as described in Roberts, et al., Blood (1994) 84:2878 was introduced into the rat basophil leukemic cell line RBL-2H3, described by Callan, M., et al., Proc Natl Acad Sci USA (1993) 9Q:10454 using the kat high e~iciency transduction system described by Finer, et al., Blood (1994) 83:43. Brie~ly, RBL-2H3 cells at 106 cells per well were cultured in 750 ml DMEMl~W +
20~ FBS (Gibco) and 16 ~g/ml polybrene with an equal volume o~
proviral supernatant ~or 2 hours at 37~C, 5~ CO2. One ml o~
medium was removed and 750 ~l o~ in~ection medium and retroviral supernatant were added to each well and the cultures incubated overnight. The cells were washed and expanded in DMEMl~W + 10~
FBS until su~icient cells were available ~or sorting. The CD4-zeta transduced RBL-2H3 cells were sorted using the FACSTAR plus W 096/34096 PCTrUS9J/05SOO
(Becton Dickinson). The cells were st~; neA ~or hllm~n CD4 with a mouse ant;hllm~n CD4- PE antibody and the top 2-3~ expressing cells were selected.
T~mlln;zationS were conducted as described in Example 1 using 10 x 106 cells per mouse except that the primary injection was subcutaneous at the base o$ the neck. The mice received ~
injections 2-3 weeks apart. Serum was prepared and analyzed by ELISA as described in Example 1 except that the initial coating o~ the ELISA plate utilized 100 ~l per well o~ recombinant soluble CD4 at 2 mg/ml of coating bu~fer. The titration curve for serum ~rom Xenomouse~ A207-1 after 6 injections is shown in Figure 4. Titers o~ hllm~n anti-CD4 reactivity were shown at concentrations representing greater than those at 1:1,000 dilution.
Example 5 Human Antibodies Aqainst ~llm~n L-selectin The antigen was prepared as a surface displayed protein in C51 cells, a high expressing clone derived by transfecting the mouse pre-B cell 300.19 with LAM-1 cDNA (hAM-1 is the gene encoding L-selectin) (Tedder, et al., J Tmmllnol (1990) 144:532) or with similarly transfected CHO cells. The trans~ected cells were sorted using ~luorescent activated cell sorting using anti-Leu-8 antibody as label.
The C51 and the trans~ected CHO cells were grown in DME 4.5 g/l glucose with 10~ FCS and 1 mg/ml G418 in 100 mm ~;~hec. Negative control cells, 3T3-P317 (trans~ected with gag/pol/env genes o~ Moloney virus) were grown in the same medium without G418.
Primary ;mmlln;zation was done by injection subcutaneously at the base o~ the neck; subsequent injections - were intraperitoneal. 70-100 million C51 or trans~ected CHO
cells were used per injection ~or a total o~ ~ive injections 2-3 weeks apart.
Sera were collected as described in Example 1 and analyzed by ELISA in a protocol s;m; 1~ to that set ~orth in Example 1.
W 096/34096 PCTrUS9~/05500 For the ELISA, the trans~ected cells were plated into 96 well plates and cell monolayers grown ~or 1-2 days depending on cell number and used ~or ELISA when con~luent. The cells were ~ixed by ~irst washing with cold 1 x PBS and then ~ixing solution (5~ glacial acetic acid, 95~ ethanol) was added. The plates were incubated at -25~C ~or 5 minutes and can be stored at this temperature i~ sealed with plate sealers.
The EhISA is begun by bringing the plates to room temperature, ~licking to remove ~ixing solution and w~h;ng 5 times with DMEM medium cont~;n;ng 10~ FCS at 200 ~l per well.
The wells were treated with various serum dilutions or with positive or negative controls. Positive control wells cont~;n~ murine IgG1 monoclonal antibody to human L-selectin.
The wells were incubated ~or 45 minutes and monolayer integrity was checked under a microscope. The wells were then incubated with either antimouse IgG (1/1000) or with ant;hllm;1n K
chain antibody or ant;hllm~n ~ chain antibody conjugates with HRP
described in Example 1. The plates were then washed with 1~
BSA/PBS and again with PBS and monolayer integrity was checked.
The plates were developed, stopped, and read as described above.
The results ~or serum ~rom ~n~mouse~ A303-3 are shown in Figs.
5 and 6; human antibodies both to L-selectin and control 3T3 cells were obt~;n~. However, the serum titers are higher ~or the L-selectin-expressing cells as compared to parental 3T3 cells. These results show that ~nomouse~ A303-3 produces antibodies speci~ic ~or L-selectin with hllm~n ~ heavy chain regions and/or hllm~n ~ light ~h~3; nc, T~T.T.~ were also per~ormed using as the immobilized antigen a ~usion protein consisting o~ the extracellular ~om~;n o~ hllm~n h-selectin ~used to the constant ~om~;n o~ human IgG
(Guo, et al., Cell Immunol (1994) 154:202). The L-selectin ~usion protein was made by transient trans~ection o~ hllm~n 293 cells using calcium phosphate trans~ection (Wigler, M., Cell (1979) 16:777). Serum preparation was per~ormed as described in Example 1. ELISAs were conducted essentially as in Example 1, except that the initial coating o~ the ELISA plate employed 100 ~l trans~ected 293 cell culture supernatant co~t~;n~ng the CA 022l9486 l997-l0-27 W 096/34096 PCTrUS95tO5500 L-selectin-Ig ~usion protein. Detection employed HRP-mouse ant; htlm~n K and HRP-goat antimouse IgG.
Figure 7 shows the results from ~r~nomouse~ A195-2;
antibodies speciEic ~or h-selectin having hnm~n K light ~h~;nc:
and/or h~lm~n variable regions with murine heavy chain ~ regions are present in the serum.
The antisera obtained ~rom the ;mmlln;zed x~nnm;ce were also tested for St~; n;ng of hllmAn neutrophils which express L-selectin. ~llm~n neutrophils were prepared as follows:
peripheral blood was collected from normal volunteers with 100 units/ml heparin. About 3.5 ml blood was layered over an e~ual volume o~ One-step Polymorph Gradient (Accurate Chemical, Westbury, NY) and spun for 30 minutes at 450 x g at 20~C. The neutrophil fraction was removed and w~h~i twice in DPBS/2~ FBS.
The neutrophils were then StA; ne~l with either:
(1) antiserum from ~nnmouse~ A195-2 ;mmlln;zed with C51 cells (expressing L-selectin);
(2) as a positive control, mouse monoclonal antibody ~AM1-3 (against L-selectin); and (3) as negative control, antiserum from a X~nomouse ;mmlln;zed with cells expressing hllm~n gp39.
The st~;n~l, w~h~-l neutrophils were analyzed by FACS.
The results f~or antiserum from Xenomouse~ A195-2 are shown in Figures 8 and 9.
These results show the presence of antibodies in ;mmnn;zed ~nnmouse~ serum which contain f~ully hllm~n variable regions ;mmllnoreactive with L-selectin. The negative control antiserum from mice ;mmlln;zed with gp39 does not contain antibodies reactive against hllm~n neutrophils. Serum from A195-2 (;mmlln;zed with L-selectin-expressing cells) contains antibodies binding to hllm~n neutrophils detectable with a goat - antimouse IgG antibody (Figure 8), which binds with heavy chain protein composed o~ ~ully hnm~n variable regions and mouse y - constant regions. St~;n;ng with anti L-selectin X~nomousen' antisera detected with a mouse monoclonal antibody against hllm~3n K chain antibody is shown in Figure 9, showing the presence oE
~ully hllm~n K light chain.
W 096/34096 PCTrUS95/05500 As explained above, thege antibodies cont~;n;ng hllm~n variable regions are readily convertible to ~ully human antibodies. For example, using hybridomas secreting these antibodies, the cDNAs encoding them can be obt~;n~. By ampli~ying the genes encoding human V regions using primers cont~;n;ng restriction enzyme recognition sites and cloning them into plasmids cont~;n;ng the coding sequences ~or human constant regions as described by Queen, et al., Proc Natl Acad Sci (1989) 86:10029, genes encoding the ~ully human antibodies can be obt~;ne~ ~or recombinant production.
Example 6 Human Antibodies Against Human gp39 gp39 (the ligand ~or CD40) is expressed on activated hllm~n CD4+ T cells. The sera o~ ~n~m;ce ;mmlln;zed with recombinant gp39 according to this example cont~;n~ antibodies ;mmllnospeci~iC ~or gp39 with ~ully human variable regions; the sera contained ~ully hllm~n IgM antibodies and ~h;m~ic IgG
antibodies cont~;n;ng human variable regions and murine constant heavy chain ~ region.
The antigen consisted o~ stable trans~ectants o~
300.19 cells or o~ CHO cells expressing gp39 cDNA cloned into the m~mm~lian expression vector PlRl.HUgp39/IRES NEO as shown in Figure 10. CHO cells were split 1:10 prior to trans~ection in DMEM 4.5 g/l glucose, 10~ FBS, 2 mM glut~m;ne, MEM, NEAA
supplemented with additional glycine, hypoxanthine and thymidine. The cells were cotrans~ected with the gp39 vector at 9 ~g/10 cm plate (6 X 105 cells) and the DHFR expressing vector pSV2DHFRs (Subranani et al . Mol Cell Biol (1981) 9:854) at 1 ~g/10 cm plate using calcium phosphate trans~ection. 24 hours later the cells were split 1:10 into the original medium cont~;n;ng G418 at 0.6 mg/ml. Cells producing gp39 were sorted by FACS using an anti-gp39 antibody.
Mice grouped as described in Example 1 were ;mmlln;zed with 300.19 cells expressing gp39 using a primary ;mmlln;zation subcutaneously at the base o~ the neck and with secondary intraperitoneal injections every 2-3 weeks. Sera were harvested as described in Example 1 ~or the ELISA assay. The EhISA
CA 022l9486 l997-l0-27 W 096/34096 PCTnUS95/05500 procedure was conducted substantially as set forth in Example 1;
the microtiter plates were coated with CHO cells expressing gp39 grown in a 100 mm dish in DMEM, 4.5 g/l glucose, 10~ FCS, 4 mM
glut~m;ne, and nonessential amino acid (NEAA) solution ~or MEM
(lOOX). On the day preceding the EhISA assay, the cells were trypsinized and plated into 96-well filtration plates at 105 cells/200 ~l well and incubated at 37~C overnight. The positive controls were mouse ant;hllm~n gp39; negative controls were antisera from mice ;mmlln;zed with an antigen other than gp39.
50 ~l of sample were used for each assay. The r~m~;nA~r of the assay is as described in Example 1.
The dilution curves for the sera obt~;neA after 4 injections from mice ;mml~n;zed with gp39 expressed on CHO cells are shown in Figure 11. As shown, the sera cont~;neA ant;hllm~n gp39 ;mmnnospecificity which is detectable with hllm~n K and hnm~n ~ chain antibodies coupled to HRP.
In addition, the sera were tested for their ability to react with activated hllm~n T cells included in PBMC using FACS
analysis. To prepare the PBMC, hllm~n peripheral blood was collected from normal volunteers with the addition of 100 unit/ml heparin. PBMC were isolated over Ficoll gradient and activated with 3 ,ug/ml PHA, 1 ~Lg/ml PMA in IMDM plus 10~ FBS
plus 25 ~M 2-mercaptoethanol for 4 hours. A~ter washing, the PBMC were st~;n~A with mouse Mab against hnm~n CD4 labeled with FITC to permit separation of CD4+ and CD4- hnm~n T cells.
The activated CD4+ and CD4- T cells were then analyzed by FACS using st~;n;ng with either:
1) antiserum from a ~onnmouse~ ;mmlln;zed with 300.19 cells producing gp39;
2) a positive control mouse Mab directed against ~-CD40L (hllm~n gp39); and - 3) a negative control antiserum from a ~nomouse~
;mmnn;zed with TNF.
The detecting antibody in the FACS analysis was goat antimouse IgG (PE). The results are shown in Figure 12.
As shown in Figure 12A, CD4+ (R2) and CD4- (R3) cells were separated prior to FACS analysis. Panel B shows the results for CD4+ cells and shows that sera from mice ;mmlln;zed W 096/34096 PCTrUS95/05500 with gp39 (labeled A247-4 in the ~igure) reacted with these activated CD4+ T cells; panel C shows that these sera did not react with CD4- cells. These antibodies carried murine heavy chain ~ constant regions. The results o~ panels B and C also con~irm that the TNF-injected ~nomouse~ did not make antibodies against gp39.
Example 7 Preparation o~ Hiqh-A~inity Human Mabs Against Tetanus Toxin The antibodies prepared in this example were secreted by hybridomas obtained by immortalizing B cells ~rom x~nnm; ce ;mmlln;zed with tetanus toxin. The ;mmlln;zation protocol was similar to that set ~orth in Example 1 using 50 ~g tetanus toxin emulsi~ied in complete Freund's adjuvant ~or intraperitoneal primary ;mmlln;zation ~ollowed by subsequent intraperitoneal injections with antigen incorporated into incomplete Freund's adjuvant. The mice received a total o~ 4 injections 2-3 weeks apart.
A~ter acceptable serum titers o~ antitetanus toxinC
(anti-TTC) were obt~;ne~, a ~inal ;mmlln;zation dose o~ antigen in PBS was given 4 days before the ~n;m~l S were sacri~iced and the spleens were harvested ~or ~usion.
The spleen cells were ~used with myeloma cells P3X63-Ag8.653 as described by Gal~re, G. and Milstein, C. Methods in Enzymoloqy (1981) 73:3-46.
A~ter ~usion the cells were resuspended in DMEM, 15~
FCS, cont~;n;ng HAT supplemented with glut~m;n~, pen/strep ~or culture at 37~C and 10~ C02. The cells were plated in microtiter trays and maint~; n~ in HAT-supplemented medium ~or two weeks be~ore trans~er to HAT-supplemented medium.
Supernatants from wells cont~;n;ng hybridomas were collected ~or a primary screen using an Ti~T.T.C~
The ELISA was conducted as described in Example 1 wherein the antigen coating consisted o~ 100 ~l/well o~ tetanus toxin C (TTC) protein at 2 mg/ml in coating bu~er, ~ollowed by ;ncllh~tion at 4~C overnight or at 37~C ~or two hours. In the primary F~T-T-C~, HRP-conjugated goat antimouse IgG at 1/2000 was W 096/34096 PCTnUS9510~500 used in addition to HRP mouse ant;hllm~n IgM as described in Example 1. Two hybridomas that secreted anti-TTC according to the ELISA assay, clone D5.1 and clone K4.1 were used for further analysis.
As shown in Figure 13, clone D5.1 secretes fully hllm~n anti-TTC which is detectable using HRP-conjugated ant;hllm~n Ghain antibody and HRP-conjugated antihllm~n ~ Gha~n antibody.
This is confirmed in Figures 18 and 19. Figure 14 shows that clone K4.1 secretes anti-TTC which is ;mmllnoreactive with antimurine ~ and ant;hllm~n ~ HRP-conjugated antibodies. Thus, clone K4.1 provides anti-TTC fully with hllm~n variable region as confirmed in Figures 16 and 17 and a murine constant heavy chain region.
The antibodies secreted by D5.1 and K4.1 did not ;mmllnoreact in ELISAs using TNF~, IL-6, or IL-8 as immobilized antigen under conditions where positive controls (sera from xenom;ce ;mmlln;zed with TNF~, IL-6 and IL-8 respectively) showed positive ELISA results.
The affinity of the monoclonal antibodies secreted by K4.1 for TTC antigen was determ;ned using commercially available reagents and instrumentation. BIAcore Instrument, CM5 sensor chips, sur~actant P20 and the amine coupling kit were purchased from phA~m~cia Biosensor (Piscataway, NJ). TTC was immobilized at two levels of antigen density on the surface of the sensor chips according to the manufacturer's instructions. Briefly, after washing and equilibrating the instrument with buf~er contA;n;ng surfactant, the surfaces were activated and the TCC
was immobilized.
For high antigen density, the surface was activated with 35 ~1 of equal volumes 0.1 M NHS and 0.1 M EDC injected across the sur~ace followed by 30 ~1 of TTC fragment at 100 ~g/ml in 10 mM sodium acetate buffer pH 5Ø The sur~ace was blocked by injecting 35 ~l 1 M ethanol~m;n~ and washed to e~--~ve noncovalently bound TCC using 5 ~l 0.1 M HCl. The entire immobilization procedure was conducted with a continuous flow of buffer at 5 ~l/min. This results in about 7500-8500 response units (RU) of TTC per chip. (1000 RU corresponds to about 1 ng o~ protein per mm2.) CA 022l9486 l997-l0-27 W 096/34096 PCTrUS95/05500 For chips with low antigen density, the procedure utilizes 15 ~l rather than 30 ~l o~ TTC, resulting in chips cont~;n;ng 550-950 RU.
Chips could be regenerated a~ter use in single det~rm;n~tions by injecting 10 ~l ~ormal or MgC12.
The chips are used to det~rm; n~ binding a~inities by determ; n; ng ka and kb (the association and dissociation rate constants) ~or the antibody with respect to the immobilized TTC.
The association rate constant is measured over six minutes at a flow rate of 5 ~l/min. at di~erent concentrations o~ K4.1 Mab in the range o~ 2.16 nm-69.33 nm. The dissociation rate constant is measured at a constant bu~er ~low rate o~ 5 ~l/min after completion o~ the antibody injection. The raw data are graphed in Figure 15 and the calculated results are shown in Table 1.
W 096/34096 PCTrUS9S/05S00 ~ o o ,C X
X 'I 'I
~ X
a U ~ o N
~ ~ a o O
~,, ~y o O
-- ~ X
a m, ~o g V g _ N .1 ~ v m o g S~ _ N N
- ~ ~ ~
~ t7-~ .~
P ~ n 0 ~ 'm ~ ~I
a.~ ~ ~ o t~ a~
r~
O O
m O ~1 rr~
~! ~ ~I) I
- ,d ~J
_, p pP
' m ,i 0 H a~
W 096/34096 PCTrUS95/05500 As shown, the K4.1 antibody has a binding constant (Ka) ~or TTC somewhat larger than 10l~ M-1.
The complete nucleotide sequence o~ the cDNAs encoding the heavy and light t-h~; n~ o~ the K4.1 and D5.1 monoclonals were det~rm;ne~ as shown in Figures 16-19. PolyA mRNA was isolated ~rom about 106 hybridoma cells and used to generate cDNA using r~n~om h~m~rs as primers. Portions o~ the product were ampli~ied by PCR using the appropriate primers.
Both cell lines were known to provide human K light ch~l; n~; ~or PCR ampli~ication oi~ light chain encoding cDNA, the primers used were HKP1 (5'-CTCTGTGACACTCTCCTGGGAGTT-3') for priming ~rom the constant region term;nll~ and two oligos, used in equal amounts to prime ~rom the variable segments: B3 (5'-CCACCATCAACTGCAAGTCCAGCCA-3') and B2/B1 (5'-GAAACGACACTCACGCAGTCTCCAGC-3').
For ampli~ication o~ the heavy chain ~rom K4.1 (which contains the murine ~1 constant region), the primers were MG-24Vi ~or the human variable regions:
5'-CAGGTGCAGCTGGAGCAGTCiGG-3' which, with inosine as shown recognizes the hllm~n variable regions VH1_2~ VH1_3' VH4 and VH6' and ~rom the constant region MG-25 i.e., 5'-GCACACCGCTGGACAGGGATCCAiAGTTTC-3~, which, cont~;n;ng inosine as shown recognizes murine ~ 2A, ~2B, and ~3.
For ampli~ication o~ the heavy chain o~ the antibody derived ~rom D5.1 (which contains the human ~ constant region), MG-24VI was used to prime ~rom the variable and ~P1 (5'-TTTT~ll"l~l-lGCCGTTGGGGTGC-3') was used to prime from the constant region t~rm;nllc.
Turning ~irst to the results shown in Figure 16 representing the heavy chain o~ the Mab secreted by K4.1, the sequence shows the presence o~ the human variable segment VH6, the hllm~n diversity region DN1, and the human joining segment JH4 linked to the murine ~1 constant region. Nine base-pair mutations ~rom the published germline sequence were present in the variable region, two o~ them within CDR2. One mutation was observed in the D segment. Three nongermline nucleotide additions were present in the DH-JH junction.
W 096/34096 PCTrUS95/05500 Referring to Figure 17 which shows the light chain of the K4.1 antibody, analysis shows the presence of the hnmAn K
variable region B3 and joining region JK4. Eight nucleotides are missing from B3 at the VR-JK junction and four mutations were found in the variable region. Five nongermline nucleotide additions were present at the VK-JK junction.
Referring now to Figure 18 which sets forth the sequence for the heavy chain of the antibody secreted by clone D5.1, this shows the heavy chain is comprised of the hnmAn variable fragment VH6, the h~lmAn diversity region DN1 and the hnmAn joining segment JH4 linked to the hnmAn ~ constant region.
There were two base-pair mutations from the germline sequence in the variable region, neither within the CDRs. Two additional mutations were in the D segment and six nongermline nucleotide additions were present at the DH-JH junction.
Finally, referring to Figure 19 which presents the light chain of the antibody secreted by D5.1, the hllmAn K
variable region B3 and hllmAn K joining region JK3 are shown.
There are nine base-pair differences from the germline sequences, three falling within CDR1.
Example 8 Production of Human Antibodies to IgE
A. Tmmlln;zation of Mice Germline ~h;me~iC mice contA;n;ng integrated hllmAn DNA
from the ;mmllnoglobulin loci were ;mmlln;zed by injection of 15-20 ~g of hllmAn IgE/~ in adjuvant. The mice were boosted with 15-20 ~g of hllmAn IgE/~ every 14 days after the primary ;mmlln;zation~ A bleed was done on the ;mmun;zed An;mAls to test the titer of serum antibodies against hllmAn IgE/~. The mice with the highest titers were sacrificed and the spleen removed.
B. Fusion of Splenocytes Myeloma cells, line P3X63-Ag8.653, used as the fusion partner for the spleen cells, were thawed 6 days prior to the fusion and grown in tissue culture. One day before the fusion, cells were split into fresh medium contA;n;ng 10~ fetal calf serum (FCS) at a ratio of 1:3.
. --CA 022l9486 l997-l0-27 W 096134096 PCTrUS9S/05S00 After sacri~icing the mouse, the spleen was aseptically removed and placed in a culture dish with serum-~ree culture medium. A single cell suspension was created by gently grinding the spleen between two ~rosted microscope slides. The cells were washed in f~resh serum-~ree medium red blood cells were lysed and debris ~iltered away.
The splenocytes were ~urther washed twice by centri~ugation in serum-~ree medium. Myeloma cells were also washed in serum-~ree medium at this time. Each cell type was 10 counted and co-mbined at a ratio of~ 1:3 (myeloma to splenocyte), m;~ gently and centri~uged once together.
A solution o~ 40~ polyethylene glycol (PEG) was slowly added to the cell pellet while the cells were gently resuspended over a period o~ one minute. Cells were incubated at room 15 temperature for one minute in the PEG solution and then slowly diluted into 5 ml serum-i~ree medium over 5 minutes. Five ml more were added over the next 90 seconds. Cells were incubated at room temperature f~or 5 minutes. The cells were centrifuged at low speed and the supernatant removed. The cells were 20 resuspended slowly and very gently in 5 ml o~ hybridoma medium cont~;n;ng 10~ FCS, lX OPI, lX NE amino acids and 10 mM HEPES.
Cells were ~urther diluted to 100 ml ~inal volume in hybridoma medium with lX HAT solution (hypoxanthine, aminopterin and thymidine). The ~used cells were aliquoted 100 ~l/well o~ 96-25 2311 plates and cultured at 37~C and 10~ CO2. Cells were fed at 10 days post-~usion with 100 ~l/well o~ hybridoma medium with lX
HT (hypoxanthine and thym;~;n~) and allowed to grow close to confluence be~ore screening.
Supernatant was aseptically taken ~rom each growing 30 well and tested ~or the presence oE ~ully hnm~3n antibodies.
Positive wells were ~urther tested ~or human IgE/~ speci~icity.
When a positive well was identi~ied, the cells were trans~erred i~rom the 96-well plate to 0 .5 ml o~ hybridoma medium with lX HT
in a 48-well plate. At this stage the cells were subcloned by 35 limiting dilution into 96-well plates so that a single antibody producing cell was in culture. As the culture became con~luent, the cells were ~n~ l to 1 ml, 3 ml, 5 ml, etc. and frozen CA 022l9486 l997-l0-27 W 096/34096 PCTrUS95/05500 aliquots were stored in liquid nitrogen to preserve the cell stocks.
Using the ~oregoing procedures, antibodies speci~ic ~or the antigens described above are prepared.
In accordance with the above procedure, mouse hybridomas producing h~m~n antibody against hllm~n IgE/~ were obtained.
In accordance with the above procedures, a ~h;m~ric nonhllm~n host, particularly a murine host, may be produced which can be ;mmlln;zed to produce hllm~n antibodies or analogs speci~ic ~or an ;mmllnQgen. In this m~nner, the problems associated with obt~;n;ng hllm~n monoclonal antibodies are avoided, because the transgenic host can be ;mmnn;zed with ;mmnnogens which could not be used with a hnm~n host. Furthermore~ one can provide ~or booster injections and adjuvants which would not be permitted with a hllm~n host. The resulting B cells may then be used ~or immortalization for the continuous production o~ the desired antibody. The immortalized cells may be used ~or isolation o~
the genes encoding the ;mmllnoglobulin or analog and be subjected to i~urther molecular modi~ication by methods such as in YitrO
mutagenesis or other techniques to modify the properties of the antibodies. These modi~ied genes may then be returned to the immortalized cells by trans~ection to provide ~or a continuous m~mm~lian cellular source o~ the desired antibodies. The subject invention provides ~or a convenient source o~ human antibodies, where the hllm~n antibodies are produced in analogous m~nn~r to the production o~ antibodies in a hnm~n host. The ~n;m~l host cells conveniently provide for the activation and rearrangement o~ hllmAn DNA in the host cells ~or production of hllm~n antibodies.
In accordance with the subject invention, hllm~n antibodies can be produced to hllm~n ;mm~lnogens, e.g., proteins, by ;mmlln;zation o~ the subject host m~mm~l with hllm~n ;mmnnogens~ The resulting antisera will be speci~ic ~or the hllm~ ;mmllnogen and may be harvested ~rom the serum o~ the host.
The ;mmlln;zed host B cells may be used for im-m--ortalization~
e.g., myeloma cell ~usion, trans~ection, etc. to provide immortal cells, e.g., hybridomas, to produce monoclonal antibodies. The antibodies, antiserum and monoclonal antibodies will be glycosylated in accordance with the species o~ the cell producing the antibodies. Rare variable regions o~ the Ig locus may be recruited in producing the antibodies, so that antibodies having rare variable regions may be obt~;ne~.
All productions and patent applications cited in this speci~ication are herein incorporated by re~erence as i~ each individual publication or patent application were speci~ically and individually indicated to be incorporated by re~erence.
Claims (49)
1. A method to produce an immunoglobulin having fully human variable region or an analog thereof, specific for a desired antigen, which method comprises:
administering said antigen or an immunogenic portion thereof to a nonhuman animal under conditions to stimulate an immune response, whereby said animal produces B cells that secrete immunoglobulin specific for said antigen; wherein said nonhuman animal is characterized by being substantially incapable of producing endogenous heavy and light immunoglobulin chain variable regions, but capable of producing human immunoglobulin variable regions; and recovering said immunoglobulin or analog.
administering said antigen or an immunogenic portion thereof to a nonhuman animal under conditions to stimulate an immune response, whereby said animal produces B cells that secrete immunoglobulin specific for said antigen; wherein said nonhuman animal is characterized by being substantially incapable of producing endogenous heavy and light immunoglobulin chain variable regions, but capable of producing human immunoglobulin variable regions; and recovering said immunoglobulin or analog.
2. The method of claim 1 wherein said recovering step comprises recovering polyclonal immunoglobulin or analog from said animal.
3. The method of claim 1 wherein said recovering step comprises immortalizing B cells from said animal immunized with said antigen, screening the resulting immortalized cells for the secretion of said immunoglobulin specific for said antigen, and 1) recovering immunoglobulin secreted by said immortalized B cells, or 2) recovering the genes encoding at least the variable region of said immunoglobulin from the immortalized B
cells, and optionally modifying said genes;
expressing said genes or modified forms thereof to produce immunoglobulin or analog; and recovering said immunoglobulin or analog.
cells, and optionally modifying said genes;
expressing said genes or modified forms thereof to produce immunoglobulin or analog; and recovering said immunoglobulin or analog.
4. The method of claim 1 wherein said recovering step comprises recovering genes encoding at least the variable region of immunoglobulins from the primary B cells of the animal immunized with said antigen;
generating a library of said genes expressing the variable regions;
screening the library for a variable region with desired affinity for the antigen;
recovering the genes encoding said variable regions and optionally modifying said genes;
expressing said recovered genes to produce an immunoglobulin or analog containing said variable region and recovering said immunoglobulin or analog.
generating a library of said genes expressing the variable regions;
screening the library for a variable region with desired affinity for the antigen;
recovering the genes encoding said variable regions and optionally modifying said genes;
expressing said recovered genes to produce an immunoglobulin or analog containing said variable region and recovering said immunoglobulin or analog.
5. The method of claim 1 wherein said immunoglobulin is fully human.
6. A recombinant DNA molecule comprising a nucleotide sequence encoding the immunoglobulin or analog produced by the method of claim 1.
7. A recombinant DNA molecule comprising an encoding nucleotide sequence corresponding to a gene prepared by a method comprising administering a desired antigen or an immunogenic portion thereof to a nonhuman animal under conditions to stimulate an immune response, whereby said animal produces B
cells that secrete immunoglobulin specific for said antigen;
wherein said nonhuman animal is characterized by being substantially incapable of producing endogenous heavy and light immunoglobulin chain variable regions, but capable of producing human immunoglobulin variable regions;
immortalizing B cells from said animal immunized with said antigen, screening the resulting immortalized cells for the secretion of said immunoglobulin specific for said antigen, and recovering the genes encoding at least the variable region of said immunoglobulin from the immortalized B cells, and optionally modifying said genes.
cells that secrete immunoglobulin specific for said antigen;
wherein said nonhuman animal is characterized by being substantially incapable of producing endogenous heavy and light immunoglobulin chain variable regions, but capable of producing human immunoglobulin variable regions;
immortalizing B cells from said animal immunized with said antigen, screening the resulting immortalized cells for the secretion of said immunoglobulin specific for said antigen, and recovering the genes encoding at least the variable region of said immunoglobulin from the immortalized B cells, and optionally modifying said genes.
8. A recombinant DNA molecule comprising an encoding nucleotide sequence corresponding to a gene prepared by a method comprising administering a desired antigen or an immunogenic portion thereof to a nonhuman animal under conditions to stimulate an immune response, whereby said animal produces B
cells that secrete immunoglobulin specific for said antigen;
wherein said nonhuman animal is characterized by being substantially incapable of producing endogenous heavy and light immunoglobulin chain variable regions, but capable of producing human immunoglobulin variable regions;
recovering genes encoding at least the variable region of immunoglobulins from the primary B cells of the animal immunized with said antigen;
generating a library of said genes expressing the variable regions;
screening the library for a variable region with desired affinity for the antigen; and recovering the genes encoding said variable regions and optionally modifying said genes.
cells that secrete immunoglobulin specific for said antigen;
wherein said nonhuman animal is characterized by being substantially incapable of producing endogenous heavy and light immunoglobulin chain variable regions, but capable of producing human immunoglobulin variable regions;
recovering genes encoding at least the variable region of immunoglobulins from the primary B cells of the animal immunized with said antigen;
generating a library of said genes expressing the variable regions;
screening the library for a variable region with desired affinity for the antigen; and recovering the genes encoding said variable regions and optionally modifying said genes.
9. The DNA molecule of claim 6, 7 or 8 wherein said encoding nucleotide sequence is operably linked to control sequences capable of effecting its expression.
10. A cell or cell line modified to contain the DNA
molecule of claim 9.
molecule of claim 9.
11. A method to produce an immunoglobulin with fully human variable region or an analog thereof which method comprises culturing the cells of claim 10 under conditions whereby said encoding nucleotide sequence is expressed to produce said immunoglobulin or analog; and recovering said immunoglobulin or analog.
12. An immortalized B cell which secretes an immunoglobulin with a fully human variable region to a desired antigen prepared by a method which comprises administering said antigen or an immunogenic portion thereof to a nonhuman animal under conditions to stimulate an immune response, whereby said animal produces B cells that secrete immunoglobulin specific for said antigen; wherein said nonhuman animal is characterized by being substantially incapable of producing endogenous heavy and light immunoglobulin chain variable regions, but capable of producing human immunoglobulin variable regions;
immortalizing B cells from said animal immunized with said antigen, screening the resulting immortalized cells for the secretion of said immunoglobulin specific for said antigen; and recovering said immortalized B cell.
immortalizing B cells from said animal immunized with said antigen, screening the resulting immortalized cells for the secretion of said immunoglobulin specific for said antigen; and recovering said immortalized B cell.
13. A method to produce an immunoglobulin or analog which comprises culturing the recovered cells of claim 12 and recovering said immunoglobulin or analog.
14. An immunoglobulin with fully human variable region or analog thereof produced by the method of claim 1.
15. The immunoglobulin or analog of claim 14 which is fully human.
16. The immunoglobulin or analog of claim 14 which is an agonist or a catalyst or wherein the immunoglobulin is chimeric.
17. The immunoglobulin or analog of claim 14 wherein the desired antigen is selected from the group consisting of transition state mimics; leukocyte markers; histocompatibility antigens; adhesion molecules; interleukins; interleukin receptors; chemokines; growth factors; growth factor receptors;
interferon receptors; Igs and their receptors; tumor antigens;
allergens; viral proteins; toxins; blood factors; enzymes; and the miscellaneous antigens ganglioside GD3, ganglioside GM2, LMP1, LMP2, eosinophil major basic protein, eosinophil cationic protein, pANCA, Amadori protein, Type IV collagen, glycated lipids, .gamma.-interferon, A7, P-glycoprotein, Fas (AFO-1) and oxidized-LDL.
interferon receptors; Igs and their receptors; tumor antigens;
allergens; viral proteins; toxins; blood factors; enzymes; and the miscellaneous antigens ganglioside GD3, ganglioside GM2, LMP1, LMP2, eosinophil major basic protein, eosinophil cationic protein, pANCA, Amadori protein, Type IV collagen, glycated lipids, .gamma.-interferon, A7, P-glycoprotein, Fas (AFO-1) and oxidized-LDL.
18. The immunoglobulin or analog of claim 17 wherein the leukocyte marker is selected from the group consisting of CD2, CD3, CD4, CD5, CD6, CD7, CD8, CD11a,b,c, CD13, CD14, CD18, CD19, CD20, CD22, CD23, CD27 and its ligand, CD28 and its ligands B7.1, B7.2, B7.3, CD29 and its ligand, CD30 and its ligand, CD40 and its ligand gp39, CD44, CD45 and isoforms, CDw52 (Campath antigen), CD56, CD58, CD69, CD72, CTLA-4, LFA-1 and TCR;
the histocompatibility antigen is selected from the group consisting of MHC class I or II, the Lewis Y antigens, SLex, SLey, SLea, and SLeb;
the adhesion molecule is selected from the group consisting of VLA-1, VLA-2, VLA-3, VLA-4, VLA-5, VLA-6, LFA-1, L-selectin, P-selectin, and E-selectin and their counterreceptors VCAM-1, ICAM-1, ICAM-2, LFA-3; Mac-1 and p150,95;
the interleukin is selected from the group consisting of IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, and IL-15;
the interleukin receptor is selected from the group consisting of IL-1R, IL-2R, IL-3R, IL-4R, IL-5R, IL-6R, IL-7R, IL-8R, IL-9R, IL-10R, IL-11R, IL-12R, IL-13R, IL-14R, and IL-15R;
the chemokine is selected from the group consisting of PF4, RANTES, MIP1.alpha., MCP1, NAP-2, Gro.alpha., Gro.beta., and IL-8;
the growth factor is selected from the group consisting of TNFalpha, TGFbeta, TSH, VEGF/VPF, PTHrP, EGF
family, FGF, PDGF family, endothelin, and gastrin releasing peptide (GRP);
the growth factor receptor is selected from the group consisting of TNFalphaR, RGFbetaR, TSHR, VEGFR/VPFR, FGFR, EGFR, PTHrPR, PDGFR family, EPO-R, GCSF-R and other hematopoietic receptors;
the interferon receptor is selected from the group consisting of IFN.alpha.R, IFN.beta.R, and IFN.gamma.R;
the Ig and its receptor is selected from the group consisting of IgE, FceRI, and FCeRII;
the tumor antigen is selected from the group consisting of her2-neu, mucin, CEA and endosialin;
the allergen is selected from the group consisting of house dust mite antigen, lol p1 (grass) antigens, and urushiol;
the viral protein is selected from the group consisting of CMV glycoproteins B, H, and gCIII, HIV-1 envelope glycoproteins, RSV envelope glycoproteins, HSV envelope glycoproteins, EBV envelope glycoproteins, VZV envelope glycoproteins, HPV envelope glycoproteins, Hepatitis family surface antigens;
the toxin is selected from the group consisting of pseudomonas endotoxin and osteopontin/uropontin, snake venom, and bee venom;
the blood factor is selected from the group consisting of complement C3b, complement C5a, complement C5b-9, Rh factor, fibrinogen, fibrin, and myelin associated growth inhibitor; and the enzyme is selected from the group consisting of cholesterol ester transfer protein, membrane bound matrix metalloproteases, and glutamic acid decarboxylase (GAD).
the histocompatibility antigen is selected from the group consisting of MHC class I or II, the Lewis Y antigens, SLex, SLey, SLea, and SLeb;
the adhesion molecule is selected from the group consisting of VLA-1, VLA-2, VLA-3, VLA-4, VLA-5, VLA-6, LFA-1, L-selectin, P-selectin, and E-selectin and their counterreceptors VCAM-1, ICAM-1, ICAM-2, LFA-3; Mac-1 and p150,95;
the interleukin is selected from the group consisting of IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, and IL-15;
the interleukin receptor is selected from the group consisting of IL-1R, IL-2R, IL-3R, IL-4R, IL-5R, IL-6R, IL-7R, IL-8R, IL-9R, IL-10R, IL-11R, IL-12R, IL-13R, IL-14R, and IL-15R;
the chemokine is selected from the group consisting of PF4, RANTES, MIP1.alpha., MCP1, NAP-2, Gro.alpha., Gro.beta., and IL-8;
the growth factor is selected from the group consisting of TNFalpha, TGFbeta, TSH, VEGF/VPF, PTHrP, EGF
family, FGF, PDGF family, endothelin, and gastrin releasing peptide (GRP);
the growth factor receptor is selected from the group consisting of TNFalphaR, RGFbetaR, TSHR, VEGFR/VPFR, FGFR, EGFR, PTHrPR, PDGFR family, EPO-R, GCSF-R and other hematopoietic receptors;
the interferon receptor is selected from the group consisting of IFN.alpha.R, IFN.beta.R, and IFN.gamma.R;
the Ig and its receptor is selected from the group consisting of IgE, FceRI, and FCeRII;
the tumor antigen is selected from the group consisting of her2-neu, mucin, CEA and endosialin;
the allergen is selected from the group consisting of house dust mite antigen, lol p1 (grass) antigens, and urushiol;
the viral protein is selected from the group consisting of CMV glycoproteins B, H, and gCIII, HIV-1 envelope glycoproteins, RSV envelope glycoproteins, HSV envelope glycoproteins, EBV envelope glycoproteins, VZV envelope glycoproteins, HPV envelope glycoproteins, Hepatitis family surface antigens;
the toxin is selected from the group consisting of pseudomonas endotoxin and osteopontin/uropontin, snake venom, and bee venom;
the blood factor is selected from the group consisting of complement C3b, complement C5a, complement C5b-9, Rh factor, fibrinogen, fibrin, and myelin associated growth inhibitor; and the enzyme is selected from the group consisting of cholesterol ester transfer protein, membrane bound matrix metalloproteases, and glutamic acid decarboxylase (GAD).
19. The immunoglobulin or analog of claim 14 wherein said desired antigen is selected from the group consisting of human IL-6, human IL-8, human TNF.alpha., human CD4, human L-selectin, human gp39, human IgE and tetanus toxin C(TTC).
20. A recombinant DNA molecule comprising a nucleotide sequence that encodes the immunoglobulin or analog of any of claims 15-19.
21. The DNA molecule of claim 20 wherein said encoding nucleotide sequence is operably linked to control sequences capable of effecting its expression.
22. A cell or cell line modified to contain the DNA
molecule of claim 21.
molecule of claim 21.
23. A method to produce an immunoglobulin or analog specific for a desired antigen which method comprises culturing the cell or cell line of claim 22 under conditions wherein said nucleotide sequence is expressed to produce said immunoglobulin or analog; and recovering the immunoglobulin or analog.
24. An antibody containing a fully human variable region or analog thereof which is specifically immunoreactive with an antigen selected from the group consisting of transition state mimics; leukocyte markers; histocompatibility antigens;
adhesion molecules; interleukins; interleukin receptors;
chemokines; growth factors; growth factor receptors; interferon receptors; Igs and their receptors; tumor antigens; allergens;
viral proteins; toxins; blood factors; enzymes; and the miscellaneous antigens ganglioside GD3, ganglioside GM2, LMP1, LMP2, eosinophil major basic protein, eosinophil cationic protein, pANCA, Amadori protein, Type IV collagen, glycated lipids, .gamma.-interferon, A7, P-glycoprotein, Fas (AFO-1) and oxidized-LDL.
adhesion molecules; interleukins; interleukin receptors;
chemokines; growth factors; growth factor receptors; interferon receptors; Igs and their receptors; tumor antigens; allergens;
viral proteins; toxins; blood factors; enzymes; and the miscellaneous antigens ganglioside GD3, ganglioside GM2, LMP1, LMP2, eosinophil major basic protein, eosinophil cationic protein, pANCA, Amadori protein, Type IV collagen, glycated lipids, .gamma.-interferon, A7, P-glycoprotein, Fas (AFO-1) and oxidized-LDL.
25. The antibody or analog of claim 24 wherein the leukocyte marker is selected from the group consisting of CD2, CD3, CD4, CD5, CD6, CD7, CD8, CD11a,b,c, CD13, CD14, CD18, CD19, CD20, CD22, CD23, CD27 and its ligand, CD28 and its ligands B7.1, B7.2, B7.3, CD29 and its ligand, CD30 and its ligand, CD40 and its ligand gp39, CD44, CD45 and isoforms, CDw52 (Campath antigen), CD56, CD58, CD69, CD72, CTLA-4, LFA-1 and TCR;
the histocompatibility antigen is selected from the group consisting of MHC class I or II, the Lewis Y antigens, SLex, SLey, SLea, and SLeb;
the adhesion molecule is selected from the group consisting of VLA-1, VLA-2, VLA-3, VLA-4, VLA-5, VLA-6, LFA-1, L-selectin, P-selectin, and E-selectin and their counterreceptors VCAM-1, ICAM-1, ICAM-2, LFA-3; Mac-1 and p150,95;
the interleukin is selected from the group consisting of IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, and IL-15;
the interleukin receptor is selected from the group consisting of IL-2R, IL-2R, IL-3R, IL-4R, IL-5R, IL-6R, IL-7R, IL-8R, IL-9R, IL-10R, IL-11R, IL-12R, IL-13R, IL-14R, and IL-15R;
the chemokine is selected from the group consisting of PF4, RANTES, MIP1.alpha., MCP1, NAP-2, Gro.alpha., Gro.beta., and IL-8;
the growth factor is selected from the group consisting of TNFalpha, TGFbeta, TSH, VEGF/VPF, PTHrP, EGF
family, FGF, PDGF family, endothelin, and gastrin releasing peptide (GRP);
the growth factor receptor is selected from the group consisting of TNFalphaR, RGFbetaR, TSHR, VEGFR/VPFR, FGFR, EGFR, PTHrPR, PDGFR family, EPO-R, GCSF-R and other hematopoietic receptors;
the interferon receptor is selected from the group consisting of IFN.alpha.R, IFN.beta.R, and IFN.gamma.R;
the Ig and its receptor is selected from the group consisting of IgE, FceRI, and FCeRII;
the tumor antigen is selected from the group consisting of her2-neu, mucin, CEA and endosialin;
the allergen is selected from the group consisting of house dust mite antigen, lol p1 (grass) antigens, and urushiol;
the viral protein is selected from the group consisting of CMV glycoproteins B, H, and gCIII, HIV-1 envelope glycoproteins, RSV envelope glycoproteins, HSV envelope glycoproteins, EBV envelope glycoproteins, VZV envelope glycoproteins, HPV envelope glycoproteins, Hepatitis family surface antigens;
the toxin is selected from the group consisting of pseudomonas endotoxin and osteopontin/uropontin, snake venom, and bee venom;
the blood factor is selected from the group consisting of complement C3b, complement C5a, complement C5b-9, Rh factor, fibrinogen, fibrin, and myelin associated growth inhibitor; and the enzyme is selected from the group consisting of cholesterol ester transfer protein, membrane bound matrix metalloproteases, and glutamic acid decarboxylase (GAD).
the histocompatibility antigen is selected from the group consisting of MHC class I or II, the Lewis Y antigens, SLex, SLey, SLea, and SLeb;
the adhesion molecule is selected from the group consisting of VLA-1, VLA-2, VLA-3, VLA-4, VLA-5, VLA-6, LFA-1, L-selectin, P-selectin, and E-selectin and their counterreceptors VCAM-1, ICAM-1, ICAM-2, LFA-3; Mac-1 and p150,95;
the interleukin is selected from the group consisting of IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, and IL-15;
the interleukin receptor is selected from the group consisting of IL-2R, IL-2R, IL-3R, IL-4R, IL-5R, IL-6R, IL-7R, IL-8R, IL-9R, IL-10R, IL-11R, IL-12R, IL-13R, IL-14R, and IL-15R;
the chemokine is selected from the group consisting of PF4, RANTES, MIP1.alpha., MCP1, NAP-2, Gro.alpha., Gro.beta., and IL-8;
the growth factor is selected from the group consisting of TNFalpha, TGFbeta, TSH, VEGF/VPF, PTHrP, EGF
family, FGF, PDGF family, endothelin, and gastrin releasing peptide (GRP);
the growth factor receptor is selected from the group consisting of TNFalphaR, RGFbetaR, TSHR, VEGFR/VPFR, FGFR, EGFR, PTHrPR, PDGFR family, EPO-R, GCSF-R and other hematopoietic receptors;
the interferon receptor is selected from the group consisting of IFN.alpha.R, IFN.beta.R, and IFN.gamma.R;
the Ig and its receptor is selected from the group consisting of IgE, FceRI, and FCeRII;
the tumor antigen is selected from the group consisting of her2-neu, mucin, CEA and endosialin;
the allergen is selected from the group consisting of house dust mite antigen, lol p1 (grass) antigens, and urushiol;
the viral protein is selected from the group consisting of CMV glycoproteins B, H, and gCIII, HIV-1 envelope glycoproteins, RSV envelope glycoproteins, HSV envelope glycoproteins, EBV envelope glycoproteins, VZV envelope glycoproteins, HPV envelope glycoproteins, Hepatitis family surface antigens;
the toxin is selected from the group consisting of pseudomonas endotoxin and osteopontin/uropontin, snake venom, and bee venom;
the blood factor is selected from the group consisting of complement C3b, complement C5a, complement C5b-9, Rh factor, fibrinogen, fibrin, and myelin associated growth inhibitor; and the enzyme is selected from the group consisting of cholesterol ester transfer protein, membrane bound matrix metalloproteases, and glutamic acid decarboxylase (GAD).
26. The antibody or analog of claim 24 wherein the desired antigen is selected from the group consisting of human IL-6, human IL-8, human TNF.alpha., human CD4, human L-selectin, human gp39, human IgE and tetanus toxin C(TTC).
27. The antibody or analog of claim 19 or 26 wherein the desired antigen is human IL-6.
28. The antibody or analog of claim 19 or 26 wherein the desired antigen is human IL-8.
29. The antibody or analog of claim 19 or 26 wherein the desired antigen is human TNF.alpha..
30. The antibody or analog of claim 19 or 26 wherein the desired antigen is human CD4.
31. The antibody or analog of claim 19 or 26 wherein the desired antigen is human L-selectin.
32. The antibody or analog of claim 19 or 26 wherein the desired antigen is human gp39.
33. The antibody or analog of claim 19 or 26 wherein the desired antigen is tetanus toxin C(TTC).
34. The antibody or analog of claim 19 or 26 wherein the desired antigen is human IgE.
35. The analog of claim 19 or 26 which is a single chain Fv.
36. The antibody or analog of claim 24 which is fully human,
37. The antibody or analog of claim 24 which is an agonist or is a catalyst or wherein the immunoglobulin is chimeric.
38. A recombinant DNA molecule encoding the antibody or analog of any of claims 26-37.
39. A recombinant DNA molecule which comprises an expression system for the production of the antibody or analog of any of claims 26-37 which expression system comprises a nucleotide sequence encoding said antibody or analog operably linked to control sequences capable of effecting its expression.
40. A recombinant host cell which is modified to contain the DNA molecule of claim 39.
41. A method to produce an antibody or analog which method comprises culturing the cells of claim 40 under conditions wherein said coding sequence is expressed; and recovering the antibody or analog produced.
42. Use of the antibody or analog of claim 36 for in vivo prophylaxis, therapy or diagnosis in humans.
43. Use of the antibody or analog of claim 27, 29, 30, 31 or 32 for treating an autoimmune disease in a mammal.
44. The use of claim 43 wherein the autoimmune disease is systemic lupus erythrematosus, rheumatoid arthritis, psoriasis, Sjogren's syndrome, scleroderma, mixed connective tissue disease, dermatomyositis, polymyositis, Reiter's syndrome, Behcet's disease, Type I diabetes, Hashimoto's thyroiditis, Graves' disease, multiple sclerosis, myasthenia gravis, or pemphigus.
45. Use of the antibody of claim 32 for preventing graft versus host disease, for preventing rejection of an organ transplant, or for treating glomerular nephritis in a mammal.
46. Use of the antibody of claim 31 for treating reperfusion ischemia in a mammal.
47. Use of the antibody of claim 27 for treating cachexia, septic shock, myeloma, renal cell carcinoma, osteoporosis, or Paget disease in a mammal.
48. Use of the antibody of claim 29 for treating septic shock, cachexia, osteoporosis, or systemic sclerosis in a mammal.
49. Use of the antibody of claim 28 for preventing tumor metastasis, and for treating asthma, rheumatoid arthritis, glomerulonephritis, reperfusion injury, adult respiratory distress syndrome, or systemic sclerosis in a mammal.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU24668/95A AU2466895A (en) | 1995-04-28 | 1995-04-28 | Human antibodies derived from immunized xenomice |
PCT/US1995/005500 WO1996034096A1 (en) | 1995-04-28 | 1995-04-28 | Human antibodies derived from immunized xenomice |
CA002219486A CA2219486A1 (en) | 1995-04-28 | 1995-04-28 | Human antibodies derived from immunized xenomice |
EP95918935A EP0823941A4 (en) | 1995-04-28 | 1995-04-28 | Human antibodies derived from immunized xenomice |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1995/005500 WO1996034096A1 (en) | 1995-04-28 | 1995-04-28 | Human antibodies derived from immunized xenomice |
CA002219486A CA2219486A1 (en) | 1995-04-28 | 1995-04-28 | Human antibodies derived from immunized xenomice |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2219486A1 true CA2219486A1 (en) | 1996-10-31 |
Family
ID=25679770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002219486A Abandoned CA2219486A1 (en) | 1995-04-28 | 1995-04-28 | Human antibodies derived from immunized xenomice |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0823941A4 (en) |
AU (1) | AU2466895A (en) |
CA (1) | CA2219486A1 (en) |
WO (1) | WO1996034096A1 (en) |
Families Citing this family (1455)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
US6300129B1 (en) * | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) * | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US7084260B1 (en) | 1996-10-10 | 2006-08-01 | Genpharm International, Inc. | High affinity human antibodies and human antibodies against human antigens |
US5795966A (en) † | 1995-02-22 | 1998-08-18 | Immunex Corp | Antagonists of interleukin-15 |
US7888466B2 (en) | 1996-01-11 | 2011-02-15 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor HSATU68 |
US6635743B1 (en) | 1996-03-22 | 2003-10-21 | Human Genome Sciences, Inc. | Apoptosis inducing molecule II and methods of use |
US7964190B2 (en) | 1996-03-22 | 2011-06-21 | Human Genome Sciences, Inc. | Methods and compositions for decreasing T-cell activity |
EP0966971A1 (en) | 1996-04-23 | 1999-12-29 | Chugai Seiyaku Kabushiki Kaisha | Cerebral stroke/cerebral edema preventive or remedy containing il-8 binding inhibitor as active ingredient |
AU4070897A (en) * | 1996-08-16 | 1998-03-06 | Kurt B. Osther | Method for treating diabetes |
AU2008200005B2 (en) * | 1996-12-03 | 2012-05-17 | Amgen Fremont Inc. | Transgenic Mammals Having Human Ig Loci Including Plural Vh and Vk Regions and Antibodies Produced Therefrom |
PT942968E (en) * | 1996-12-03 | 2008-03-27 | Amgen Fremont Inc | Fully human antibodies that bind egfr |
DK2011514T3 (en) | 1997-03-21 | 2012-03-26 | Chugai Pharmaceutical Co Ltd | Preventive or therapeutic agent for sensitized T cell mediated diseases comprising IL-6 antagonist as an active ingredient |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
US20020173629A1 (en) | 1997-05-05 | 2002-11-21 | Aya Jakobovits | Human monoclonal antibodies to epidermal growth factor receptor |
EP1004315B1 (en) | 1997-08-15 | 2008-05-21 | Chugai Seiyaku Kabushiki Kaisha | Preventives and/or remedies containing anti-il-6 receptor neutralizing antibodies for reducing the excretion of urinary protein in systemic lupus erythematosus |
EP1895001B1 (en) | 1998-11-04 | 2011-08-03 | Chugai Seiyaku Kabushiki Kaisha | Novel trypsin family serine proteases |
ES2251248T3 (en) | 1998-12-09 | 2006-04-16 | Protein Design Labs, Inc. | USE OF ANTIBODIES AGAINST IL-12 TO TREAT PSORIASIS. |
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
SI2112166T1 (en) | 1998-12-23 | 2019-05-31 | Pfizer Inc. | Human monoclonal antibodies to ctla-4 |
EE05627B1 (en) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | Human monoclonal antibodies to CTLA-4 |
EP1161451A4 (en) | 1999-02-26 | 2006-05-17 | Human Genome Sciences Inc | Human endokine alpha and methods of use |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
WO2000061744A1 (en) | 1999-04-09 | 2000-10-19 | Chugai Research Institute For Molecular Medicine, Inc. | Novel fetal genes |
WO2000067796A1 (en) | 1999-05-07 | 2000-11-16 | Genentech, Inc. | Treatment of autoimmune diseases with antagonists which bind to b cell surface markers |
SI2314315T1 (en) | 1999-06-01 | 2015-04-30 | Biogen Idec Ma Inc. | A blocking monoclonal antibody to the human alpha1 I-domain of VLA-1, and its use for the treatment of inflammatory disorders |
DE60043728D1 (en) | 1999-06-02 | 2010-03-11 | Chugai Pharmaceutical Co Ltd | NEW HEMOPOIETIN RECEPTOR PROTEIN NR10 |
US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
CA2380783C (en) * | 1999-07-29 | 2009-01-27 | Yashwant Deo | Human monoclonal antibodies to prostate specific membrane antigen |
TWI290832B (en) | 1999-08-23 | 2007-12-11 | Chugai Pharmaceutical Co Ltd | Expression enhancer for HM1.24 antigen |
CA2589418A1 (en) * | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
AU6871900A (en) | 1999-09-06 | 2001-04-10 | Chugai Seiyaku Kabushiki Kaisha | Tsg-like gene |
EP1223217A4 (en) | 1999-09-21 | 2003-06-25 | Chugai Pharmaceutical Co Ltd | Transporter genes oatp-b, c, d and e |
CA2388408A1 (en) | 1999-10-01 | 2001-04-12 | Chugai Seiyaku Kabushiki Kaisha | Prevention and treatment of diseases associated with blood coagulation |
BR0107799A (en) | 2000-01-24 | 2002-10-22 | Haruo Sugiyama | Wt1 interaction protein wtip |
SK12942002A3 (en) | 2000-02-10 | 2003-05-02 | Abbott Laboratories | Antibodies that bind human interleukin-18 and methods of making and using |
US6653448B1 (en) | 2000-03-29 | 2003-11-25 | Curagen Corporation | Wnt-7B-like polypeptides and nucleic acids encoding same |
GB0006398D0 (en) * | 2000-03-16 | 2000-05-03 | Novartis Ag | Organic compounds |
EP1832599A3 (en) | 2000-04-12 | 2007-11-21 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2001083755A2 (en) * | 2000-04-28 | 2001-11-08 | La Jolla Institute For Allergy And Immunology | Human anti-cd40 antibodies and methods of making and using same |
US7063845B2 (en) | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
ATE551363T1 (en) * | 2000-05-26 | 2012-04-15 | Immunex Corp | USE OF ANTIBODIES TO INTERLEUKIN-4 RECEPTOR AND COMPOSITIONS THEREOF |
US20030031675A1 (en) | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
EP2431054A3 (en) | 2000-06-15 | 2013-03-06 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta and epsilon |
NZ522700A (en) | 2000-06-16 | 2006-02-24 | Human Genome Sciences Inc | Antibodies that immunospecifically bind to blys |
EP2386575A3 (en) | 2000-06-29 | 2011-11-30 | Abbott Laboratories | Dual specificity antibodies and methods of making and using |
UA81743C2 (en) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS |
US7288390B2 (en) | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
US6902734B2 (en) | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
WO2002028481A2 (en) | 2000-10-02 | 2002-04-11 | Chiron Corporation | Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
AU1994402A (en) | 2000-11-28 | 2002-06-11 | Mediummune Inc | Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment |
DK1355919T3 (en) | 2000-12-12 | 2011-03-14 | Medimmune Llc | Molecules with longer half-lives, compositions and uses thereof |
CA2433800C (en) | 2001-01-05 | 2016-09-13 | Pfizer Inc. | Antibodies to insulin-like growth factor i receptor |
EP1373318A2 (en) * | 2001-01-26 | 2004-01-02 | Abgenix, Inc. | Neutralizing human monoclonal antibodies against hiv-1, their production and uses |
JP3986439B2 (en) | 2001-02-07 | 2007-10-03 | 中外製薬株式会社 | Hematopoietic tumor therapeutic agent |
EP1366058B1 (en) | 2001-02-09 | 2011-01-26 | Human Genome Sciences, Inc. | Human g-protein chemokine receptor (ccr5) hdgnr10 |
US7087726B2 (en) * | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
MXPA03008454A (en) | 2001-03-22 | 2004-06-30 | Abbott Gmbh & Co Kg | Transgenic animals expressing antibodies specific for genes of interest and uses thereof. |
UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
WO2002081641A2 (en) | 2001-04-06 | 2002-10-17 | Georgetown University | Gene scc-112 and diagnostic and therapeutic uses thereof |
AU2002258728A1 (en) | 2001-04-06 | 2002-10-21 | Georgetown University | Gene brcc-3 and diagnostic and therapeutic uses thereof |
AU2002303261A1 (en) | 2001-04-06 | 2002-10-21 | Georgetown University | Gene brcc2 and diagnostic and therapeutic uses thereof |
MXPA03009390A (en) | 2001-04-13 | 2004-01-29 | Biogen Inc | Antibodies to vla-1. |
ATE470676T1 (en) | 2001-04-13 | 2010-06-15 | Human Genome Sciences Inc | ANTI-VEGF-2 ANTIBODIES |
EP2009027B1 (en) | 2001-04-27 | 2014-05-21 | Kyowa Hakko Kirin Co., Ltd. | Anti-CD40 monoclonal antibody |
EP1463522A4 (en) | 2001-05-16 | 2005-04-13 | Einstein Coll Med | Human antipneumococcal antibodies from non-human animals |
DK1572874T3 (en) | 2001-05-25 | 2013-12-16 | Human Genome Sciences Inc | Antibodies that immunospecifically bind to TRAIL receptors |
EA014802B1 (en) | 2001-08-23 | 2011-02-28 | Генмаб А/С | HUMAN ANTIBODIES SPECIFIC FOR INTERLEUKIN 15 (IL-15)\ (VARIANTS), A METHOD OF PRODUCING THEREOF, AN IMMUNOCONJUGATE BASED THEREON, A TRANSFECTOMA, A HYBRIDOMA, A TRANSGENIC ANIMAL, AN EXPRESSION VECTOR (VARIANTS) AND NUCLEIC ACID FOR PRODUCING THEREOF, A METHOD OF TREATMENT (VARIANTS) AND DIAGNOSING AN IL-15 MEDIATED DISEASE, A METHOD OF INHIBITING IL-15 INDUCED TNF-α, AND A METHOD OF INHIBITING INDUCED IL-15 CELL PROLIFERATION. |
US7329405B2 (en) | 2001-08-23 | 2008-02-12 | Genmab A/S | Human antibodies specific for interleukin 15 (IL-15) |
US7247304B2 (en) | 2001-08-23 | 2007-07-24 | Genmab A/S | Methods of treating using anti-IL-15 antibodies |
US7981863B2 (en) | 2001-09-19 | 2011-07-19 | Neuronova Ab | Treatment of Parkinson's disease with PDGF |
WO2003029296A1 (en) * | 2001-10-02 | 2003-04-10 | Chiron Corporation | Human anti-cd40 antibodies |
AR039067A1 (en) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | ANTIBODIES FOR CD40 |
DK2319301T3 (en) | 2001-11-30 | 2017-12-04 | Amgen Fremont Inc | Transgenic animals with human Ig lambda light chain genes |
EP2277910A1 (en) | 2001-12-21 | 2011-01-26 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2005077042A2 (en) | 2004-02-09 | 2005-08-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2003104428A2 (en) | 2002-01-21 | 2003-12-18 | Vaccinex, Inc. | Gene differentially expressed in breast and bladder cancer and encoded polypeptides |
WO2003068259A1 (en) | 2002-02-14 | 2003-08-21 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing solution pharmaceuticals |
AU2003220930A1 (en) | 2002-03-29 | 2003-10-13 | Chugai Seiyaku Kabushiki Kaisha | Emthod of screening transporter inhibitor |
CN1326879C (en) | 2002-03-29 | 2007-07-18 | 先灵公司 | Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same |
US7244565B2 (en) | 2002-04-10 | 2007-07-17 | Georgetown University | Gene shinc-3 and diagnostic and therapeutic uses thereof |
AU2003226065B2 (en) | 2002-04-12 | 2009-02-26 | Ludwig Institute For Cancer Research, Ltd | Recombinant anti-interleukin-9 antibodies |
CN1652820A (en) | 2002-04-12 | 2005-08-10 | 梅达雷克斯公司 | Methods of treatment using CTLA-4 antibodies |
CA2429483A1 (en) | 2002-05-17 | 2003-11-17 | Amrad Operations Pty Ltd. | Immunointeractive molecules |
CN100532549C (en) | 2002-06-06 | 2009-08-26 | 肿瘤疗法科学股份有限公司 | Genes and polypeptides relating to human colon cancers |
CN101613405A (en) | 2002-06-06 | 2009-12-30 | 肿瘤疗法科学股份有限公司 | Gene relevant and polypeptide with human colon carcinoma |
US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
EA011686B1 (en) | 2002-07-15 | 2009-04-28 | Уайт | Method for modulating t helper (t) cell development |
EP2371389A3 (en) | 2002-08-14 | 2012-04-18 | MacroGenics, Inc. | FcgammaRIIB-specific antibodies and methods of use thereof |
WO2004019966A1 (en) | 2002-08-27 | 2004-03-11 | Chugai Seiyaku Kabushiki Kaisha | Method of stabilizing protein solution preparation |
CA2496400A1 (en) | 2002-09-09 | 2004-03-18 | Dana-Farber Cancer Institute, Inc. | Bh3 peptides and method of use thereof |
HUE027134T2 (en) | 2002-09-11 | 2016-10-28 | Chugai Pharmaceutical Co Ltd | Method of purifying protein |
TW200413725A (en) | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Method for diagnosing non-small cell lung cancers |
TW200418988A (en) | 2002-09-30 | 2004-10-01 | Oncotherapy Science Inc | Method for diagnosing prostate cancer |
SG146441A1 (en) | 2002-10-22 | 2008-10-30 | Eisai R&D Man Co Ltd | Gene specifically expressed in postmitotic dopaminergic neuron precursor cells |
EP1559786A4 (en) | 2002-10-30 | 2006-01-11 | Chugai Pharmaceutical Co Ltd | Mast cell-derived membrane proteins |
EP3299393A1 (en) | 2002-11-08 | 2018-03-28 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
US9320792B2 (en) | 2002-11-08 | 2016-04-26 | Ablynx N.V. | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
US20060034845A1 (en) | 2002-11-08 | 2006-02-16 | Karen Silence | Single domain antibodies directed against tumor necrosis factor alpha and uses therefor |
CN1787837A (en) | 2002-11-15 | 2006-06-14 | 希龙公司 | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
CA2537263C (en) | 2002-11-27 | 2017-05-30 | Minerva Biotechnologies Corporation | Techniques and compositions for the diagnosis and treatment of cancer (muc1) |
EP1578799B8 (en) | 2002-12-02 | 2011-03-23 | Amgen Fremont Inc. | Antibodies directed to tumor necrosis factor and uses thereof |
EP1589106B1 (en) | 2002-12-29 | 2010-12-01 | Toudai Tlo, Ltd. | Adiponectin receptor and gene coding for the same |
EP2368578A1 (en) | 2003-01-09 | 2011-09-28 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
DE10303974A1 (en) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid β (1-42) oligomers, process for their preparation and their use |
EP1638587A4 (en) | 2003-02-14 | 2007-04-18 | Univ Missouri | Contraceptive methods and compositions related to proteasomal interference |
ATE472338T1 (en) | 2003-02-20 | 2010-07-15 | Seattle Genetics Inc | ANTI-CD70 ANTIBODY DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER |
JP2007525434A (en) | 2003-03-19 | 2007-09-06 | アブジェニックス インコーポレイテッド | Antibodies to T cells, immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof. |
SI1606409T1 (en) | 2003-03-19 | 2011-01-31 | Biogen Idec Inc | Nogo receptor binding protein |
WO2004091510A2 (en) | 2003-04-11 | 2004-10-28 | Medimmune, Inc. | Recombinant il-9 antibodies and uses thereof |
WO2004092220A1 (en) * | 2003-04-14 | 2004-10-28 | Board Of Regents, The University Of Texas System | Methods for ex vivo hybridoma-free production of polyclonal and monoclonal antibodies and generation of immortalized cell populations |
GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
US9708410B2 (en) | 2003-05-30 | 2017-07-18 | Janssen Biotech, Inc. | Anti-tissue factor antibodies and compositions |
DE602004028249D1 (en) | 2003-06-18 | 2010-09-02 | Chugai Pharmaceutical Co Ltd | FUCOSETRANSPORTER |
CN102675462A (en) | 2003-06-27 | 2012-09-19 | 艾默根佛蒙特有限公司 | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
JP2008500005A (en) | 2003-07-15 | 2008-01-10 | バロス リサーチ インスティテュート | Compositions and methods for immunotherapy of cancer and infectious diseases |
HN2004000285A (en) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTIBODIES DIRECTED TO c-MET |
WO2005014818A1 (en) | 2003-08-08 | 2005-02-17 | Perseus Proteomics Inc. | Gene overexpressed in cancer |
CN1838968A (en) | 2003-08-08 | 2006-09-27 | 艾伯吉尼斯公司 | Antibodies aimed to parathyroid hormone (PTH) and uses thereof |
EP1668111A4 (en) | 2003-08-08 | 2008-07-02 | Genenews Inc | Osteoarthritis biomarkers and uses thereof |
WO2005014854A1 (en) | 2003-08-08 | 2005-02-17 | Licentia, Ltd. | Materials and methods for colorectal cancer screening, diagnosis, and therapy |
AR045563A1 (en) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | ANTIBODIES DIRECTED TO M-CSF |
WO2005035754A1 (en) | 2003-10-14 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
AU2003271174A1 (en) | 2003-10-10 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
KR101225463B1 (en) | 2003-11-07 | 2013-01-24 | 임뮤넥스 코포레이션 | Antibodies that bind interleukin-4 receptor |
US20050100965A1 (en) | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
US8454963B2 (en) * | 2003-11-13 | 2013-06-04 | Musc Foundation For Research Development | Tissue targeted complement modulators |
US7750123B2 (en) | 2003-11-25 | 2010-07-06 | Dana Farber Cancer Institute, Inc. | Antibodies against SARS-CoV and methods of use thereof |
EP2070947B1 (en) | 2003-12-05 | 2014-06-11 | multimmune GmbH | Therapeutic and diagnostic anti-Hsp70 antibodies |
US7312320B2 (en) | 2003-12-10 | 2007-12-25 | Novimmune Sa | Neutralizing antibodies and methods of use thereof |
CA2550651C (en) | 2003-12-23 | 2018-01-23 | Tanox, Inc. | Novel anti-il 13 antibodies and uses thereof |
PT1704166E (en) | 2004-01-07 | 2015-09-04 | Novartis Vaccines & Diagnostic | M-csf-specific monoclonal antibody and uses thereof |
PT2177537E (en) | 2004-01-09 | 2011-12-13 | Pfizer | Antibodies to madcam |
AU2005227313A1 (en) | 2004-03-19 | 2005-10-06 | Amgen Inc. | Reducing the risk of human and anti-human antibodies through V gene manipulation |
US7625549B2 (en) | 2004-03-19 | 2009-12-01 | Amgen Fremont Inc. | Determining the risk of human anti-human antibodies in transgenic mice |
TW200600785A (en) | 2004-03-23 | 2006-01-01 | Oncotherapy Science Inc | Method for diagnosing non-small cell lung cancer |
EP1786463A4 (en) | 2004-03-26 | 2009-05-20 | Human Genome Sciences Inc | Antibodies against nogo receptor |
CA2562771C (en) | 2004-04-12 | 2013-04-09 | Medimmune, Inc. | Anti-il-9 antibody formulations and uses thereof |
WO2005116657A2 (en) | 2004-05-24 | 2005-12-08 | Universität Zu Köln | Identification of ergothioneine transporter and therapeutic uses thereof |
US9228008B2 (en) | 2004-05-28 | 2016-01-05 | Idexx Laboratories, Inc. | Canine anti-CD20 antibodies |
US8921528B2 (en) | 2004-06-01 | 2014-12-30 | Domantis Limited | Bispecific fusion antibodies with enhanced serum half-life |
DK1773384T3 (en) | 2004-06-01 | 2015-11-23 | Us Agriculture | GM swine influenza virus and uses thereof |
EP1602926A1 (en) | 2004-06-04 | 2005-12-07 | University of Geneva | Novel means and methods for the treatment of hearing loss and phantom hearing |
ES2395094T3 (en) | 2004-06-24 | 2013-02-08 | Biogen Idec Ma Inc. | Treatment of conditions that involve demyelination |
CN1997670B (en) | 2004-07-01 | 2014-04-30 | 诺和诺德公司 | Human anti-KIR antibodies |
JP2008506681A (en) | 2004-07-16 | 2008-03-06 | ファイザー・プロダクツ・インク | Combination therapy for non-blood malignant tumors using anti-IGF-1R antibody |
CN101027390B (en) | 2004-07-22 | 2012-12-12 | 卫材R&D管理有限公司 | Lrp4/Corin dopamine-producing neuron precursor cell marker |
CN101014245A (en) | 2004-08-03 | 2007-08-08 | 比奥根艾迪克Ma公司 | Taj in neuronal function |
WO2006023544A2 (en) | 2004-08-16 | 2006-03-02 | Quark Biotech, Inc. | Therapeutic uses of inhibitors of rtp801 |
CA2478458A1 (en) | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
CA2486285C (en) | 2004-08-30 | 2017-03-07 | Viktor S. Goldmakher | Immunoconjugates targeting syndecan-1 expressing cells and use thereof |
US20060051347A1 (en) | 2004-09-09 | 2006-03-09 | Winter Charles M | Process for concentration of antibodies and therapeutic products thereof |
WO2006034292A2 (en) | 2004-09-21 | 2006-03-30 | Medimmune, Inc. | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
EP1805222B1 (en) | 2004-10-01 | 2011-02-02 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Antibodies directed to the mammalian eag1 ion channel protein |
US20080026457A1 (en) | 2004-10-22 | 2008-01-31 | Kevin Wells | Ungulates with genetically modified immune systems |
ES2679282T3 (en) | 2004-10-22 | 2018-08-23 | Revivicor Inc. | Transgenic pigs that lack endogenous immunoglobulin light chain |
AU2005299355A1 (en) | 2004-10-27 | 2006-05-04 | Medimmune, Llc | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
DE602005025525D1 (en) | 2004-11-17 | 2011-02-03 | Amgen Inc | COMPLETE HUMAN MONOCLONAL ANTIBODIES AGAINST IL-13 |
WO2006055871A2 (en) | 2004-11-19 | 2006-05-26 | Biogen Idec Ma Inc. | Treatment for multiple sclerosis |
GB0426146D0 (en) | 2004-11-29 | 2004-12-29 | Bioxell Spa | Therapeutic peptides and method |
SG157423A1 (en) | 2004-12-02 | 2009-12-29 | Domantis Ltd | Bispecific domain antibodies targeting serum albumin and glp-1 or pyy |
CA2585104A1 (en) | 2004-12-06 | 2006-06-15 | Kirin Beer Kabushiki Kaisha | Human monoclonal antibodies to influenza m2 protein and methods of making and using same |
ATE504602T1 (en) | 2004-12-20 | 2011-04-15 | Amgen Fremont Inc | BINDING PROTEINS SPECIFIC TO HUMAN MATRIPTASE |
SI1838733T1 (en) | 2004-12-21 | 2011-12-30 | Medimmune Ltd | Antibodies directed to angiopoietin-2 and uses thereof |
US20090061485A1 (en) | 2004-12-22 | 2009-03-05 | Chugai Seiyaku Kabushiki Kaisha | Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited |
JP2008528486A (en) | 2005-01-21 | 2008-07-31 | ジェネンテック・インコーポレーテッド | Fixed dose of HER antibody |
US7566772B2 (en) | 2005-01-26 | 2009-07-28 | Amgen Fremont Inc. | Antibodies against interleukin-1β |
CN103497993A (en) | 2005-02-07 | 2014-01-08 | 基因信息公司 | Mild osteoarthritis biomarkers and uses thereof |
CN101175862A (en) | 2005-02-10 | 2008-05-07 | 肿瘤疗法科学股份有限公司 | Method of diagnosing bladder cancer |
MX2007009811A (en) | 2005-02-14 | 2007-09-07 | Wyeth Corp | Interleukin-17f antibodies and other il-17f signaling antagonists and uses therefor. |
MX2007009810A (en) | 2005-02-14 | 2008-03-07 | Wyeth Corp | Use of il17-f in diagnosis and therapy of airway inflammation. |
WO2006089133A2 (en) | 2005-02-15 | 2006-08-24 | Duke University | Anti-cd19 antibodies and uses in oncology |
EP2332408B1 (en) | 2005-02-17 | 2013-11-13 | Biogen Idec MA Inc. | Treating neurological disorders |
EP1871807B1 (en) | 2005-02-18 | 2012-11-28 | Dana-Farber Cancer Institute, Inc. | Antibodies against cxcr4 and methods of use thereof |
TWI406870B (en) | 2005-02-21 | 2013-09-01 | Chugai Pharmaceutical Co Ltd | A method of making a protein using hamster IGF-1 |
ZA200707078B (en) | 2005-02-23 | 2008-11-26 | Genentech Inc | Extending time to disease progression or survival in cancer patients |
CN101166542A (en) | 2005-03-02 | 2008-04-23 | 比奥根艾迪克Ma公司 | KIM-1 antibodies for treatment of TH2-mediated conditions |
WO2006096565A2 (en) | 2005-03-04 | 2006-09-14 | Curedm Inc. | Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions |
WO2006096461A2 (en) | 2005-03-08 | 2006-09-14 | Pharmacia & Upjohn Company Llc | Composition comprising an antibody against macrophage colony-stimulating factor (m-csf) and a chelating agent |
ES2720288T3 (en) | 2005-03-30 | 2019-07-19 | Minerva Biotechnologies Corp | Proliferation of cells expressing MUC1 |
EP1875244B1 (en) | 2005-03-30 | 2019-01-23 | Minerva Biotechnologies Corporation | Proliferation of muc1 expressing cells |
CN101198698B (en) | 2005-03-31 | 2014-03-19 | 中外制药株式会社 | Process for production of polypeptide by regulation of assembly |
KR20140068234A (en) | 2005-03-31 | 2014-06-05 | 더 제너럴 하스피탈 코포레이션 | Monitoring and modulating hgf/hgfr activity |
PL3264094T3 (en) | 2005-04-04 | 2021-04-19 | Biogen Ma Inc. | Methods for evaluating an immune response to a therapeutic agent |
US20100003254A1 (en) | 2005-04-08 | 2010-01-07 | Chugai Seiyaku Kabushiki Kaisha | Antibody Substituting for Function of Blood Coagulation Factor VIII |
GT200600148A (en) | 2005-04-14 | 2006-11-22 | METHODS FOR THE TREATMENT AND PREVENTION OF FIBROSIS | |
JP5838021B2 (en) | 2005-04-15 | 2015-12-24 | マクロジェニクス,インコーポレーテッド | Covalently bonded diabody and its use |
US8604174B2 (en) | 2005-04-20 | 2013-12-10 | Amgen Inc. | High affinity fully human monoclonal antibodies to interleukin-8 |
US7807159B2 (en) | 2005-04-25 | 2010-10-05 | Amgen Fremont Inc. | Antibodies to myostatin |
CA2604357C (en) | 2005-04-26 | 2012-01-17 | Pfizer Inc. | P-cadherin antibodies |
PE20061324A1 (en) | 2005-04-29 | 2007-01-15 | Centocor Inc | ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES |
WO2006121852A2 (en) | 2005-05-05 | 2006-11-16 | Duke University | Anti-cd19 antibody therapy for autoimmune disease |
WO2006124269A2 (en) * | 2005-05-16 | 2006-11-23 | Amgen Fremont Inc. | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders |
NZ581779A (en) | 2005-05-17 | 2011-09-30 | Univ Connecticut | Composition and methods for immunomodulation in an organism comprising interleukin-15 polypeptide and interleukin-15 receptor subunit A polypeptide complex |
US7393919B2 (en) | 2005-05-25 | 2008-07-01 | Cure Dm, Inc. | Peptides, derivatives and analogs thereof, and methods of using same |
ME00261B (en) | 2005-05-27 | 2011-02-10 | Biogen Idec Inc | Tweak binding antibodies |
US8945543B2 (en) | 2005-06-10 | 2015-02-03 | Chugai Seiyaku Kabushiki Kaisha | Stabilizer for protein preparation comprising meglumine and use thereof |
MX2007016343A (en) * | 2005-06-22 | 2008-03-05 | Genentech Inc | Methods and compositions for targeting ifnar2. |
AU2006261920A1 (en) | 2005-06-23 | 2007-01-04 | Medimmune, Llc | Antibody formulations having optimized aggregation and fragmentation profiles |
WO2007005955A2 (en) | 2005-06-30 | 2007-01-11 | Centocor, Inc. | Anti-il-23 antibodies, compositions, methods and uses |
BRPI0613387A2 (en) | 2005-07-08 | 2011-01-11 | Biogen Idec Inc | isolated antibody or antigen binding fragment thereof and its use, isolated polynucleotide, composition, vector, host cell, anti-sp35 antibody and method for producing the same, isolated polypeptide, in vitro method for reducing inhibition of axonal growth and in vitro method for inhibiting cone collapse growth |
CN101273271A (en) | 2005-07-27 | 2008-09-24 | 肿瘤疗法科学股份有限公司 | Genes and polypeptides relating to prostate cancers |
US8652469B2 (en) | 2005-07-28 | 2014-02-18 | Novartis Ag | M-CSF-specific monoclonal antibody and uses thereof |
PT2573114T (en) | 2005-08-10 | 2016-07-13 | Macrogenics Inc | Identification and engineering of antibodies with variant fc regions and methods of using same |
US9309315B2 (en) | 2005-08-18 | 2016-04-12 | Genmab A/S | Therapy with CD4 binding peptides and radiation |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
EP2500359A3 (en) | 2005-08-19 | 2012-10-17 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
PT1915397E (en) | 2005-08-19 | 2015-04-30 | Univ Pennsylvania | Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders |
SG2014010029A (en) | 2005-08-19 | 2014-08-28 | Abbott Lab | Dual variable domain immunoglobin and uses thereof |
UY29783A1 (en) | 2005-09-07 | 2007-04-30 | Pfizer | HUMAN MONOCLONAL ANTIBODIES FOR KINASE-1 ACTIVINE RECEPTOR TYPE |
US9062126B2 (en) | 2005-09-16 | 2015-06-23 | Raptor Pharmaceuticals Inc. | Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof |
CA2623236A1 (en) | 2005-09-26 | 2007-04-05 | Medarex, Inc. | Human monoclonal antibodies to cd70 |
ES2542501T3 (en) | 2005-09-30 | 2015-08-06 | Abbvie Deutschland Gmbh & Co Kg | Protein binding domains of the protein family of repulsive targeting molecules (RGM) and functional fragments thereof, as well as their use |
CA2625773C (en) | 2005-10-14 | 2015-05-12 | Fukuoka University | Inhibition of interleukin-6 (il-6) receptor promotes pancreatic islet transplantation |
US8239136B2 (en) | 2005-10-21 | 2012-08-07 | Genenews Inc. | Method, computer system and computer-readable medium for determining a probability of colorectal cancer in a test subject |
AR058135A1 (en) | 2005-10-21 | 2008-01-23 | Chugai Pharmaceutical Co Ltd | AGENTS FOR THE TREATMENT OF CARDIOPATIAS |
MX2008005764A (en) | 2005-11-04 | 2008-11-18 | Biogen Idec Inc | Methods for promoting neurite outgrowth and survival of dopaminergic neurons. |
DK2500030T4 (en) | 2005-11-04 | 2018-10-29 | Genentech Inc | Use of complement pathway inhibitors for the treatment of eye diseases |
EA014900B1 (en) | 2005-11-07 | 2011-02-28 | Зе Скрипс Ресеч Инститьют | Compositions and methods for controlling tissue factor signaling specificity |
EP2548583A3 (en) | 2005-11-10 | 2013-02-27 | Curagen Corporation | Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen |
JP5398987B2 (en) | 2005-11-14 | 2014-01-29 | セルミド リミテッド | Method for treating and preventing diseases based on abnormal function of regulatory T cells |
AR057582A1 (en) | 2005-11-15 | 2007-12-05 | Nat Hospital Organization | AGENTS TO DELETE INDUCTION OF CYTOTOXIC T LYMPHOCYTES |
TWI461436B (en) | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | Human monoclonal antibody human cd134 (ox40) and methods of making and using same |
EP1967209B1 (en) | 2005-11-25 | 2012-06-06 | Keio University | Therapeutic agent for prostate cancer |
DK1963369T3 (en) | 2005-11-28 | 2013-06-03 | Zymogenetics Inc | IL-21 Antagonists |
RU2432362C2 (en) | 2005-11-30 | 2011-10-27 | Эбботт Лэборетриз | Monoclonal antibodies and applications thereof |
DK1954718T3 (en) | 2005-11-30 | 2014-12-15 | Abbvie Inc | Anti-A-globulomer antibodies antigenbindingsgrupper thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods for producing said antibodies, |
KR101453570B1 (en) | 2005-12-02 | 2014-10-22 | 제넨테크, 인크. | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r |
EP1979379B1 (en) | 2005-12-02 | 2013-09-18 | Dana-Farber Cancer Institute | Carbonic anhydrase ix (g250) antibodies and methods of use thereof |
MX2008007056A (en) | 2005-12-02 | 2008-11-12 | Sinai School Medicine | Chimeric viruses presenting non-native surface proteins and uses thereof. |
EP2543384A3 (en) | 2005-12-02 | 2013-04-10 | Biogen Idec MA Inc. | Treatment of conditions involving demyelination |
US8110194B2 (en) | 2005-12-07 | 2012-02-07 | Medarex, Inc. | CTLA-4 antibody dosage escalation regimens |
JP5302007B2 (en) | 2005-12-13 | 2013-10-02 | アストラゼネカ アクチボラグ | Binding protein specific for insulin-like growth factor and use thereof |
CN103396485B (en) | 2005-12-15 | 2016-08-10 | 健泰科生物技术公司 | The method and composition of targeting polyubiquitin |
US9084777B2 (en) | 2005-12-28 | 2015-07-21 | Chugai Seiyaku Kabushiki Kaisha | Stabilized antibody-containing formulations |
US7745587B2 (en) | 2005-12-30 | 2010-06-29 | Dyax Corp. | Antibodies that bind MMP-14 |
AR056857A1 (en) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | DIRECTED ANTIBODIES TO HER-3 (RECEIVER OF THE HUMAN EPIDERMAL GROWTH FACTOR-3) AND ITS USES |
ES2709672T3 (en) | 2006-01-12 | 2019-04-17 | Alexion Pharma Inc | Antibodies for OX-2 / CD200 and uses thereof |
TWI428143B (en) | 2006-01-18 | 2014-03-01 | Gen Hospital Corp | Methods of increasing lymphatic function |
DOP2007000015A (en) | 2006-01-20 | 2007-08-31 | Quark Biotech Inc | THERAPEUTIC USES OF RTP801 INHIBITORS |
EP1991580A2 (en) | 2006-01-25 | 2008-11-19 | Erasmus University Medical Center Rotterdam | Generation of heavy-chain only antibodies in transgenic animals |
US8771686B2 (en) | 2006-01-27 | 2014-07-08 | Chugai Seiyaku Kabushiki Kaisha | Methods for treating a disease involving choroidal neovascularization by administering an IL-6 receptor antibody |
EP2526968A3 (en) | 2006-01-27 | 2013-05-22 | Biogen Idec MA Inc. | Nogo receptor antagonists |
US7803561B2 (en) | 2006-02-06 | 2010-09-28 | Rhode Island Hospital | GPR30 estrogen receptor in breast cancers |
TW200744634A (en) | 2006-02-21 | 2007-12-16 | Wyeth Corp | Methods of using antibodies against human IL-22 |
TWI417301B (en) | 2006-02-21 | 2013-12-01 | Wyeth Corp | Antibodies against human il-22 and uses therefor |
EP2311478B1 (en) | 2006-03-20 | 2014-07-16 | Japan Science and Technology Agency | Use of ip3 receptor-binding protein for controlling intracellular pH |
US8278421B2 (en) | 2006-03-20 | 2012-10-02 | Xoma Techolology Ltd. | Human antibodies specific for gastrin materials and methods |
CA2638774C (en) | 2006-03-31 | 2015-11-24 | Medarex, Inc. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
EP3345616A1 (en) | 2006-03-31 | 2018-07-11 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
WO2007123791A2 (en) | 2006-03-31 | 2007-11-01 | Dana-Farber Cancer Institute | Methods of determining cellular chemosensitivity |
CA2647846C (en) | 2006-03-31 | 2016-06-21 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
EP2007428A2 (en) | 2006-04-05 | 2008-12-31 | Genentech, Inc. | Method for using boc/cdo to modulate hedgehog signaling |
CA2648644C (en) | 2006-04-07 | 2016-01-05 | Osaka University | Muscle regeneration promoter |
CA2648846A1 (en) | 2006-04-07 | 2007-10-18 | The Government Of The United States Of America As Represented By The Sec Retary, Department Of Health And Human Services | Antibody compositions and methods for treatment of neoplastic disease |
TW200813091A (en) | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
US20100080794A1 (en) | 2006-04-14 | 2010-04-01 | Takashi Tsuji | Mutant polypeptide having effector function |
EP2839843B1 (en) | 2006-05-25 | 2018-06-20 | Biogen MA Inc. | VLA-1 antagonist for use in treating stroke |
MX2008015132A (en) | 2006-05-30 | 2008-12-10 | Genentech Inc | Antibodies and immunoconjugates and uses therefor. |
KR20090027227A (en) | 2006-06-06 | 2009-03-16 | 제넨테크, 인크. | Anti-dll4 antibodies and methods using same |
WO2007142325A1 (en) | 2006-06-08 | 2007-12-13 | Chugai Seiyaku Kabushiki Kaisha | Preventive or remedy for inflammatory disease |
SG10201504662WA (en) | 2006-06-14 | 2015-07-30 | Macrogenics Inc | Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity |
DK2029173T3 (en) | 2006-06-26 | 2016-11-07 | Macrogenics Inc | FC-RIIB-specific antibodies and methods of use thereof |
US7572618B2 (en) | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
WO2008054561A2 (en) | 2006-07-11 | 2008-05-08 | University Of Medicine And Dentistry Of New Jersey | Proteins, nucleic acids encoding the same and associated methods of use |
US20100150927A1 (en) | 2006-07-13 | 2010-06-17 | Chugai Seiyaku Kabushiki Kaisha | Cell death inducer |
WO2008010101A2 (en) | 2006-07-18 | 2008-01-24 | Sanofi-Aventis | Antagonist antibody against epha2 for the treatment of cancer |
JP5175729B2 (en) | 2006-07-21 | 2013-04-03 | 中外製薬株式会社 | Kidney disease treatment |
MX2009001293A (en) | 2006-08-03 | 2009-02-11 | Astrazeneca Ab | Antibodies directed to â¿vãy6 and uses thereof. |
CL2007002225A1 (en) | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | SPECIFIC UNION AGENT FOR A RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES (PDGFR-ALFA); NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CONJUGADO UNDERSTANDING THE AGENT; AND USE OF THE AGENT OF A |
EP2057193B1 (en) | 2006-08-04 | 2013-12-18 | Novartis AG | Ephb3-specific antibody and uses thereof |
LT2511301T (en) | 2006-08-04 | 2018-04-10 | Medimmune Limited | Human antibodies to erbb 2 |
WO2008020586A1 (en) | 2006-08-14 | 2008-02-21 | Forerunner Pharma Research Co., Ltd. | Diagnosis and treatment of cancer using anti-desmoglein-3 antibody |
SI2059535T1 (en) | 2006-08-18 | 2014-03-31 | Novartis Ag | Prlr-specific antibody and uses thereof |
AU2007290570C1 (en) | 2006-08-28 | 2013-08-15 | Kyowa Kirin Co., Ltd. | Antagonistic human LIGHT-specific human monoclonal antibodies |
EP2471816A1 (en) | 2006-08-30 | 2012-07-04 | Genentech, Inc. | Multispecific antibodies |
JP5087625B2 (en) | 2006-09-01 | 2012-12-05 | セラピューティック・ヒューマン・ポリクローナルズ・インコーポレーテッド | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals |
ES2817756T3 (en) | 2006-09-08 | 2021-04-08 | Abbvie Bahamas Ltd | Interleukin-13 binding proteins |
CA2662236A1 (en) | 2006-09-12 | 2008-03-20 | Genentech, Inc. | Methods and compositions for the diagnosis and treatment of cancer |
EP2083017A4 (en) | 2006-09-14 | 2011-01-12 | Med & Biological Lab Co Ltd | Antibody having enhanced adcc activity and method for production thereof |
KR101161923B1 (en) | 2006-10-03 | 2012-07-03 | 유니버시티 오브 메디신 앤드 덴티스트리 오브 뉴 저지 | Atap peptides, nucleic acids encoding the same and associated methods of use |
WO2008045563A2 (en) | 2006-10-12 | 2008-04-17 | Wyeth | Modification of ionic strength in antibody-solutions to reduce opalescence/aggregates |
WO2008047723A1 (en) | 2006-10-12 | 2008-04-24 | Forerunner Pharma Research Co., Ltd. | Diagnosis and treatment of cancer using anti-ereg antibody |
EP2407548A1 (en) | 2006-10-16 | 2012-01-18 | MedImmune, LLC | Molecules with reduced half-lives, compositions and uses thereof |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
EP2093237B1 (en) | 2006-10-20 | 2015-12-30 | Chugai Seiyaku Kabushiki Kaisha | Anti-cancer agent comprising anti-hb-egf antibody as active ingredient |
JP5378795B2 (en) | 2006-10-20 | 2013-12-25 | 中外製薬株式会社 | Pharmaceutical composition comprising anti-HB-EGF antibody as an active ingredient |
US7846434B2 (en) | 2006-10-24 | 2010-12-07 | Trubion Pharmaceuticals, Inc. | Materials and methods for improved immunoglycoproteins |
LT2845866T (en) | 2006-10-27 | 2017-07-10 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
EP2094733A1 (en) | 2006-11-03 | 2009-09-02 | U3 Pharma GmbH | Fgfr4 antibodies |
CA2666317C (en) | 2006-11-03 | 2013-08-06 | Wyeth | Glycolysis-inhibiting substances in cell culture |
WO2008064306A2 (en) | 2006-11-22 | 2008-05-29 | Curedm, Inc. | Methods and compositions relating to islet cell neogenesis |
EP2101813B1 (en) | 2006-11-27 | 2014-04-02 | Patrys Limited | Novel glycosylated peptide target in neoplastic cells |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
EP2687232A1 (en) | 2006-12-06 | 2014-01-22 | MedImmune, LLC | Methods of treating systemic lupus erythematosus |
MX2009006034A (en) | 2006-12-07 | 2009-10-12 | Novartis Ag | Antagonist antibodies against ephb3. |
WO2008072723A1 (en) | 2006-12-14 | 2008-06-19 | Forerunner Pharma Research Co., Ltd. | ANTI-Claudin-3 MONOCLONAL ANTIBODY, AND TREATMENT AND DIAGNOSIS OF CANCER USING THE SAME |
AU2007333805B2 (en) | 2006-12-18 | 2013-07-25 | Genentech, Inc. | Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases |
CN103405768A (en) | 2006-12-20 | 2013-11-27 | 爱克索马技术有限公司 | Methods for the treatment of IL-1[beta] related diseases |
PT2099826E (en) | 2007-01-05 | 2014-01-09 | Univ Zuerich | Anti-beta-amyloid antibody and uses thereof |
WO2008081942A1 (en) | 2007-01-05 | 2008-07-10 | The University Of Tokyo | Diagnosis and treatment of cancer by using anti-prg-3 antibody |
ES2673153T3 (en) | 2007-01-09 | 2018-06-20 | Biogen Ma Inc. | Sp35 antibodies and uses thereof |
US8128926B2 (en) | 2007-01-09 | 2012-03-06 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
AU2008205512B2 (en) | 2007-01-16 | 2014-06-12 | Abbvie Inc. | Methods for treating psoriasis |
US9725514B2 (en) | 2007-01-23 | 2017-08-08 | Shinshu University | Chronic rejection inhibitor |
BRPI0806403A2 (en) | 2007-02-09 | 2011-09-06 | Genentech Inc | anti-robo4 antibody, use an antibody and imaging method |
EP2119777A4 (en) | 2007-02-09 | 2011-05-25 | Eisai R&D Man Co Ltd | Gaba neuron progenitor cell marker 65b13 |
WO2008101184A2 (en) | 2007-02-16 | 2008-08-21 | The Board Of Trustees Of Southern Illinois University | Arl-1 specific antibodies |
US8685666B2 (en) | 2007-02-16 | 2014-04-01 | The Board Of Trustees Of Southern Illinois University | ARL-1 specific antibodies and uses thereof |
KR101508397B1 (en) | 2007-02-22 | 2015-04-08 | 제넨테크, 인크. | Methods for detecting inflammatory bowel disease |
JP5374360B2 (en) | 2007-02-27 | 2013-12-25 | 中外製薬株式会社 | Pharmaceutical composition comprising anti-GRP78 antibody as an active ingredient |
US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
PL2132573T3 (en) | 2007-03-02 | 2014-09-30 | Genentech Inc | Predicting response to a her dimerisation inhbitor based on low her3 expression |
CL2008000719A1 (en) | 2007-03-12 | 2008-09-05 | Univ Tokushima Chugai Seiyaku | THERAPEUTIC AGENT FOR CANCER RESISTANT TO CHEMOTHERAPEUTIC AGENTS THAT UNDERSTAND AN ANTIBODY THAT RECOGNIZES IT CLASS I AS ACTIVE INGREDIENT; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH ANTIBODY; AND METHOD TO TREAT CANCER RESISTANT TO |
EP3159355A1 (en) | 2007-03-13 | 2017-04-26 | Universität Zürich | Monoclonal human tumor-specific antibody |
TWI417299B (en) | 2007-03-22 | 2013-12-01 | Biogen Idec Inc | Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof |
US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
WO2008118324A2 (en) | 2007-03-26 | 2008-10-02 | Macrogenics, Inc. | Composition and method of treating cancer with an anti-uroplakin ib antibody |
US20100209434A1 (en) | 2007-03-30 | 2010-08-19 | Medimmune, Llc | Antibody formulation |
SG182985A1 (en) | 2007-04-02 | 2012-08-30 | Amgen Fremont Inc | Anti-ige antibodies |
NO3072525T3 (en) | 2007-05-14 | 2018-06-30 | ||
EP2158335A2 (en) | 2007-05-21 | 2010-03-03 | Genetech, Inc. | Methods and compositions for identifying and treating lupus |
JP5117765B2 (en) | 2007-05-28 | 2013-01-16 | 国立大学法人 東京大学 | Tumor diagnostic agent for PET containing anti-ROBO1 antibody |
ES2417148T3 (en) | 2007-06-08 | 2013-08-06 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
EP2170390B1 (en) | 2007-06-14 | 2018-11-07 | Biogen MA Inc. | Natalizumab antibody formulations |
EP3424951A1 (en) | 2007-06-21 | 2019-01-09 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
SG10202005450PA (en) | 2007-07-09 | 2020-07-29 | Genentech Inc | Prevention of disulfide bond reduction during recombinant production of polypeptides |
WO2009014263A1 (en) | 2007-07-26 | 2009-01-29 | Osaka University | Agent for treatment of ophthalmia containing interleukin-6 receptor inhibitor as active ingredient |
US8012474B2 (en) | 2007-08-02 | 2011-09-06 | Nov Immune S.A. | Anti-RANTES antibodies |
CN108117584B (en) | 2007-08-20 | 2021-08-24 | 肿瘤疗法科学股份有限公司 | FOXM1 peptides and medicaments comprising FOXM1 peptides |
CA2696701C (en) | 2007-08-20 | 2017-01-24 | Oncotherapy Science, Inc. | Cdca1 peptide and pharmaceutical agent comprising the same |
MX2010002018A (en) | 2007-08-20 | 2010-05-27 | Oncotherapy Science Inc | Cdh3 peptide and medicinal agent comprising the same. |
EP2615114B1 (en) | 2007-08-23 | 2022-04-06 | Amgen Inc. | Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) |
JOP20080381B1 (en) | 2007-08-23 | 2023-03-28 | Amgen Inc | Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9) |
MX338474B (en) | 2007-08-29 | 2016-04-18 | Sanofi Aventis | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses. |
EP2570431A3 (en) | 2007-08-30 | 2013-05-01 | CureDM Group Holdings, LLC | Compositions and methods of using proislet peptides and analogs thereof |
EP2527369A3 (en) | 2007-09-13 | 2012-12-19 | University Of Zurich Prorektorat Forschung | Monoclonal amyloid beta (abeta)-specific antibody and uses thereof |
WO2009040134A1 (en) | 2007-09-26 | 2009-04-02 | U3 Pharma Gmbh | Heparin-binding epidermal growth factor-like growth factor antigen binding proteins |
CN106519025B (en) | 2007-09-26 | 2021-04-23 | 中外制药株式会社 | Method for changing isoelectric point of antibody by using amino acid substitution of CDR |
AU2008304111B2 (en) | 2007-09-27 | 2014-04-24 | Amgen Inc. | Pharmaceutical formulations |
KR20100085067A (en) | 2007-09-28 | 2010-07-28 | 추가이 세이야쿠 가부시키가이샤 | Anti-glypican-3 antibody having improved kinetics in plasma |
CN101815532B (en) | 2007-10-02 | 2012-08-15 | 中外制药株式会社 | Remedy for graft-versus-host disease comprising interleukin-6 receptor inhibitor as the active ingredient |
US9683027B2 (en) | 2007-10-15 | 2017-06-20 | Chugai Seiyaku Kabushiki Kaisha | Method for production of antibody |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
SG185316A1 (en) | 2007-10-19 | 2012-11-29 | Immunas Pharma Inc | ANTIBODY CAPABLE OF SPECIFICALLY BINDING TO Aβ OLIGOMER, AND USE THEREOF |
EP2230300A4 (en) | 2007-10-24 | 2012-08-08 | Otsuka Chemical Holdings Co Ltd | Polypeptide having enhanced effector function |
PE20091163A1 (en) | 2007-11-01 | 2009-08-09 | Wyeth Corp | ANTIBODIES FOR GDF8 |
EP2219452B1 (en) | 2007-11-05 | 2015-10-14 | MedImmune, LLC | Methods of treating scleroderma |
PT2514436T (en) | 2007-11-07 | 2018-03-21 | Genentech Inc | Il-22 for use in treating microbial disorders |
KR101620642B1 (en) | 2007-11-07 | 2016-05-12 | 제넨테크, 인크. | Methods and compositions for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies |
US8933202B2 (en) | 2007-11-12 | 2015-01-13 | U3 Pharma Gmbh | AXL antibodies |
AU2008321840B2 (en) | 2007-11-14 | 2014-02-06 | Chugai Seiyaku Kabushiki Kaisha | Diagnosis and treatment of cancer using anti-GPR49 antibody |
BRPI0820543A2 (en) | 2007-11-15 | 2015-06-16 | Chugai Pharmaceutical Co Ltd | Monoclonal antibody capable of binding to annexelekto, and use of it |
US8796206B2 (en) | 2007-11-15 | 2014-08-05 | Amgen Inc. | Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration |
EP2225275A4 (en) | 2007-11-28 | 2013-04-03 | Medimmune Llc | Protein formulation |
AR069501A1 (en) | 2007-11-30 | 2010-01-27 | Genentech Inc | ANTI-VEGF ANTIBODIES (VASCULAR ENDOTELIAL GROWTH FACTOR) |
ES2585480T3 (en) | 2007-12-05 | 2016-10-06 | Chugai Seiyaku Kabushiki Kaisha | Anti-NR10 antibody and use thereof |
US8431127B2 (en) | 2007-12-05 | 2013-04-30 | Chugai Seiyaku Kabushiki Kaisha | Method for treating pruritus comprising administering an NR10 antagonist |
WO2009079259A2 (en) | 2007-12-06 | 2009-06-25 | Dana-Farber Cancer Institute, Inc. | Antibodies against influenza virus and methods of use thereof |
WO2009075344A1 (en) | 2007-12-12 | 2009-06-18 | Japan As Represented By Director General Of Agency Of National Cancer Center | Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof |
DK2391650T3 (en) | 2007-12-20 | 2015-01-12 | Xoma Us Llc | Methods of treating gout |
CA2710483C (en) | 2007-12-26 | 2018-05-08 | Biotest Ag | Methods and agents for improving targeting of cd138 expressing tumor cells |
CN101952315B (en) | 2007-12-26 | 2015-04-01 | 生物测试股份公司 | Agents targeting CD138 and uses thereof |
AR069979A1 (en) | 2007-12-26 | 2010-03-03 | Biotest Ag | METHOD FOR DECREASING SECONDARY CYTOTOXIC EFFECTS AND IMPROVING THE EFFECTIVENESS OF IMMUNOCATE PLAYERS |
KR101654822B1 (en) | 2007-12-26 | 2016-09-06 | 바이오테스트 아게 | Immunoconjugates targeting cd138 and uses thereof |
PE20091174A1 (en) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT |
US8962806B2 (en) | 2007-12-28 | 2015-02-24 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
KR20100107501A (en) | 2008-01-18 | 2010-10-05 | 메디뮨 엘엘씨 | Cysteine engineered antibodies for site-specific conjugation |
US9175078B2 (en) | 2008-01-25 | 2015-11-03 | Amgen Inc. | Ferroportin antibodies and methods of use |
CN102124105A (en) | 2008-02-08 | 2011-07-13 | 伊缪纳斯制药株式会社 | Antibody capable of binding specifically to Abeta-oligomer, and use thereof |
BR122020023189B1 (en) | 2008-02-08 | 2022-02-01 | Astrazeneca Ab | Use of a pharmaceutical composition comprising an antibody specific for ifnar1 |
US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
EP2274333A4 (en) | 2008-03-18 | 2011-06-15 | Abbott Lab | Methods for treating psoriasis |
EP2260102A1 (en) | 2008-03-25 | 2010-12-15 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating cancer by down-regulating frizzled-4 and/or frizzled-1 |
NZ601815A (en) | 2008-03-31 | 2014-10-31 | Genentech Inc | Compositions and methods for treating and diagnosing asthma |
CL2009000647A1 (en) | 2008-04-04 | 2010-06-04 | Chugai Pharmaceutical Co Ltd | Pharmaceutical composition for treating or preventing liver cancer comprising a combination of a chemotherapeutic agent and an anti-glypican 3 antibody; agent for attenuating a side effect comprising said antibody; method of treating or preventing liver cancer of a subject. |
WO2009124109A1 (en) | 2008-04-04 | 2009-10-08 | The Government Of The U.S. A. As Represented By The Secretary Of The Dept. Of Health &Human Services | Human monoclonal antibodies specific for cd22 |
EP2275443B1 (en) | 2008-04-11 | 2015-12-02 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
EP3348573B1 (en) | 2008-04-25 | 2020-04-22 | Dyax Corp. | Method of producing antibodies against fcrn and use thereof |
NZ588554A (en) | 2008-04-29 | 2013-03-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
EP2620448A1 (en) | 2008-05-01 | 2013-07-31 | Amgen Inc. | Anti-hepcidin antibodies and methods of use |
CA2723197C (en) | 2008-05-02 | 2017-09-19 | Seattle Genetics, Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
MY159667A (en) | 2008-05-09 | 2017-01-13 | Abbvie Inc | Antibodies to receptor of advanced glycation end products (rage) and uses thereof |
WO2009148896A2 (en) | 2008-05-29 | 2009-12-10 | Nuclea Biotechnologies, LLC | Anti-phospho-akt antibodies |
EP2283862B1 (en) | 2008-06-02 | 2018-08-08 | The University of Tokyo | Combination treatment of cancer comprising anti-mfg-e8 antibody |
CN102112495A (en) | 2008-06-03 | 2011-06-29 | 雅培制药有限公司 | Dual variable domain immunoglobulins and uses thereof |
MX2010013236A (en) | 2008-06-03 | 2011-02-24 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof. |
TWI528973B (en) | 2008-06-05 | 2016-04-11 | Chugai Pharmaceutical Co Ltd | Nerve infiltration inhibitor |
NZ589795A (en) | 2008-06-16 | 2013-02-22 | Patrys Ltd | Use of LM-1 antibody which binds to NONO/nmt55 protein to prevent metastasis |
WO2009154025A1 (en) | 2008-06-20 | 2009-12-23 | 国立大学法人岡山大学 | ANTIBODY AGAINST OXIDIZED LDL/β2GPI COMPLEX AND USE OF THE SAME |
US8187601B2 (en) | 2008-07-01 | 2012-05-29 | Aveo Pharmaceuticals, Inc. | Fibroblast growth factor receptor 3 (FGFR3) binding proteins |
EP2810654A1 (en) | 2008-07-08 | 2014-12-10 | AbbVie Inc. | Prostaglandin E2 binding proteins and uses thereof |
RU2011104348A (en) | 2008-07-08 | 2012-08-20 | Эбботт Лэборетриз (Us) | IMMUNOGLOBULINS WITH DOUBLE VARIABLE DOMAIN AGAINST PROSTAGLANDINE E2 AND THEIR APPLICATION |
US8058406B2 (en) | 2008-07-09 | 2011-11-15 | Biogen Idec Ma Inc. | Composition comprising antibodies to LINGO or fragments thereof |
DK2318832T3 (en) | 2008-07-15 | 2014-01-20 | Academia Sinica | Glycan arrays on PTFE-like aluminum coated slides and related methods |
AU2009281713B9 (en) | 2008-08-14 | 2014-05-29 | Teva Pharmaceuticals Australia Pty Ltd | Anti-IL-12/IL-23 antibodies |
JP5685535B2 (en) | 2008-08-18 | 2015-03-18 | ファイザー インコーポレイティッド | Antibodies against CCR2 |
US20120128684A1 (en) | 2008-08-25 | 2012-05-24 | Burnham Institute For Medical Research | Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use |
CA2734905A1 (en) | 2008-09-03 | 2010-03-11 | Jenny M. Bostrom | Multispecific antibodies |
MX2011002478A (en) | 2008-09-07 | 2011-04-05 | Glyconex Inc | Anti-extended type i glycosphingolipid antibody, derivatives thereof and use. |
AU2009294415B2 (en) | 2008-09-19 | 2015-09-24 | Medimmune Llc | Antibodies directed to DLL4 and uses thereof |
US20100075329A1 (en) | 2008-09-23 | 2010-03-25 | O'toole Margot | Methods for predicting production of activating signals by cross-linked binding proteins |
PL2346994T3 (en) | 2008-09-30 | 2022-04-19 | Ablexis, Llc | Knock-in mice for the production of chimeric antibodies |
KR20110069144A (en) | 2008-10-09 | 2011-06-22 | 미네르바 바이오테크놀로지 코포레이션 | Method for inducing pluripotency in cells |
JP2012505900A (en) | 2008-10-14 | 2012-03-08 | ダイアクス コーポレーション | Use of an IGF-II / IGF-IIE binding protein for the treatment and prevention of pulmonary fibrosis associated with systemic scleroderma |
SG10201605250SA (en) | 2008-10-14 | 2016-08-30 | Genentech Inc | Immunoglobulin variants and uses thereof |
CA2741523C (en) | 2008-10-24 | 2022-06-21 | Jonathan S. Towner | Human ebola virus species and compositions and methods thereof |
EP2348827B1 (en) | 2008-10-27 | 2015-07-01 | Revivicor, Inc. | Immunocompromised ungulates |
US10118962B2 (en) | 2008-10-29 | 2018-11-06 | Ablynx N.V. | Methods for purification of single domain antigen binding molecules |
AU2009333791B2 (en) | 2008-10-29 | 2013-04-04 | Ablynx N.V. | Formulations of single domain antigen binding molecules |
WO2010052288A1 (en) | 2008-11-07 | 2010-05-14 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research | Teneurin and cancer |
EP3101031A1 (en) | 2008-11-10 | 2016-12-07 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
EP2191842A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
EP2191841A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
EP2191840A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
EP2191843A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
CN104479018B (en) | 2008-12-09 | 2018-09-21 | 霍夫曼-拉罗奇有限公司 | Anti- PD-L1 antibody and they be used to enhance the purposes of T cell function |
CN106432503B (en) | 2008-12-19 | 2020-03-06 | 宏观基因有限公司 | Covalent diabodies and uses thereof |
SI2370466T1 (en) | 2008-12-19 | 2015-11-30 | Biogen International Neuroscience Gmbh | Human anti-alpha-synuclein autoantibodies |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
EP2377921B1 (en) | 2008-12-22 | 2016-04-13 | Eisai R&D Management Co., Ltd. | Method for obtaining pancreatic progenitor cell using neph3 |
JP2012513194A (en) | 2008-12-23 | 2012-06-14 | アストラゼネカ アクチボラグ | Targeted binding agents directed to α5β1 and uses thereof |
CN102264759B (en) | 2008-12-23 | 2016-05-11 | 弗·哈夫曼-拉罗切有限公司 | Immunoglobulin variants with the Binding change of albumin A |
EP2377891B1 (en) | 2008-12-26 | 2018-11-21 | The University of Tokyo | Diagnosis and treatment of cancer using anti-lgr7 antibody |
AU2009334498A1 (en) | 2008-12-31 | 2011-07-21 | Biogen Idec Ma Inc. | Anti-lymphotoxin antibodies |
CA2749572A1 (en) | 2009-01-14 | 2010-07-22 | Iq Therapeutics Bv | Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins |
WO2010085510A1 (en) | 2009-01-20 | 2010-07-29 | Zadeh Homayoun H | Antibody mediated osseous regeneration |
US8852608B2 (en) | 2009-02-02 | 2014-10-07 | Medimmune, Llc | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
US8309530B2 (en) | 2009-02-04 | 2012-11-13 | Washington State University | Compositions and methods for modulating ghrelin-mediated conditions |
US9085795B2 (en) | 2009-02-04 | 2015-07-21 | Molecular Innovations, Inc. | Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin and antibodies |
EP2396035A4 (en) | 2009-02-12 | 2012-09-12 | Human Genome Sciences Inc | Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance |
RU2011140335A (en) | 2009-03-05 | 2013-04-10 | Эбботт Лэборетриз | BINDING IL-17 PROTEINS |
WO2010100247A1 (en) | 2009-03-06 | 2010-09-10 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research | Novel therapy for anxiety |
JP2010210772A (en) | 2009-03-13 | 2010-09-24 | Dainippon Screen Mfg Co Ltd | Method of manufacturing liquid crystal display device |
US8597652B2 (en) | 2009-03-20 | 2013-12-03 | Genentech, Inc. | Multispecific anti-HER antibodies |
EP2411412B1 (en) | 2009-03-24 | 2015-05-27 | Teva Biopharmaceuticals USA, Inc. | Humanized antibodies against light and uses thereof |
AU2010234849B2 (en) | 2009-03-30 | 2017-06-22 | Mount Sinai School Of Medicine | Influenza virus vaccines and uses thereof |
NZ595005A (en) | 2009-04-01 | 2014-04-30 | Genentech Inc | Treatment of insulin-resistant disorders |
US20100297127A1 (en) | 2009-04-08 | 2010-11-25 | Ghilardi Nico P | Use of il-27 antagonists to treat lupus |
US8647623B2 (en) | 2009-04-10 | 2014-02-11 | Kyowa Hakko Kirin Co., Ltd | Method for treatment of blood tumor using anti-TIM-3 antibody |
EP2241323A1 (en) | 2009-04-14 | 2010-10-20 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Tenascin-W and brain cancers |
KR20110138412A (en) | 2009-04-16 | 2011-12-27 | 애보트 바이오테라퓨틱스 코포레이션 | ANTI-TNF-α ANTIBODIES AND THEIR USES |
WO2010119704A1 (en) | 2009-04-17 | 2010-10-21 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
JP5836929B2 (en) | 2009-04-18 | 2015-12-24 | ジェネンテック, インコーポレイテッド | Method for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibody |
CN104558179A (en) | 2009-04-27 | 2015-04-29 | 协和发酵麒麟株式会社 | Anti-iL-3R[alpha] antibody for use in treatment of blood tumor |
WO2010126972A1 (en) | 2009-04-29 | 2010-11-04 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Erg monoclonal antibodies |
KR20120051603A (en) | 2009-05-01 | 2012-05-22 | 고쿠리츠다이가쿠호징 도쿄다이가쿠 | Anti-cadherin antibody |
PE20160652A1 (en) | 2009-05-05 | 2016-07-09 | Novimmune Sa | ANTIBODIES THAT JOIN IL-17F |
CA2800182A1 (en) | 2009-05-26 | 2010-12-02 | Mount Sinai School Of Medicine | Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof |
WO2010137654A1 (en) | 2009-05-29 | 2010-12-02 | 株式会社未来創薬研究所 | Pharmaceutical composition containing antagonist of egf family ligand as component |
US20100316639A1 (en) | 2009-06-16 | 2010-12-16 | Genentech, Inc. | Biomarkers for igf-1r inhibitor therapy |
WO2010148223A2 (en) | 2009-06-17 | 2010-12-23 | Facet Biotech Corporation | Anti-vegf antibodies and their uses |
RU2012101999A (en) | 2009-06-22 | 2013-07-27 | МЕДИММЬЮН, ЭлЭлСи | Fc RECOMBINED SITES FOR SITE-SPECIFIC CONJUGATION |
CN102481380A (en) | 2009-07-09 | 2012-05-30 | 霍夫曼-拉罗奇有限公司 | In vivo tumor vasculature imaging |
WO2011006001A1 (en) | 2009-07-09 | 2011-01-13 | Genentech, Inc. | Animal model for the evaluation of adjuvant therapies of cancer |
KR20120106935A (en) | 2009-07-13 | 2012-09-27 | 제넨테크, 인크. | Diagnostic methods and compositions for treatment of cancer |
WO2011014504A1 (en) | 2009-07-27 | 2011-02-03 | Mount Sinai School Of Medicine Of New York University | Recombinant influenza virus vectors and uses thereof |
WO2011014457A1 (en) | 2009-07-27 | 2011-02-03 | Genentech, Inc. | Combination treatments |
JP5845180B2 (en) | 2009-07-30 | 2016-01-20 | モウント シナイ スクール オフ メディシネ | Influenza viruses and their use |
TWI523661B (en) | 2009-07-31 | 2016-03-01 | Shin Maeda | Anti-IL-6 receptor antibody in the manufacture of inhibitors of metastatic inhibition of lung cancer metastasis to the liver |
US20110027275A1 (en) | 2009-07-31 | 2011-02-03 | Napoleone Ferrara | Inhibition of tumor metastasis |
AU2010280981B2 (en) | 2009-08-05 | 2016-01-28 | Nexigen Gmbh | Human HCV-interacting proteins and methods of use |
EP2462161B1 (en) | 2009-08-06 | 2017-03-08 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
ES2614949T3 (en) | 2009-08-06 | 2017-06-02 | Immunas Pharma, Inc. | Antibodies that specifically bind to beta A oligomers and use thereof |
WO2011019620A1 (en) | 2009-08-10 | 2011-02-17 | Genentech, Inc. | Antibodies with enhanced adcc function |
RU2017138926A (en) | 2009-08-11 | 2019-02-11 | Дженентек, Инк. | PRODUCTION OF PROTEINS IN CULTURAL MEDIA WITHOUT GLUTAMINE |
DK2464664T3 (en) | 2009-08-13 | 2016-01-18 | Crucell Holland Bv | ANTIBODIES AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) AND METHODS FOR USING IT |
WO2011019622A1 (en) | 2009-08-14 | 2011-02-17 | Genentech, Inc. | Cell culture methods to make antibodies with enhanced adcc function |
RU2012109556A (en) | 2009-08-14 | 2013-09-20 | Дженентек, Инк. | BIOLOGICAL MARKERS FOR MONITORING THE PATIENT'S RESPONSE TO VEGF ANTAGONISTS |
AU2010285974A1 (en) | 2009-08-17 | 2012-03-22 | Forerunner Pharma Research Co., Ltd. | Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient |
WO2011024114A1 (en) | 2009-08-25 | 2011-03-03 | Ecole Polytechnique Federale De Lausanne (Epfl) | Targeting extracellular matrix molecules for the treatment of cancer |
EP2292266A1 (en) | 2009-08-27 | 2011-03-09 | Novartis Forschungsstiftung, Zweigniederlassung | Treating cancer by modulating copine III |
AU2010286518C1 (en) | 2009-08-29 | 2015-08-27 | Abbvie Inc. | Therapeutic DLL4 binding proteins |
SG178602A1 (en) | 2009-09-01 | 2012-04-27 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
WO2011028950A1 (en) | 2009-09-02 | 2011-03-10 | Genentech, Inc. | Mutant smoothened and methods of using the same |
WO2011028945A1 (en) | 2009-09-03 | 2011-03-10 | Genentech, Inc. | Methods for treating, diagnosing, and monitoring rheumatoid arthritis |
US20110064670A1 (en) | 2009-09-11 | 2011-03-17 | Genentech, Inc. | Method to identify a patient with an increased likelihood of responding to an anti-cancer agent |
CN102630168A (en) | 2009-09-14 | 2012-08-08 | 雅培制药有限公司 | Methods for treating psoriasis |
CA2772670A1 (en) | 2009-09-17 | 2011-03-24 | F. Hoffmann-La Roche Ag | Methods and compositions for diagnostics use in cancer patients |
US20120244170A1 (en) | 2009-09-22 | 2012-09-27 | Rafal Ciosk | Treating cancer by modulating mex-3 |
TW201118166A (en) | 2009-09-24 | 2011-06-01 | Chugai Pharmaceutical Co Ltd | HLA class I-recognizing antibodies |
US8926976B2 (en) | 2009-09-25 | 2015-01-06 | Xoma Technology Ltd. | Modulators |
JP5885664B2 (en) | 2009-09-25 | 2016-03-15 | ゾーマ テクノロジー リミテッド | Screening method |
EP2305285A1 (en) | 2009-09-29 | 2011-04-06 | Julius-Maximilians-Universität Würzburg | Means and methods for treating ischemic conditions |
CA2775880A1 (en) | 2009-09-30 | 2011-04-07 | Genentech, Inc. | Anti-notch3 antagonist antibodies to treat gamma secretase inhibitor responsive and anti-notch1 antagonist antibody unresponsive t-cell leukemias |
AR078470A1 (en) | 2009-10-02 | 2011-11-09 | Sanofi Aventis | ANTIBODIES THAT SPECIFICALLY JOIN THE EPHA2 RECEIVER |
JP5898082B2 (en) | 2009-10-07 | 2016-04-06 | マクロジェニクス,インコーポレーテッド | Fc region-containing polypeptide exhibiting improved effector function by changing the degree of fucosylation and use thereof |
EP3839068A3 (en) | 2009-10-07 | 2021-10-20 | F. Hoffmann-La Roche AG | Methods for treating, diagnosing, and monitoring lupus |
EP3349010A1 (en) | 2009-10-11 | 2018-07-18 | Biogen MA Inc. | Anti-vla-4 related assays |
WO2011045352A2 (en) | 2009-10-15 | 2011-04-21 | Novartis Forschungsstiftung | Spleen tyrosine kinase and brain cancers |
EP2488658A4 (en) | 2009-10-15 | 2013-06-19 | Abbvie Inc | Dual variable domain immunoglobulins and uses thereof |
WO2011056497A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor type iib compositions and methods of use |
WO2011056494A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations |
EP2494356B1 (en) | 2009-10-26 | 2017-03-15 | Genentech, Inc. | Assays for detecting antibodies specific to therapeutic anti-ige antibodies and their use in anaphylaxis |
WO2011056502A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Bone morphogenetic protein receptor type ii compositions and methods of use |
ES2639056T3 (en) | 2009-10-28 | 2017-10-25 | Abbvie Biotherapeutics Inc. | Anti-EGFR antibodies and their uses |
UY32979A (en) | 2009-10-28 | 2011-02-28 | Abbott Lab | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
US20120213801A1 (en) | 2009-10-30 | 2012-08-23 | Ekaterina Gresko | Phosphorylated Twist1 and cancer |
WO2011053707A1 (en) | 2009-10-31 | 2011-05-05 | Abbott Laboratories | Antibodies to receptor for advanced glycation end products (rage) and uses thereof |
WO2011060015A1 (en) | 2009-11-11 | 2011-05-19 | Genentech, Inc. | Methods and compositions for detecting target proteins |
TWI630916B (en) | 2009-11-13 | 2018-08-01 | 第一三共歐洲公司 | Materials and methods for treating or preventing her-3 associated diseases |
US9260517B2 (en) | 2009-11-17 | 2016-02-16 | Musc Foundation For Research Development | Human monoclonal antibodies to human nucleolin |
KR101573109B1 (en) | 2009-11-24 | 2015-12-01 | 메디뮨 리미티드 | Targeted binding agents against b7-h1 |
US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
US9175075B2 (en) | 2009-12-08 | 2015-11-03 | AbbVie Deutschland GmbH & Co. KG | Methods of treating retinal nerve fiber layer degeneration with monoclonal antibodies against a retinal guidance molecule (RGM) protein |
WO2011071577A1 (en) | 2009-12-11 | 2011-06-16 | Genentech, Inc. | Anti-vegf-c antibodies and methods using same |
EP2513148B1 (en) | 2009-12-16 | 2016-08-31 | AbbVie Biotherapeutics Inc. | Anti-her2 antibodies and their uses |
AU2010339770B2 (en) | 2009-12-21 | 2015-02-12 | Genentech, Inc. | Antibody formulation |
DK2516465T3 (en) | 2009-12-23 | 2016-06-06 | Hoffmann La Roche | ANTI-BV8 ANTIBODIES AND APPLICATIONS THEREOF |
PT3459564T (en) | 2010-01-06 | 2022-01-31 | Takeda Pharmaceuticals Co | Plasma kallikrein binding proteins |
NZ601111A (en) | 2010-01-11 | 2014-07-25 | Alexion Pharma Inc | Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies |
TWI505838B (en) | 2010-01-20 | 2015-11-01 | Chugai Pharmaceutical Co Ltd | Stabilized antibody |
JP5104996B2 (en) | 2010-01-29 | 2012-12-19 | 東レ株式会社 | Polylactic acid resin sheet |
CN102892787B (en) | 2010-02-10 | 2015-04-29 | 富士胶片Ri制药株式会社 | Radioactive metal-labeled anti-cadherin antibody |
JP5841072B2 (en) | 2010-02-10 | 2016-01-06 | イミュノジェン・インコーポレーテッド | CD20 antibody and use thereof |
MX342716B (en) | 2010-02-18 | 2016-10-11 | Sinai School Medicine | Vaccines for use in the prophylaxis and treatment of influenza virus disease. |
EP2536761B1 (en) | 2010-02-19 | 2017-09-20 | The Board Of Regents Of The University Of Oklahoma | Monoclonal antibodies that inhibit the wnt signaling pathway and methods of production and use thereof |
BR112012021941A2 (en) | 2010-03-02 | 2022-02-01 | Abbvie Inc | Therapeutic dll4 binding proteins |
JP5889181B2 (en) | 2010-03-04 | 2016-03-22 | 中外製薬株式会社 | Antibody constant region variants |
WO2011107586A1 (en) | 2010-03-05 | 2011-09-09 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research, | Smoc1, tenascin-c and brain cancers |
TWI667346B (en) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | Antibodies with modified affinity to fcrn that promote antigen clearance |
EP3248615A1 (en) | 2010-03-30 | 2017-11-29 | Mount Sinai School of Medicine of New York University | Influenza virus vaccines and uses thereof |
KR20210010942A (en) | 2010-03-31 | 2021-01-28 | 아블렉시스, 엘엘씨 | Genetic engineering of non-human animals for the production of chimeric antibodies |
US10338069B2 (en) | 2010-04-12 | 2019-07-02 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
ES2608475T3 (en) | 2010-04-13 | 2017-04-11 | Celldex Therapeutics, Inc. | Antibodies that bind to human CD27 and uses thereof |
MX336196B (en) | 2010-04-15 | 2016-01-11 | Abbvie Inc | Amyloid-beta binding proteins. |
ME03813B (en) | 2010-04-16 | 2021-04-20 | Biogen Ma Inc | Anti-vla-4 antibodies |
US20130034543A1 (en) | 2010-04-19 | 2013-02-07 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear | Modulating xrn1 |
WO2011133931A1 (en) | 2010-04-22 | 2011-10-27 | Genentech, Inc. | Use of il-27 antagonists for treating inflammatory bowel disease |
BR112012027900A2 (en) | 2010-04-30 | 2020-05-12 | Alexion Pharmaceuticals, Inc. | ANTI-C5A ANTIBODIES AND METHODS FOR USING ANTIBODIES |
IL208820A0 (en) | 2010-10-19 | 2011-01-31 | Rachel Teitelbaum | Biologic female contraceptives |
CN104777301B (en) | 2010-05-10 | 2018-04-20 | 中央研究院 | The measure of the Oseltamivir neurological susceptibility of zanamivir phosphonate ester congener and influenza virus with anti-influenza activity |
US20110293629A1 (en) | 2010-05-14 | 2011-12-01 | Bastid Jeremy | Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists |
DK2571532T3 (en) | 2010-05-14 | 2017-08-28 | Abbvie Inc | IL-1 BINDING PROTEINS |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
WO2011149051A1 (en) | 2010-05-28 | 2011-12-01 | 中外製薬株式会社 | Antitumor t cell response enhancer |
JP5904552B2 (en) | 2010-05-28 | 2016-04-13 | 国立研究開発法人国立がん研究センター | Pancreatic cancer treatment |
CA2800531C (en) | 2010-06-02 | 2021-05-25 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
WO2011153224A2 (en) | 2010-06-02 | 2011-12-08 | Genentech, Inc. | Diagnostic methods and compositions for treatment of cancer |
CA2795972A1 (en) | 2010-06-03 | 2011-12-08 | Genentech, Inc. | Immuno-pet imaging of antibodies and immunoconjugates and uses therefor |
EP2580239A1 (en) | 2010-06-10 | 2013-04-17 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating cancer by modulating mammalian sterile 20-like kinase 3 |
JP6029581B2 (en) | 2010-06-19 | 2016-11-24 | メモリアル スローン−ケタリング キャンサー センター | Anti-GD2 antibody |
JP2013533243A (en) | 2010-06-22 | 2013-08-22 | ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド,ア ボディ コーポレート | Antibody to C3d fragment of complement component 3 |
ES2706913T3 (en) | 2010-06-25 | 2019-04-01 | Univ Aston | Glycoproteins that have lipid mobilization properties and therapeutic uses thereof |
WO2012006500A2 (en) | 2010-07-08 | 2012-01-12 | Abbott Laboratories | Monoclonal antibodies against hepatitis c virus core protein |
KR101896124B1 (en) | 2010-07-09 | 2018-09-07 | 얀센 백신스 앤드 프리벤션 비.브이. | Anti-human respiratory syncytial virus(rsv) antibodies and methods of use |
UY33492A (en) | 2010-07-09 | 2012-01-31 | Abbott Lab | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
WO2012009705A1 (en) | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Ang-2 binding complexes and uses thereof |
CA2805572A1 (en) | 2010-07-16 | 2012-01-19 | Martin Hegen | Modified single domain antigen binding molecules and uses thereof |
KR20130126576A (en) | 2010-07-19 | 2013-11-20 | 에프. 호프만-라 로슈 아게 | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
CN103180737A (en) | 2010-07-19 | 2013-06-26 | 霍夫曼-拉罗奇有限公司 | A method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
CN103221422B (en) | 2010-07-29 | 2017-03-29 | 十一生物治疗股份有限公司 | 1 receptor type I agonist of chimeric IL and antagonist |
CA2807127C (en) | 2010-08-02 | 2019-02-12 | Leslie S. Johnson | Covalent diabodies and uses thereof |
EP3252072A3 (en) | 2010-08-03 | 2018-03-14 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
CA2815154A1 (en) | 2010-08-06 | 2012-02-09 | U3 Pharma Gmbh | Use of her3 binding agents in prostate treatment |
EP2420250A1 (en) | 2010-08-13 | 2012-02-22 | Universitätsklinikum Münster | Anti-Syndecan-4 antibodies |
MX358739B (en) | 2010-08-14 | 2018-09-03 | Abbvie Inc Star | Amyloid-beta binding proteins. |
PL3333188T3 (en) | 2010-08-19 | 2022-05-09 | Zoetis Belgium S.A. | Anti-ngf antibodies and their use |
US9046513B2 (en) | 2010-08-26 | 2015-06-02 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
WO2012025636A1 (en) | 2010-08-27 | 2012-03-01 | University Of Zurich | Method for target and drug validation in inflammatory and/or cardiovascular diseases |
WO2012028697A1 (en) | 2010-09-01 | 2012-03-08 | Eth Zürich, Institute Of Molecular Biology And Biophysics | Affinity purification system based on donor strand complementation |
US20130171159A1 (en) | 2010-09-10 | 2013-07-04 | Brian Arthur Hemmings | Phosphorylated twist1 and metastasis |
JP6055412B2 (en) | 2010-09-17 | 2016-12-27 | バクスアルタ ゲーエムベーハー | Immunoglobulin stabilization via aqueous formulations with histidine at mildly acidic to neutral pH |
AU2011312205B2 (en) | 2010-10-05 | 2015-08-13 | Curis, Inc. | Mutant smoothened and methods of using the same |
EA031698B1 (en) | 2010-10-11 | 2019-02-28 | Байоджен Интернэшнл Нейросайенз Гмбх | Human anti-tau antibodies |
CN106563128B (en) | 2010-10-22 | 2020-05-22 | 西雅图遗传学公司 | Use of auristatin-based antibody drug conjugates and mTOR-binding inhibitors in the manufacture of a medicament for the treatment of cancer |
KR20140014077A (en) | 2010-10-25 | 2014-02-05 | 리전츠 오브 더 유니버스티 오브 미네소타 | Therapeutic composition for treatment of glioblastoma |
JP6006640B2 (en) | 2010-10-29 | 2016-10-12 | 株式会社ペルセウスプロテオミクス | Anti-CDH3 antibody with high internalization ability |
US20140093506A1 (en) | 2010-11-15 | 2014-04-03 | Marc Buehler | Anti-fungal-agents |
WO2012067176A1 (en) | 2010-11-17 | 2012-05-24 | 中外製薬株式会社 | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
CA2819530C (en) | 2010-11-30 | 2023-01-10 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
CN108715614A (en) | 2010-11-30 | 2018-10-30 | 中外制药株式会社 | The antigen binding molecules combined are repeated with polymolecular antigen |
UA112170C2 (en) | 2010-12-10 | 2016-08-10 | Санофі | ANTI-TUMOR COMBINATION CONTAINING AN ANTIBODY SPECIFICALLY RECOGNIZING CD38 AND BORTESOMB |
US9283271B2 (en) | 2010-12-17 | 2016-03-15 | Neurimmune Holding Ag | Human anti-SOD1 antibodies |
TW201307388A (en) | 2010-12-21 | 2013-02-16 | Abbott Lab | IL-1 binding proteins |
EP2655417A2 (en) | 2010-12-21 | 2013-10-30 | AbbVie Inc. | Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use |
RU2603097C2 (en) | 2010-12-21 | 2016-11-20 | Селексис Фармасьютикалс Корпорейшн | P-selectin antibodies and methods for their using and identification |
CA2824279A1 (en) | 2010-12-22 | 2012-06-28 | Cephalon Australia Pty Ltd | Modified antibody with improved half-life |
AU2011352207B2 (en) | 2010-12-31 | 2016-03-03 | Bioatla, Llc | Comprehensive monoclonal antibody generation |
WO2012092539A2 (en) | 2010-12-31 | 2012-07-05 | Takeda Pharmaceutical Company Limited | Antibodies to dll4 and uses thereof |
US20120171195A1 (en) | 2011-01-03 | 2012-07-05 | Ravindranath Mepur H | Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use |
CN103619883A (en) | 2011-01-19 | 2014-03-05 | 拜耳知识产权有限责任公司 | Binding proteins to inhibitors of coagulation factors |
EP2668207A4 (en) | 2011-01-24 | 2015-06-10 | Univ Singapore | Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins |
WO2012103240A2 (en) | 2011-01-25 | 2012-08-02 | Eleven Biotherapeutics, Inc. | Receptor binding agents |
EP3763740A1 (en) | 2011-01-26 | 2021-01-13 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
JP6150734B2 (en) | 2011-02-03 | 2017-06-21 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | Use of anti-CD200 antibodies to prolong allograft survival |
WO2012104824A1 (en) | 2011-02-04 | 2012-08-09 | Ecole polytechnique fédérale de Lausanne (EPFL) | Therapeutic antibodies targeting app-c99 |
WO2012113775A1 (en) | 2011-02-21 | 2012-08-30 | University Of Zurich | Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders |
CA2827923C (en) | 2011-02-25 | 2021-11-23 | Chugai Seiyaku Kabushiki Kaisha | Fc.gamma.riib-specific fc antibody |
CN103502472B (en) | 2011-02-28 | 2017-06-06 | 弗·哈夫曼-拉罗切有限公司 | Biomarker and the method for predicting the response to B cell antagonists |
JP2014510730A (en) | 2011-03-16 | 2014-05-01 | サノフイ | Use of dual V region antibody-like proteins |
EP2500073A1 (en) | 2011-03-17 | 2012-09-19 | ChromaCon AG | Method for identification and purification of multi-specific polypeptides |
US20140010756A1 (en) | 2011-03-18 | 2014-01-09 | Kagoshima University | Composition for treatment and diagnosis of pancreatic cancer |
WO2012129520A1 (en) | 2011-03-24 | 2012-09-27 | Texas Tech University System | Tcr mimic antibodies as vascular targeting tools |
AU2012237287B2 (en) | 2011-03-30 | 2016-09-08 | Ablynx Nv | Methods of treating immune disorders with single domain antibodies against TNF-alpha |
EP3825325A3 (en) | 2011-03-30 | 2021-10-13 | Chugai Seiyaku Kabushiki Kaisha | Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity |
CN103826657A (en) | 2011-04-04 | 2014-05-28 | 衣阿华大学研究基金会 | Methods of improving vaccine immunogenicity |
KR102001686B1 (en) | 2011-04-07 | 2019-07-18 | 암젠 인크 | Novel egfr binding proteins |
US9150644B2 (en) | 2011-04-12 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II |
RU2625034C2 (en) | 2011-04-20 | 2017-07-11 | МЕДИММЬЮН, ЭлЭлСи | Antibodies and other molecules binding b7-h1 and pd-1 |
US9062106B2 (en) | 2011-04-27 | 2015-06-23 | Abbvie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
JOP20200043A1 (en) | 2011-05-10 | 2017-06-16 | Amgen Inc | Methods of treating or preventing cholesterol related disorders |
CN107936121B (en) | 2011-05-16 | 2022-01-14 | 埃泰美德(香港)有限公司 | Multispecific FAB fusion proteins and methods of use thereof |
NZ618016A (en) | 2011-05-21 | 2015-05-29 | Macrogenics Inc | Deimmunized serum-binding domains and their use for extending serum half-life |
CN106432506A (en) | 2011-05-24 | 2017-02-22 | 泽恩格尼亚股份有限公司 | Multivalent and monovalent multispecific complexes and their uses |
AR086543A1 (en) | 2011-05-25 | 2014-01-08 | Bg Medicine Inc | GALECTIN-3 INHIBITORS AND METHODS OF USE OF THE SAME, PHARMACEUTICAL COMPOSITION |
EP2530088A1 (en) | 2011-05-30 | 2012-12-05 | Klinikum rechts der Isar der Technischen Universität München | Means and methods for diagnosing and treating multiple sclerosis |
WO2012167039A1 (en) | 2011-06-02 | 2012-12-06 | Dyax Corp. | Fc RECEPTOR BINDING PROTEINS |
BR112013030958B1 (en) | 2011-06-03 | 2022-02-08 | Xoma Technology Ltd | ANTIBODY BINDING GROWTH TRANSFORMATION FACTOR BETA, PHARMACEUTICAL COMPOSITION, USES THEREOF, NUCLEIC ACID MOLECULE, EXPRESSION VECTOR, AND METHOD FOR PRODUCTION OF AN ANTIBODY |
US9181553B2 (en) | 2011-06-06 | 2015-11-10 | Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Method of treatment of breast cancers over-expressing the SHP2 signature genes |
US9574002B2 (en) | 2011-06-06 | 2017-02-21 | Amgen Inc. | Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor |
JP6305919B2 (en) | 2011-06-06 | 2018-04-04 | プロセナ バイオサイエンシーズ リミテッド | MCAM antagonists and methods of treatment |
WO2012170740A2 (en) | 2011-06-07 | 2012-12-13 | University Of Hawaii | Biomarker of asbestos exposure and mesothelioma |
US9561274B2 (en) | 2011-06-07 | 2017-02-07 | University Of Hawaii | Treatment and prevention of cancer with HMGB1 antagonists |
CA2838211C (en) | 2011-06-10 | 2023-08-01 | Medimmmune Limited | Anti-pseudomonas psl binding molecules and uses thereof |
US20140120555A1 (en) | 2011-06-20 | 2014-05-01 | Pierre Fabre Medicament | Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer |
DK2723379T3 (en) | 2011-06-23 | 2018-10-15 | Biogen Int Neuroscience Gmbh | ANTI-ALPHA SYNUCLEIN BINDING MOLECULES |
RU2641256C2 (en) | 2011-06-30 | 2018-01-16 | Чугаи Сейяку Кабусики Кайся | Heterodimerizated polypeptide |
JP2013040160A (en) | 2011-07-01 | 2013-02-28 | Genentech Inc | Use of anti-cd83 agonist antibody for treating autoimmune disease |
DE202011103324U1 (en) | 2011-07-12 | 2012-01-02 | Nekonal S.A.R.L. | Therapeutic anti-TIRC7 antibodies for use in immune and other diseases |
KR20140061403A (en) | 2011-07-13 | 2014-05-21 | 애브비 인코포레이티드 | Methods and compositions for treating asthma using anti-il-13 antibodies |
JP6176849B2 (en) | 2011-07-19 | 2017-08-09 | 中外製薬株式会社 | A stable protein-containing preparation containing arginine amide or a similar compound |
UA117220C2 (en) | 2011-08-01 | 2018-07-10 | Дженентек, Інк. | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
WO2013017656A1 (en) | 2011-08-02 | 2013-02-07 | Medizinische Universität Wien | Antagonists of ribonucleases for treating obesity |
EP2739652B1 (en) | 2011-08-04 | 2017-04-05 | Medizinische Universität Innsbruck | Cahgt1p inhibitors for use in the treatment of candidiasis |
EP2756094B1 (en) | 2011-08-15 | 2017-12-27 | Medlmmune, LLC | Anti-b7-h4 antibodies and their uses |
MX2014001736A (en) | 2011-08-17 | 2014-03-31 | Genentech Inc | Inhibition of angiogenesis in refractory tumors. |
EP2749572A4 (en) | 2011-08-23 | 2015-04-01 | Chugai Pharmaceutical Co Ltd | Novel anti-ddr1 antibody having anti-tumor activity |
CA2848074A1 (en) | 2011-09-09 | 2013-03-14 | Medimmune Limited | Anti-siglec-15 antibodies and uses thereof |
IN2014CN02114A (en) | 2011-09-20 | 2015-05-29 | Sinai School Medicine | |
CN103827145A (en) | 2011-09-21 | 2014-05-28 | 富士瑞必欧株式会社 | Antibody against affinity complex |
WO2013041687A1 (en) | 2011-09-23 | 2013-03-28 | Amgen Research (Munich) Gmbh | Bispecific binding molecules for 5t4 and cd3 |
JP6322411B2 (en) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | Antigen-binding molecules that promote the disappearance of antigens with multiple physiological activities |
TW201817745A (en) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance |
CA2850322C (en) | 2011-09-30 | 2023-10-10 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule inducing immune response to target antigen |
RU2732151C2 (en) | 2011-09-30 | 2020-09-11 | Чугаи Сейяку Кабусики Кайся | Library of concentration-dependent binding molecules |
CA2850194C (en) | 2011-09-30 | 2023-03-21 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for promoting elimination of antigens |
AU2012319150B2 (en) | 2011-10-05 | 2017-08-17 | Genentech, Inc. | Methods of treating liver conditions using Notch2 antagonists |
EP2764118A1 (en) | 2011-10-05 | 2014-08-13 | University of Bremen | Wnt4 and med12 for use in the diagnosis and treatment of tumor diseases |
US20150299313A1 (en) | 2011-10-05 | 2015-10-22 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for promoting clearance from plasma of antigen comprising suger chain receptor-binding domain |
DK2768851T3 (en) | 2011-10-21 | 2017-09-18 | Augurex Life Sciences Corp | ANTIGENS DERIVED BY CITRULLINATED 14-3-3 AND APPLICATIONS THEREOF IN THE DIAGNOSIS OF RHEUMATOID ARTHRITIS |
RU2014120981A (en) | 2011-10-24 | 2015-12-10 | Эббви Инк. | IMMUNE BINDING AGENTS AGAINST SCLEROSTINE |
BR112014009799A2 (en) | 2011-10-24 | 2017-06-13 | Abbvie Inc | tnf directed immunoligants |
WO2013063419A2 (en) | 2011-10-28 | 2013-05-02 | The Trustees Of The University Of Pennsylvania | A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting |
KR102398736B1 (en) | 2011-10-31 | 2022-05-16 | 추가이 세이야쿠 가부시키가이샤 | Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain |
RU2665810C2 (en) | 2011-10-31 | 2018-09-04 | Дженентек, Инк. | Antibody formulations |
EP2773373B1 (en) | 2011-11-01 | 2018-08-22 | Bionomics, Inc. | Methods of blocking cancer stem cell growth |
WO2013067057A1 (en) | 2011-11-01 | 2013-05-10 | Bionomics, Inc. | Anti-gpr49 antibodies |
CN104053671A (en) | 2011-11-01 | 2014-09-17 | 生态学有限公司 | Antibodies and methods of treating cancer |
AU2012332593B2 (en) | 2011-11-01 | 2016-11-17 | Bionomics, Inc. | Anti-GPR49 antibodies |
WO2013067492A1 (en) | 2011-11-03 | 2013-05-10 | The Trustees Of The University Of Pennsylvania | Isolated b7-h4 specific compositions and methods of use thereof |
EP2776838A1 (en) | 2011-11-08 | 2014-09-17 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Early diagnostic of neurodegenerative diseases |
EP2776022A1 (en) | 2011-11-08 | 2014-09-17 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | New treatment for neurodegenerative diseases |
US20140322216A1 (en) | 2011-11-08 | 2014-10-30 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
EP2776565A1 (en) | 2011-11-08 | 2014-09-17 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the nervous system |
AU2012335247A1 (en) | 2011-11-08 | 2014-05-29 | Pfizer Inc. | Methods of treating inflammatory disorders using anti-M-CSF antibodies |
TWI679212B (en) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | Binding molecules for e3 of bcma and cd3 |
CN104168922A (en) | 2011-11-16 | 2014-11-26 | 安姆根有限公司 | Methods of treating epidermal growth factor deletion mutant VIII related disorders |
HUE051954T2 (en) | 2011-11-28 | 2021-03-29 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
WO2013081143A1 (en) | 2011-11-30 | 2013-06-06 | 中外製薬株式会社 | Drug containing carrier into cell for forming immune complex |
MX358680B (en) | 2011-12-08 | 2018-08-31 | Biotest Ag | Uses of immunoconjugates targeting cd138. |
EP2602621A1 (en) | 2011-12-08 | 2013-06-12 | Julius-Maximilians-Universität Würzburg | LASP-1, a novel urinary marker for transitional cell carcinoma detection |
EP3800200A1 (en) | 2011-12-14 | 2021-04-07 | AbbVie Deutschland GmbH & Co. KG | Composition and method for the diagnosis and treatment of iron-related disorders |
MX356933B (en) | 2011-12-14 | 2018-06-20 | Abbvie Deutschland | Composition and method for the diagnosis and treatment of iron-related disorders. |
EP3050900A1 (en) | 2011-12-19 | 2016-08-03 | Xoma (Us) Llc | Methods for treating acne |
EP3539982A3 (en) | 2011-12-23 | 2020-01-15 | Pfizer Inc | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
EP2794660A2 (en) | 2011-12-23 | 2014-10-29 | Phenoquest AG | Antibodies for the treatment and diagnosis of affective and anxiety disorders |
TWI593705B (en) | 2011-12-28 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient |
ES2964168T3 (en) | 2011-12-28 | 2024-04-04 | Immunoqure Ag | Anti-interleukin 22 antibody (IL-22) and its uses |
CA2861610A1 (en) | 2011-12-30 | 2013-07-04 | Abbvie Inc. | Dual specific binding proteins directed against il-13 and/or il-17 |
WO2013102825A1 (en) | 2012-01-02 | 2013-07-11 | Novartis Ag | Cdcp1 and breast cancer |
CN104411717A (en) | 2012-01-09 | 2015-03-11 | 斯克利普斯研究所 | Humanized antibodies with ultralong CDR3S |
US10774132B2 (en) | 2012-01-09 | 2020-09-15 | The Scripps Research Instittue | Ultralong complementarity determining regions and uses thereof |
US20130177574A1 (en) | 2012-01-11 | 2013-07-11 | Paul I. Terasaki Foundation Laboratory | ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE |
US10800847B2 (en) | 2012-01-11 | 2020-10-13 | Dr. Mepur Ravindranath | Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use |
MX356802B (en) | 2012-01-13 | 2018-06-13 | Genentech Inc | Biological markers for identifying patients for treatment with vegf antagonists. |
WO2013107290A1 (en) | 2012-01-20 | 2013-07-25 | The Government of the Hong Kong Special Administrative Region of the People's Republic of China | A novel paramyxovirus and uses thereof |
AU2013211939C1 (en) | 2012-01-27 | 2018-06-07 | AbbVie Deutschland GmbH & Co. KG | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration |
AU2013215332A1 (en) | 2012-01-31 | 2014-09-04 | Genentech, Inc. | Anti-Ig-E M1' antibodies and methods using same |
MY169341A (en) | 2012-02-06 | 2019-03-21 | Inhibrx Inc | Cd47 antibodies and methods of use thereof |
SG10201704849PA (en) | 2012-02-09 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Modified fc region of antibody |
CA2864092C (en) | 2012-02-10 | 2021-06-29 | Seattle Genetics, Inc. | Detection and treatment of cd30+ cancers |
US9550830B2 (en) | 2012-02-15 | 2017-01-24 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
EP2814842B1 (en) | 2012-02-15 | 2018-08-22 | Novo Nordisk A/S | Antibodies that bind peptidoglycan recognition protein 1 |
EP2814844B1 (en) | 2012-02-15 | 2017-08-02 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1) |
WO2013123114A2 (en) | 2012-02-16 | 2013-08-22 | Santarus, Inc. | Antibody formulations |
AU2013223087B2 (en) | 2012-02-24 | 2018-02-22 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for promoting disappearance of antigen via FcgammaRIIb |
CA2864177C (en) | 2012-03-01 | 2019-11-26 | Amgen Research (Munich) Gmbh | Prolonged half-life albumin-binding protein fused bispecific antibodies |
SI2883449T1 (en) | 2012-03-16 | 2018-05-31 | Regeneron Pharmaceuticals, Inc. | Histidine engineered light chain antibodies and genetically modified rodents for generating the same |
US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
NZ629077A (en) | 2012-03-16 | 2015-12-24 | Regeneron Pharma | Non-human animals expressing ph-sensitive immunoglobulin sequences |
CN106318951A (en) | 2012-03-16 | 2017-01-11 | 瑞泽恩制药公司 | Mice that produce antigen-binding proteins with PH-dependent binding characteristics |
US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
MX370486B (en) | 2012-03-27 | 2019-12-16 | Genentech Inc | Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis. |
SG11201406079TA (en) | 2012-03-27 | 2014-10-30 | Genentech Inc | Diagnosis and treatments relating to her3 inhibitors |
EP2831112A1 (en) | 2012-03-29 | 2015-02-04 | Friedrich Miescher Institute for Biomedical Research | Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer |
EP2832856A4 (en) | 2012-03-29 | 2016-01-27 | Chugai Pharmaceutical Co Ltd | Anti-lamp5 antibody and utilization thereof |
HUE037613T2 (en) | 2012-03-29 | 2018-09-28 | Novimmune Sa | Anti-tlr4 antibodies and uses thereof |
CN104271157A (en) | 2012-03-30 | 2015-01-07 | 霍夫曼-拉罗奇有限公司 | Diagnostic methods and compositions for treatment of cancer |
US9764041B2 (en) | 2012-04-04 | 2017-09-19 | Perseus Proteomics Inc. | Drug conjugate comprising anti-CDH3 (P-cadherin) antibody |
WO2013151649A1 (en) | 2012-04-04 | 2013-10-10 | Sialix Inc | Glycan-interacting compounds |
WO2013155447A1 (en) | 2012-04-13 | 2013-10-17 | Children's Medical Center Corporation | Tiki inhibitors |
US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
WO2013166043A1 (en) | 2012-05-02 | 2013-11-07 | Children's Hospital Medical Center | Rejuvenation of precursor cells |
EA039663B1 (en) | 2012-05-03 | 2022-02-24 | Амген Инк. | Use of an anti-pcsk9 antibody for lowering serum cholesterol ldl and treating cholesterol related disorders |
ES2718472T3 (en) | 2012-05-03 | 2019-07-02 | Fibrogen Inc | Methods to treat idiopathic pulmonary fibrosis |
WO2013166290A1 (en) | 2012-05-04 | 2013-11-07 | Abbvie Biotherapeutics Inc. | P21 biomarker assay |
US9441045B2 (en) | 2012-05-04 | 2016-09-13 | Dana-Farber Cancer Institute, Inc. | Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use |
EA030716B1 (en) | 2012-05-14 | 2018-09-28 | Байоджен Ма Инк. | Lingo-2 antagonists for treatment of conditions involving motor neurons |
AU2013263349B2 (en) | 2012-05-17 | 2016-09-08 | Extend Biosciences, Inc | Carriers for improved drug delivery |
WO2013177386A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Biotherapeutics Inc. | Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy |
WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
TWI617578B (en) | 2012-05-30 | 2018-03-11 | Chugai Pharmaceutical Co Ltd | Target tissue-specific antigen binding molecule |
ES2856272T3 (en) | 2012-05-30 | 2021-09-27 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule to remove aggregated antigens |
CA2874144C (en) | 2012-05-31 | 2023-12-19 | Genentech, Inc. | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists |
US9617334B2 (en) | 2012-06-06 | 2017-04-11 | Zoetis Services Llc | Caninized anti-NGF antibodies and methods thereof |
WO2013187495A1 (en) | 2012-06-14 | 2013-12-19 | 中外製薬株式会社 | ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED Fc REGION |
KR101704893B1 (en) | 2012-06-15 | 2017-02-08 | 화이자 인코포레이티드 | Improved antagonist antibodies against gdf-8 and uses therefor |
IN2014MN02635A (en) | 2012-06-22 | 2015-10-16 | Cytomx Therapeutics Inc | |
WO2014001482A1 (en) | 2012-06-29 | 2014-01-03 | Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research | Treating diseases by modulating a specific isoform of mkl1 |
WO2014006114A1 (en) | 2012-07-05 | 2014-01-09 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | New treatment for neurodegenerative diseases |
US10656156B2 (en) | 2012-07-05 | 2020-05-19 | Mepur Ravindranath | Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E |
WO2014006115A1 (en) | 2012-07-06 | 2014-01-09 | Novartis Ag | Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction |
WO2014011955A2 (en) | 2012-07-12 | 2014-01-16 | Abbvie, Inc. | Il-1 binding proteins |
EP2872526B1 (en) | 2012-07-13 | 2020-04-01 | The Trustees of the University of Pennsylvania | Enhancing activity of car t cells by co-introducing a bispecific antibody |
WO2014031498A1 (en) | 2012-08-18 | 2014-02-27 | Academia Sinica | Cell-permeable probes for identification and imaging of sialidases |
US9547009B2 (en) | 2012-08-21 | 2017-01-17 | Academia Sinica | Benzocyclooctyne compounds and uses thereof |
EP2889376A4 (en) | 2012-08-24 | 2016-11-02 | Chugai Pharmaceutical Co Ltd | MOUSE Fc RII-SPECIFIC Fc ANTIBODY |
TWI717591B (en) | 2012-08-24 | 2021-02-01 | 日商中外製藥股份有限公司 | Fcγ riib-specific fc region variant |
KR20150046316A (en) | 2012-08-31 | 2015-04-29 | 이뮤노젠 아이엔씨 | Diagnostic assays and kits for detection of folate receptor 1 |
AU2013308409A1 (en) | 2012-08-31 | 2015-03-26 | University Of Birmingham | Target peptides for immunotherapy and diagnostics |
EP2890782A1 (en) | 2012-09-02 | 2015-07-08 | AbbVie Inc. | Methods to control protein heterogeneity |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
AU2013312529A1 (en) | 2012-09-05 | 2015-04-16 | The University Of Birmingham | Target peptides for colorectal cancer therapy and diagnostics |
TWI595007B (en) | 2012-09-10 | 2017-08-11 | Neotope Biosciences Ltd | Anti-mcam antibodies and associated methods of use |
AU2013317985B2 (en) | 2012-09-19 | 2019-06-13 | Dana-Farber Cancer Institute, Inc. | Dynamic BH3 profiling |
EP2711016A1 (en) | 2012-09-21 | 2014-03-26 | Covagen AG | Novel IL-17A binding molecules and medical uses thereof |
TWI606066B (en) | 2012-09-27 | 2017-11-21 | 中外製藥股份有限公司 | FGFR3 Fusion Gene and Its Targeted Medicine |
CN104937423B (en) | 2012-09-28 | 2017-05-24 | 中外制药株式会社 | Method for evaluating blood coagulation reaction |
NO2760138T3 (en) | 2012-10-01 | 2018-08-04 | ||
EP2904106A4 (en) | 2012-10-01 | 2016-05-11 | Univ Pennsylvania | Compositions and methods for targeting stromal cells for the treatment of cancer |
CN107892719B (en) | 2012-10-04 | 2022-01-14 | 达纳-法伯癌症研究所公司 | Human monoclonal anti-PD-L1 antibodies and methods of use |
US9598489B2 (en) | 2012-10-05 | 2017-03-21 | The Trustees Of The Univeristy Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
US10253107B2 (en) | 2012-10-26 | 2019-04-09 | The University Of Queensland | Use of endocytosis inhibitors and antibodies for cancer therapy |
TW202014439A (en) | 2012-11-01 | 2020-04-16 | 美商艾伯維有限公司 | Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof |
RS57696B1 (en) | 2012-11-08 | 2018-12-31 | Univ Miyazaki | Antibody capable of specifically recognizing transferrin receptor |
US20140154255A1 (en) | 2012-11-30 | 2014-06-05 | Abbvie Biotherapeutics Inc. | Anti-vegf antibodies and their uses |
CN110183534A (en) | 2012-12-03 | 2019-08-30 | 诺夫免疫股份有限公司 | Anti-cd 47 antibody and its application method |
US10342869B2 (en) | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
UA118255C2 (en) | 2012-12-07 | 2018-12-26 | Санофі | Compositions comprising anti-cd38 antibodies and lenalidomide |
AU2013359419B2 (en) | 2012-12-10 | 2018-03-15 | Biogen Ma Inc. | Anti-blood dendritic cell antigen 2 antibodies and uses thereof |
WO2014093855A1 (en) | 2012-12-13 | 2014-06-19 | University Of Virginia Patent Foundation | Target peptides for ovarian cancer therapy and diagnostics |
NZ627796A (en) | 2012-12-18 | 2017-07-28 | Icahn School Med Mount Sinai | Influenza virus vaccines and uses thereof |
WO2014100439A2 (en) | 2012-12-19 | 2014-06-26 | Amplimmune, Inc. | B7-h4 specific antibodies, and compositions and methods of use thereof |
JP6284548B2 (en) | 2012-12-21 | 2018-02-28 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | Human anti-tau antibody |
JP6359031B2 (en) | 2012-12-21 | 2018-07-18 | メディミューン,エルエルシー | Anti-H7CR antibody |
WO2014104165A1 (en) | 2012-12-27 | 2014-07-03 | 中外製薬株式会社 | Heterodimerized polypeptide |
EP3517545A1 (en) | 2012-12-31 | 2019-07-31 | Neurimmune Holding AG | Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases |
US10717965B2 (en) | 2013-01-10 | 2020-07-21 | Gloriana Therapeutics, Inc. | Mammalian cell culture-produced neublastin antibodies |
JO3519B1 (en) | 2013-01-25 | 2020-07-05 | Amgen Inc | Antibody constructs for CDH19 and CD3 |
ES2728936T3 (en) | 2013-01-25 | 2019-10-29 | Amgen Inc | Antibodies directed against CDH19 for melanoma |
EP2951199A4 (en) | 2013-01-31 | 2016-07-20 | Univ Jefferson | Fusion proteins for modulating regulatory and effector t cells |
CN105101997B (en) | 2013-02-06 | 2018-11-09 | 印希彼有限合伙公司 | Blood platelet is not reduced and does not reduce the CD47 antibody and its application method of erythrocyte |
WO2014130923A2 (en) | 2013-02-25 | 2014-08-28 | Genentech, Inc. | Methods and compositions for detecting and treating drug resistant akt mutant |
AU2013381687A1 (en) | 2013-03-12 | 2015-09-24 | Abbvie Inc. | Human antibodies that bind human TNF-alpha and methods of preparing the same |
NZ711567A (en) | 2013-03-13 | 2020-04-24 | Genentech Inc | Antibody formulations |
RU2707092C2 (en) | 2013-03-13 | 2019-11-22 | Дженентек, Инк. | Compositions with reduced oxidation |
IL292978A (en) | 2013-03-13 | 2022-07-01 | Univ California | Compositions comprising anti-cd38 antibodies and carfilzomib |
ES2884813T3 (en) | 2013-03-13 | 2021-12-13 | Buzzard Pharmaceuticals AB | Chimeric Cytokine Formulations for Ocular Administration |
AR095398A1 (en) | 2013-03-13 | 2015-10-14 | Genentech Inc | FORMULATIONS WITH REDUCED OXIDATION |
CA3135558A1 (en) | 2013-03-13 | 2014-10-02 | Genentech, Inc. | Prevention of protein oxidation in a composition |
AR095399A1 (en) | 2013-03-13 | 2015-10-14 | Genentech Inc | FORMULATIONS WITH REDUCED OXIDATION, METHOD |
US20140271629A1 (en) | 2013-03-14 | 2014-09-18 | Amgen Inc. | Chrdl-1 antigen binding proteins and methods of treatment |
WO2014159242A1 (en) | 2013-03-14 | 2014-10-02 | Novartis Ag | Notch 3 mutants and uses thereof |
MX362075B (en) | 2013-03-14 | 2019-01-07 | Abbott Lab | Hcv antigen-antibody combination assay and methods and compositions for use therein. |
US8921526B2 (en) | 2013-03-14 | 2014-12-30 | Abbvie, Inc. | Mutated anti-TNFα antibodies and methods of their use |
JP2016512241A (en) | 2013-03-14 | 2016-04-25 | アボット・ラボラトリーズAbbott Laboratories | HCVNS3 recombinant antigen for improved antibody detection and mutants thereof |
WO2014159960A1 (en) | 2013-03-14 | 2014-10-02 | Icahn School Of Medicine At Mount Sinai | Antibodies against influenza virus hemagglutinin and uses thereof |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
CA2906688A1 (en) | 2013-03-14 | 2014-09-25 | Parkash S. Gill | Cancer treatment using antibodies that bind cell surface grp78 |
WO2014143343A1 (en) | 2013-03-14 | 2014-09-18 | Abbott Laboratories | Hcv core lipid binding domain monoclonal antibodies |
WO2014140368A1 (en) | 2013-03-15 | 2014-09-18 | Amgen Research (Munich) Gmbh | Antibody constructs for influenza m2 and cd3 |
SG11201507359SA (en) | 2013-03-15 | 2015-10-29 | Dana Farber Cancer Inst Inc | Flavivirus neutralizing antibodies and methods of use thereof |
AU2014233478A1 (en) | 2013-03-15 | 2015-09-24 | Abbvie Biotechnology Ltd. | Anti-CD25 antibodies and their uses |
US10160797B2 (en) | 2013-03-15 | 2018-12-25 | Sanofi Pasteur Biologics, Llc | Antibodies against Clostridium difficile toxins and methods of using the same |
MX368665B (en) | 2013-03-15 | 2019-10-10 | Abbvie Biotherapeutics Inc | Fc variants. |
SG11201507367PA (en) | 2013-03-15 | 2015-10-29 | Genentech Inc | Cell culture compositions with antioxidants and methods for polypeptide production |
US9469686B2 (en) | 2013-03-15 | 2016-10-18 | Abbott Laboratories | Anti-GP73 monoclonal antibodies and methods of obtaining the same |
US10167341B2 (en) | 2013-03-15 | 2019-01-01 | Memorial Sloan Kettering Cancer Center | High affinity anti-GD2 antibodies |
LT2970449T (en) | 2013-03-15 | 2019-11-25 | Amgen Res Munich Gmbh | Single chain binding molecules comprising n-terminal abp |
AR095374A1 (en) | 2013-03-15 | 2015-10-14 | Amgen Res (Munich) Gmbh | UNION MOLECULES FOR BCMA AND CD3 |
CN105121470A (en) | 2013-03-15 | 2015-12-02 | 艾伯维生物技术有限公司 | Anti-cd25 antibodies and their uses |
EA201890895A1 (en) | 2013-03-15 | 2019-02-28 | Зинджения, Инк. | MULTIVALENT AND MONOVALENT MULTIS-SPECIFIC COMPLEXES AND THEIR APPLICATION |
CN105324396A (en) | 2013-03-15 | 2016-02-10 | 艾伯维公司 | Dual specific binding proteins directed against il-1 beta and il-17 |
RU2015144020A (en) | 2013-03-15 | 2017-04-21 | Дженентек, Инк. | ENVIRONMENTS FOR CULTIVATION OF CELLS AND METHODS FOR PRODUCING ANTIBODIES |
AU2014236986A1 (en) | 2013-03-15 | 2015-09-03 | Biogen Ma Inc. | Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies |
SG11201508170TA (en) | 2013-04-02 | 2015-11-27 | Chugai Pharmaceutical Co Ltd | Fc REGION VARIANT |
WO2014165818A2 (en) | 2013-04-05 | 2014-10-09 | T Cell Therapeutics, Inc. | Compositions and methods for preventing and treating prostate cancer |
WO2014169076A1 (en) | 2013-04-09 | 2014-10-16 | Annexon,,Inc. | Methods of treatment for neuromyelitis optica |
TWI679019B (en) | 2013-04-29 | 2019-12-11 | 法商賽諾菲公司 | Anti-il-4/anti-il-13 bispecific antibody formulations |
EP2981822B1 (en) | 2013-05-06 | 2020-09-02 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
US9989540B2 (en) | 2013-05-10 | 2018-06-05 | The Regents Of The University Of California | Diagnostic and monitoring system for Huntington's disease |
JP6537143B2 (en) | 2013-05-16 | 2019-07-03 | 国立大学法人京都大学 | Method of diagnosing prognosis of cancer |
KR20160129698A (en) | 2013-05-24 | 2016-11-09 | 메디뮨 엘엘씨 | Anti-b7-h5 antibodies and their uses |
WO2014197866A1 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Modified antibodies and related compounds, compositions, and methods of use |
AU2014274660B2 (en) | 2013-06-06 | 2019-05-16 | Pierre Fabre Médicament | Anti-C10orf54 antibodies and uses thereof |
WO2014197885A2 (en) | 2013-06-07 | 2014-12-11 | Duke University | Inhibitors of complement factor h |
WO2014200018A1 (en) | 2013-06-11 | 2014-12-18 | 独立行政法人 国立精神・神経医療研究センター | Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy |
US9499628B2 (en) | 2013-06-14 | 2016-11-22 | Children's Hospital Medical Center | Method of boosting the immune response in neonates |
KR20160022354A (en) | 2013-06-24 | 2016-02-29 | 추가이 세이야쿠 가부시키가이샤 | Therapeutic agent comprising humanized anti-Epiregulin antibody as active ingredient for non-small-cell lung carcinoma excluding adenocarcinoma |
WO2014210397A1 (en) | 2013-06-26 | 2014-12-31 | Academia Sinica | Rm2 antigens and use thereof |
EP3013347B1 (en) | 2013-06-27 | 2019-12-11 | Academia Sinica | Glycan conjugates and use thereof |
JP6267792B2 (en) | 2013-06-28 | 2018-01-24 | アムジエン・インコーポレーテツド | Methods for treating homozygous familial hypercholesterolemia |
ES2911663T3 (en) | 2013-07-03 | 2022-05-20 | Immunoqure Ag | Human anti-IFN-alpha antibodies |
CA2916521C (en) | 2013-07-09 | 2023-03-07 | Annexon, Inc. | Anti-complement factor c1q antibodies and uses thereof |
TW202100181A (en) | 2013-07-16 | 2021-01-01 | 美商建南德克公司 | Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors |
US20160168231A1 (en) | 2013-07-18 | 2016-06-16 | Fabrus, Inc. | Antibodies with ultralong complementarity determining regions |
CN111518199A (en) | 2013-07-18 | 2020-08-11 | 图鲁斯生物科学有限责任公司 | Humanized antibodies with ultralong complementarity determining regions |
EP3030902B1 (en) | 2013-08-07 | 2019-09-25 | Friedrich Miescher Institute for Biomedical Research | New screening method for the treatment friedreich's ataxia |
WO2015021308A1 (en) | 2013-08-07 | 2015-02-12 | Astute Medical, Inc. | Assays for timp2 having improved performance in biological samples |
WO2015023851A1 (en) | 2013-08-14 | 2015-02-19 | The Governing Council Of The University Of Toronto | Antibodies against frizzled proteins and methods of use thereof |
DK3036320T3 (en) | 2013-08-19 | 2021-07-12 | Biogen Ma Inc | MANAGEMENT OF PROTEIN GLYCOSYLATION BY CULTIVATION MEDIA ADDITION AND CELL CULTURE PROCESS PARAMETERS |
US10456470B2 (en) | 2013-08-30 | 2019-10-29 | Genentech, Inc. | Diagnostic methods and compositions for treatment of glioblastoma |
US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
WO2015035044A2 (en) | 2013-09-04 | 2015-03-12 | Abbvie Biotherapeutics Inc. | Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY |
JP6486368B2 (en) | 2013-09-06 | 2019-03-20 | アカデミア シニカAcademia Sinica | Activation of human iNKT cells using glycolipids containing modified glycosyl groups |
JP6663852B2 (en) | 2013-09-19 | 2020-03-13 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | BH3 profiling method |
WO2015041310A1 (en) | 2013-09-20 | 2015-03-26 | 中外製薬株式会社 | Treatment for hemorrhagic diseases by anti-protein-c antibody |
KR102441231B1 (en) | 2013-09-27 | 2022-09-06 | 추가이 세이야쿠 가부시키가이샤 | Method for producing polypeptide heteromultimer |
SG11201602283UA (en) | 2013-09-27 | 2016-04-28 | Genentech Inc | Anti-pdl1 antibody formulations |
EP3052640A2 (en) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
EP3054973B1 (en) | 2013-10-10 | 2020-12-02 | Beth Israel Deaconess Medical Center, Inc. | Tm4sf1 binding proteins and methods of using same |
US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
WO2015066027A2 (en) | 2013-10-28 | 2015-05-07 | Dots Devices, Inc. | Allergen detection |
AU2014342103B2 (en) | 2013-10-31 | 2020-06-04 | Sanofi-Aventis U.S. Llc. | Specific anti-CD38 antibodies for treating human cancers |
CN105793439B (en) | 2013-11-06 | 2020-09-04 | 阿斯图特医药公司 | Assays with improved performance against IGFBP7 with biological samples |
CN113307873A (en) | 2013-11-11 | 2021-08-27 | 中外制药株式会社 | Antigen binding molecules comprising altered antibody variable regions |
WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
TWI664331B (en) | 2013-12-04 | 2019-07-01 | 日商中外製藥股份有限公司 | Antigen-binding molecules that change antigen-binding ability in response to compound concentration and its database |
JP2017502002A (en) | 2013-12-09 | 2017-01-19 | ニューヨーク・ユニバーシティ | Composition and method for phagocytic cell delivery of anti-staphylococcal agents |
WO2015088346A1 (en) | 2013-12-13 | 2015-06-18 | Rijksuniversiteit Groningen | Antibodies against staphylococcus aureus and uses thereof. |
RU2719487C2 (en) | 2013-12-17 | 2020-04-17 | Дженентек, Инк. | Methods of treating cancer using antagonists binding to components of the signal path pd-1, and taxanes |
CN105899535A (en) | 2013-12-17 | 2016-08-24 | 豪夫迈·罗氏有限公司 | Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody |
EP3527587A1 (en) | 2013-12-17 | 2019-08-21 | F. Hoffmann-La Roche AG | Combination therapy comprising ox40 binding agonists and pd-l1 binding antagonists |
SG11201604815RA (en) | 2013-12-19 | 2016-07-28 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
WO2015095809A1 (en) | 2013-12-20 | 2015-06-25 | Biogen Idec Ma Inc. | Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality |
KR20230155605A (en) | 2013-12-20 | 2023-11-10 | 제넨테크, 인크. | Dual specific antibodies |
ES2920677T3 (en) | 2013-12-24 | 2022-08-08 | Janssen Pharmaceutica Nv | Anti-VISTA Antibodies and Fragments |
DK3087986T3 (en) | 2013-12-27 | 2019-12-02 | Chugai Pharmaceutical Co Ltd | MUTANT FGFR GATEKEEPERGEN AND ACTIVE SUBSTANCE AIMED AT THE SAME |
AU2014370873B2 (en) | 2013-12-27 | 2020-06-11 | Chugai Seiyaku Kabushiki Kaisha | Method for purifying antibody having low isoelectric point |
EP2893939A1 (en) | 2014-01-10 | 2015-07-15 | Netris Pharma | Anti-netrin-1 antibody |
WO2016114819A1 (en) | 2015-01-16 | 2016-07-21 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
CA2937123A1 (en) | 2014-01-16 | 2015-07-23 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
WO2015116902A1 (en) | 2014-01-31 | 2015-08-06 | Genentech, Inc. | G-protein coupled receptors in hedgehog signaling |
CA2937539A1 (en) | 2014-02-04 | 2015-08-13 | Genentech, Inc. | Mutant smoothened and methods of using the same |
WO2015121383A1 (en) | 2014-02-12 | 2015-08-20 | Michael Uhlin | Bispecific antibodies for use in stem cell transplantation |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
EP3119804A2 (en) | 2014-03-19 | 2017-01-25 | Dana-Farber Cancer Institute, Inc. | Immunogenetic restriction on elicitation of antibodies |
DK3122869T3 (en) | 2014-03-24 | 2019-09-09 | Biogen Ma Inc | PROCEDURES FOR REDUCING GLUTAMINE DEPRESSION IN MAMMAL CULTURE CULTURE |
KR102352250B1 (en) | 2014-03-25 | 2022-01-17 | 제넨테크, 인크. | Methods of preparing a poloxamer for use in cell culture medium |
WO2015148915A1 (en) | 2014-03-27 | 2015-10-01 | Academia Sinica | Reactive labelling compounds and uses thereof |
SG11201607772WA (en) | 2014-03-31 | 2016-10-28 | Debiopharm Int Sa | Fgfr fusions |
JP6588461B2 (en) | 2014-03-31 | 2019-10-09 | ジェネンテック, インコーポレイテッド | Combination therapy comprising an anti-angiogenic agent and an OX40 binding agonist |
CN106536556B (en) | 2014-04-04 | 2020-02-07 | 生态学有限公司 | Humanized antibodies that bind LGR5 |
EP3134111B1 (en) | 2014-04-25 | 2022-06-08 | Dana-Farber Cancer Institute, Inc. | Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof |
WO2015164364A2 (en) | 2014-04-25 | 2015-10-29 | The Brigham And Women's Hospital, Inc. | Methods to manipulate alpha-fetoprotein (afp) |
AU2015254596B2 (en) | 2014-04-30 | 2020-10-22 | Klinikum Rechts Der Isar Der Technischen Universitat Munchen | Diagnosis of multiple sclerosis |
US20170267780A1 (en) | 2014-05-16 | 2017-09-21 | Medimmune, Llc | Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties |
US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
JP2017518989A (en) | 2014-05-27 | 2017-07-13 | アカデミア シニカAcademia Sinica | Anti-CD20 glycoengineered antibody group and use thereof |
US10005847B2 (en) | 2014-05-27 | 2018-06-26 | Academia Sinica | Anti-HER2 glycoantibodies and uses thereof |
JP6894239B2 (en) | 2014-05-27 | 2021-06-30 | アカデミア シニカAcademia Sinica | Compositions and methods for universal glycoforms for enhanced antibody efficacy |
DK3148579T3 (en) | 2014-05-28 | 2021-03-08 | Agenus Inc | ANTI-GITR ANTIBODIES AND METHODS OF USING IT |
US11332523B2 (en) | 2014-05-28 | 2022-05-17 | Academia Sinica | Anti-TNF-alpha glycoantibodies and uses thereof |
WO2015189816A1 (en) | 2014-06-13 | 2015-12-17 | Friedrich Miescher Institute For Biomedical Research | New treatment against influenza virus |
TWI695011B (en) | 2014-06-18 | 2020-06-01 | 美商梅爾莎納醫療公司 | Monoclonal antibodies against her2 epitope and methods of use thereof |
TW201625299A (en) | 2014-06-20 | 2016-07-16 | Chugai Pharmaceutical Co Ltd | Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii |
WO2015198202A1 (en) | 2014-06-23 | 2015-12-30 | Friedrich Miescher Institute For Biomedical Research | Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas |
US20170165261A1 (en) | 2014-07-01 | 2017-06-15 | Brian Arthur Hemmings | Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma |
WO2016007752A1 (en) | 2014-07-09 | 2016-01-14 | Genentech, Inc. | Ph adjustment to improve thaw recovery of cell banks |
EP3169801A1 (en) | 2014-07-14 | 2017-05-24 | F. Hoffmann-La Roche AG | Diagnostic methods and compositions for treatment of glioblastoma |
JP6673896B2 (en) | 2014-07-15 | 2020-03-25 | ジェネンテック, インコーポレイテッド | Compositions for treating cancer using PD-1 axis binding antagonists and MEK inhibitors |
MX2017000484A (en) | 2014-07-17 | 2017-05-01 | Novo Nordisk As | Site directed mutagenesis of trem-1 antibodies for decreasing viscosity. |
WO2018140026A1 (en) | 2017-01-27 | 2018-08-02 | Memorial Sloan Kettering Cancer Center | Bispecific her2 and cd3 binding molecules |
TW201609811A (en) | 2014-07-31 | 2016-03-16 | 安美基研究(慕尼黑)公司 | Bispecific single chain antibody construct with enhanced tissue distribution |
AR101936A1 (en) | 2014-07-31 | 2017-01-25 | Amgen Res (Munich) Gmbh | SPECIFIC BIESPECIFIC CHAIN ANTIBODY CONSTRUCTS SPECIFIED FOR OPTIMIZED CROSSED SPECIES |
AR101669A1 (en) | 2014-07-31 | 2017-01-04 | Amgen Res (Munich) Gmbh | ANTIBODY CONSTRUCTS FOR CDH19 AND CD3 |
WO2016023019A2 (en) | 2014-08-08 | 2016-02-11 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
WO2016025880A1 (en) | 2014-08-14 | 2016-02-18 | Novartis Ag | Treatment of cancer using gfr alpha-4 chimeric antigen receptor |
JP6858559B2 (en) | 2014-08-20 | 2021-04-14 | 中外製薬株式会社 | Method for measuring viscosity of protein solution |
EP3183002B1 (en) | 2014-08-21 | 2021-03-03 | Walter Reed Army Institute of Research | Monoclonal antibodies for treatment of microbial infections |
KR20240011258A (en) | 2014-09-02 | 2024-01-25 | 이뮤노젠 아이엔씨 | Methods for formulating antibody drug conjugate compositions |
WO2016040369A2 (en) | 2014-09-08 | 2016-03-17 | Academia Sinica | HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS |
WO2016040767A2 (en) | 2014-09-12 | 2016-03-17 | Amgen Inc. | Chrdl-1 epitopes and antibodies |
US20160137727A1 (en) | 2014-09-15 | 2016-05-19 | Genentech, Inc. | Antibody formulations |
WO2016046768A1 (en) | 2014-09-24 | 2016-03-31 | Friedrich Miescher Institute For Biomedical Research | Lats and breast cancer |
MA40764A (en) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | THERAPEUTIC AGENT INDUCING CYTOTOXICITY |
MY180054A (en) | 2014-09-30 | 2020-11-20 | Neurimmune Holding Ag | Human-derived anti-dipeptide repeats (dprs) antibody |
US10463732B2 (en) | 2014-10-03 | 2019-11-05 | Dana-Farber Cancer Institute, Inc. | Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof |
WO2016057488A1 (en) | 2014-10-06 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof |
MA41685A (en) | 2014-10-17 | 2017-08-22 | Biogen Ma Inc | COPPER SUPPLEMENT FOR THE REGULATION OF GLYCOSYLATION IN A MAMMAL CELL CULTURE PROCESS |
US9616109B2 (en) | 2014-10-22 | 2017-04-11 | Extend Biosciences, Inc. | Insulin vitamin D conjugates |
US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
WO2016065042A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Therapeutic vitamin d conjugates |
SG11201703446RA (en) | 2014-10-31 | 2017-05-30 | Abbvie Biotherapeutics Inc | Anti-cs1 antibodies and antibody drug conjugates |
AU2015339106B2 (en) | 2014-10-31 | 2020-07-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods of stimulating and expanding T cells |
EA201790953A1 (en) | 2014-10-31 | 2017-10-31 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | CHANGES IN THE EXPRESSION OF GENE IN CART-CELLS AND THEIR APPLICATION |
MA40864A (en) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | HYPOTAURINE, GABA, BETA-ALANINE AND CHOLINE FOR THE REGULATION OF THE ACCUMULATION OF RESIDUAL BY-PRODUCTS IN MAMMAL CELL CULTURE PROCESSES |
MX2017005930A (en) | 2014-11-05 | 2017-06-30 | Genentech Inc | Methods of producing two chain proteins in bacteria. |
AU2015343029B2 (en) | 2014-11-05 | 2021-07-29 | Annexon, Inc. | Humanized anti-complement factor C1q antibodies and uses thereof |
WO2016073794A1 (en) | 2014-11-05 | 2016-05-12 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
WO2016073157A1 (en) | 2014-11-06 | 2016-05-12 | Genentech, Inc. | Anti-ang2 antibodies and methods of use thereof |
US20160152720A1 (en) | 2014-11-06 | 2016-06-02 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and tigit inhibitors |
CA2967595A1 (en) | 2014-11-12 | 2016-05-19 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
US9879087B2 (en) | 2014-11-12 | 2018-01-30 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
EP3221360A1 (en) | 2014-11-17 | 2017-09-27 | F. Hoffmann-La Roche AG | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
SG11201704058TA (en) | 2014-11-18 | 2017-06-29 | Janssen Pharmaceutica Nv | Cd47 antibodies, methods, and uses |
RU2758608C2 (en) | 2014-11-19 | 2021-11-01 | Конинклейке Филипс Н.В. | Diagnostics method using hnl |
US10517898B2 (en) | 2014-11-20 | 2019-12-31 | The Regents Of The University Of California | Compositions and methods related to hematologic recovery |
ES2832802T3 (en) | 2014-11-21 | 2021-06-11 | Univ Maryland | Systems of directed administration of the specific particulate of a structure |
JP2017537929A (en) | 2014-12-05 | 2017-12-21 | ジェネンテック, インコーポレイテッド | Methods and compositions for cancer treatment using PD-1 axis antagonists and HPK1 antagonists |
PT3333191T (en) | 2014-12-11 | 2020-12-15 | Pf Medicament | Anti-c10orf54 antibodies and uses thereof |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
JP6827928B2 (en) | 2014-12-19 | 2021-02-10 | ユニヴェルシテ・ドゥ・ナント | Anti-IL-34 antibody |
US10221248B2 (en) | 2014-12-22 | 2019-03-05 | The Rockefeller University | Anti-MERTK agonistic antibodies and uses thereof |
AU2016205197B2 (en) | 2015-01-08 | 2021-10-21 | Biogen Ma Inc. | LINGO-1 antagonists and uses for treatment of demyelinating disorders |
JP7152156B2 (en) | 2015-01-14 | 2022-10-12 | ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド | Treatment of cancer with anti-LAP monoclonal antibodies |
US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
CA2974699A1 (en) | 2015-01-23 | 2016-07-28 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccination regimens |
CN107430127B (en) | 2015-01-24 | 2020-08-28 | 中央研究院 | Cancer markers and methods of use thereof |
US10342858B2 (en) | 2015-01-24 | 2019-07-09 | Academia Sinica | Glycan conjugates and methods of use thereof |
CN107407677B (en) | 2015-01-28 | 2020-07-17 | 豪夫迈·罗氏有限公司 | Gene expression markers and treatment of multiple sclerosis |
JP6942633B2 (en) | 2015-01-30 | 2021-09-29 | アカデミア シニカAcademia Sinica | Compositions and Methods for Universal Glycoforms for Enhanced Efficacy of Antibodies |
EP4223873A3 (en) | 2015-01-31 | 2023-09-06 | The Trustees of the University of Pennsylvania | Compositions and methods for t cell delivery of therapeutic molecules |
CN107636170A (en) | 2015-02-04 | 2018-01-26 | 健泰科生物技术公司 | Saltant type Smoothened and its application method |
KR20170110129A (en) | 2015-02-05 | 2017-10-10 | 추가이 세이야쿠 가부시키가이샤 | Antibodies comprising ionic concentration dependent antigen binding domains, Fc region variants, antibodies that bind to IL-8, and their use |
CA2976074A1 (en) | 2015-02-09 | 2016-08-18 | Memorial Sloan Kettering Cancer Center | Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof |
CN107405401B (en) | 2015-02-26 | 2022-02-01 | 默克专利股份公司 | PD-1/PD-L1 inhibitors for the treatment of cancer |
AU2016224409B2 (en) | 2015-02-27 | 2021-01-28 | Chugai Seiyaku Kabushiki Kaisha | Composition for treating IL-6-related diseases |
EP3265491A1 (en) | 2015-03-03 | 2018-01-10 | Xoma (Us) Llc | Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery |
SG10201907901XA (en) | 2015-03-03 | 2019-10-30 | Kymab Ltd | Antibodies, uses & methods |
KR20170125941A (en) | 2015-03-06 | 2017-11-15 | 체에스엘 베링 리컴비넌트 퍼실리티 아게 | Modified von Willebrand factor with improved half-life |
RU2733496C2 (en) | 2015-03-16 | 2020-10-02 | Гельмгольц Центрум Мюнхен - Дойчес Форшунгсцентрум Фюр Гезундхайт Унд Умвельт (Гмбх) | Trispecific binding molecules for treating viral hepatitis b infection and bound states |
CN107667120B (en) | 2015-03-17 | 2022-03-08 | 纪念斯隆-凯特林癌症中心 | anti-MUC 16 antibodies and uses thereof |
EP3271397B1 (en) | 2015-03-18 | 2021-03-03 | The Johns Hopkins University | Inhibitory monoclonal antibody targeting potassium channel kcnk9 |
US20180074077A1 (en) | 2015-03-25 | 2018-03-15 | Alexion Pharmaceuticals, Inc. | A method for measuring the protease activity of factor d of the alternative complement pathway |
TR201904903T4 (en) | 2015-03-25 | 2019-05-21 | Alexion Pharma Inc | A method for measuring the protease activity of C3 and C5 convertase of the alternative complement pathway. |
CN108136001B (en) | 2015-04-03 | 2022-07-29 | 佐马技术有限公司 | Treatment of cancer using TGF-beta inhibitors and PD-1 inhibitors |
WO2016164637A1 (en) | 2015-04-07 | 2016-10-13 | Alector Llc | Anti-sortilin antibodies and methods of use thereof |
WO2016164608A1 (en) | 2015-04-07 | 2016-10-13 | Alector Llc | Methods of screening for sortilin binding antagonists |
EP3280730B1 (en) | 2015-04-08 | 2024-01-03 | Dana-Farber Cancer Institute, Inc. | Humanized influenza monoclonal antibodies and methods of use thereof |
MX2017010734A (en) | 2015-04-17 | 2017-12-04 | Hoffmann La Roche | Combination therapy with coagulation factors and multispecific antibodies. |
FI3283524T3 (en) | 2015-04-17 | 2023-05-05 | Amgen Res Munich Gmbh | Bispecific antibody constructs for cdh3 and cd3 |
KR20180018507A (en) | 2015-04-20 | 2018-02-21 | 톨레로 파마수티컬스, 인크. | Prediction of Response to Albosis Dip by Mitochondrial Profiling |
US20180120297A1 (en) | 2015-04-27 | 2018-05-03 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for assessing toxicity using dynamic bh3 profiling |
KR20170138556A (en) | 2015-05-01 | 2017-12-15 | 다나-파버 캔서 인스티튜트 인크. | Methods for mediating cytokine expression using anti-CCR4 antibodies |
EA201792451A1 (en) | 2015-05-07 | 2018-05-31 | Агенус Инк. | ANTIBODIES TO OX40 AND METHODS OF THEIR APPLICATION |
EP3936524A3 (en) | 2015-05-11 | 2022-06-15 | F. Hoffmann-La Roche AG | Compositions and methods of treating lupus nephritis |
SI3294770T1 (en) | 2015-05-12 | 2021-01-29 | F. Hoffmann-La Roche Ag | Therapeutic and diagnostic methods for cancer |
EP3294773A1 (en) | 2015-05-15 | 2018-03-21 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
MX2017014645A (en) | 2015-05-18 | 2018-01-23 | Tolero Pharmaceuticals Inc | Alvocidib prodrugs having increased bioavailability. |
EP4209228A1 (en) | 2015-05-22 | 2023-07-12 | Translational Drug Development, LLC | Benzamide and active compound compositions and methods of use |
AU2016270625B2 (en) | 2015-05-29 | 2022-10-06 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
CR20170592A (en) | 2015-05-29 | 2018-02-13 | Abbvie Inc | ANTI-CD40 ANTIBODIES AND THEIR USES |
RS60792B1 (en) | 2015-05-29 | 2020-10-30 | Agenus Inc | Anti-ctla-4 antibodies and methods of use thereof |
AU2016269839B2 (en) | 2015-06-03 | 2021-07-08 | The University Of Queensland | Mobilizing agents and uses therefor |
CA2988982A1 (en) | 2015-06-12 | 2016-12-15 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
WO2016201389A2 (en) | 2015-06-12 | 2016-12-15 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
TW201710286A (en) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | Binding proteins against VEGF, PDGF, and/or their receptors |
EP3310810A1 (en) | 2015-06-16 | 2018-04-25 | Merck Patent GmbH | Pd-l1 antagonist combination treatments |
CN107771076A (en) | 2015-06-17 | 2018-03-06 | 豪夫迈·罗氏有限公司 | Use the axle binding antagonists of PD 1 and the method for Taxane treatment Locally Advanced or metastatic breast cancer |
BR112017027870A2 (en) | 2015-06-24 | 2018-08-28 | Janssen Pharmaceutica Nv | antibodies and anti-sight fragments |
MX2017016645A (en) | 2015-06-29 | 2018-11-09 | Genentech Inc | Type ii anti-cd20 antibody for use in organ transplantation. |
TWI717375B (en) | 2015-07-31 | 2021-02-01 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for cd70 and cd3 |
TWI744242B (en) | 2015-07-31 | 2021-11-01 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for egfrviii and cd3 |
TWI796283B (en) | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for msln and cd3 |
TW202346349A (en) | 2015-07-31 | 2023-12-01 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for dll3 and cd3 |
TWI829617B (en) | 2015-07-31 | 2024-01-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for flt3 and cd3 |
WO2017024073A1 (en) | 2015-08-03 | 2017-02-09 | Tolero Pharmaceuticals, Inc. | Combination therapies for treatment of cancer |
TWI797060B (en) | 2015-08-04 | 2023-04-01 | 美商再生元醫藥公司 | Taurine supplemented cell culture medium and methods of use |
JP2018532693A (en) | 2015-08-06 | 2018-11-08 | ゾーマ (ユーエス) リミテッド ライアビリティ カンパニー | Antibody fragments against the insulin receptor and their use to treat hypoglycemia |
MA45352A (en) | 2015-08-07 | 2018-06-13 | Univ Birmingham | IDENTIFICATION OF GLYCOPEPTIDES ASSOCIATED WITH CATEGORY I HCM AS TARGETS FOR CANCER IMMUNOTHERAPY |
CN105384825B (en) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | A kind of bispecific chimeric antigen receptor and its application based on single domain antibody |
EP3337822A1 (en) | 2015-08-19 | 2018-06-27 | Rutgers, The State University of New Jersey | Novel methods of generating antibodies |
PL3338094T3 (en) | 2015-08-20 | 2019-09-30 | F. Hoffmann-La Roche Ag | Particle-based immunoassay using a pegylated analyte-specific binding agent |
CA2996059A1 (en) | 2015-08-28 | 2017-03-09 | Alector Llc | Anti-siglec-7 antibodies and methods of use thereof |
US10323091B2 (en) | 2015-09-01 | 2019-06-18 | Agenus Inc. | Anti-PD-1 antibodies and methods of use thereof |
EP3344806A4 (en) | 2015-09-04 | 2019-03-20 | OBI Pharma, Inc. | Glycan arrays and method of use |
CN108271372B (en) | 2015-09-18 | 2021-07-09 | 中外制药株式会社 | IL-8-binding antibodies and uses thereof |
CA3000386A1 (en) | 2015-09-30 | 2017-04-06 | Merck Patent Gmbh | Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer |
KR20180068999A (en) | 2015-10-06 | 2018-06-22 | 알렉터 엘엘씨 | Anti-TREM2 antibodies and methods of use thereof |
WO2017072669A1 (en) | 2015-10-28 | 2017-05-04 | Friedrich Miescher Institute For Biomedical Research | Tenascin-w and biliary tract cancers |
AU2016343987B2 (en) | 2015-10-29 | 2023-11-23 | Alector Llc | Anti-Siglec-9 antibodies and methods of use thereof |
AR106543A1 (en) | 2015-11-02 | 2018-01-24 | Netris Pharma | NTN1 NEUTRALIZING AGENT COMBINATION THERAPY WITH DRUGS THAT INHIBIT EPIGENTICAL CONTROL |
CN108350078A (en) | 2015-11-03 | 2018-07-31 | 默克专利股份公司 | Bispecific antibody and application thereof for improving tumor-selective and inhibition |
IL258768B2 (en) | 2015-11-12 | 2023-11-01 | Siamab Therapeutics Inc | Glycan-interacting compounds and methods of use |
EP3378487B1 (en) | 2015-11-18 | 2022-03-16 | Chugai Seiyaku Kabushiki Kaisha | Combination therapy using t cell redirection antigen binding molecule against cell having immunosuppressing function |
JP6925278B2 (en) | 2015-11-18 | 2021-08-25 | 中外製薬株式会社 | Method of enhancing humoral immune response |
FI3380525T3 (en) | 2015-11-25 | 2024-01-30 | Immunogen Inc | Pharmaceutical formulations and methods of use thereof |
JP2019500327A (en) | 2015-11-30 | 2019-01-10 | アッヴィ・インコーポレイテッド | Anti-huLRRC15 antibody drug conjugate and method of use thereof |
JP2019501124A (en) | 2015-11-30 | 2019-01-17 | アッヴィ・インコーポレイテッド | Anti-huLRRC15 antibody drug conjugate and method of use thereof |
JP7227007B2 (en) | 2015-12-02 | 2023-02-21 | ストサイエンシス, インコーポレイテッド | Antibodies specific for glycosylated BTLA (B- and T-lymphocyte-attenuating factor) |
ES2861449T3 (en) | 2015-12-02 | 2021-10-06 | Stcube & Co Inc | Antibodies and Molecules that Immunospecifically Bind to BTN1A1 and Their Therapeutic Uses |
EP3184544A1 (en) | 2015-12-23 | 2017-06-28 | Julius-Maximilians-Universität Würzburg | Glycoprotein v inhibitors for use as coagulants |
US20200270363A1 (en) | 2015-12-25 | 2020-08-27 | Chugai Seiyaku Kabushiki Kaisha | Antibody having enhanced activity, and method for modifying same |
CN115400220A (en) | 2015-12-30 | 2022-11-29 | 豪夫迈·罗氏有限公司 | Preparation for reducing degradation of polysorbate |
CA3007491A1 (en) | 2015-12-30 | 2017-07-06 | Genentech, Inc. | Use of tryptophan derivatives for protein formulations |
US11760808B2 (en) | 2015-12-31 | 2023-09-19 | Progastrine Et Cancers S.À R.L. | Compositions and methods for detecting and treating ovarian cancer |
WO2017114975A1 (en) | 2015-12-31 | 2017-07-06 | Progastrine Et Cancers S.À R.L. | Compositions and methods for detecting and treating gastric cancer |
CA3009785A1 (en) | 2015-12-31 | 2017-07-06 | Progastrine Et Cancers S.A R.L. | Compositions and methods for detecting and treating esophageal cancer |
CN108700586A (en) | 2015-12-31 | 2018-10-23 | Syncerus有限责任公司 | Composition and method for the risk for assessing cancer generation |
WO2017118675A1 (en) | 2016-01-08 | 2017-07-13 | F. Hoffmann-La Roche Ag | Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies |
WO2017120536A1 (en) | 2016-01-08 | 2017-07-13 | Apg Therapeutics, Inc. | Polyethylenimine (pei)-polypeptide conjugates and methods of use thereof |
EA039859B1 (en) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Bispecific antibody constructs binding egfrviii and cd3 |
MD3411402T2 (en) | 2016-02-03 | 2022-05-31 | Amgen Res Munich Gmbh | BCMA and CD3 bispecific T cell engaging antibody constructs |
FI3411404T3 (en) | 2016-02-03 | 2023-01-31 | Psma and cd3 bispecific t cell engaging antibody constructs | |
AU2017213826A1 (en) | 2016-02-04 | 2018-08-23 | Curis, Inc. | Mutant smoothened and methods of using the same |
US11262359B2 (en) | 2016-02-05 | 2022-03-01 | NanoView Biosciences, Inc. | Detection of exosomes having surface markers |
MX2018009800A (en) | 2016-02-12 | 2018-11-09 | Janssen Pharmaceutica Nv | Anti-vista (b7h5) antibodies. |
CN109196121B (en) | 2016-02-29 | 2022-01-04 | 基因泰克公司 | Methods for treatment and diagnosis of cancer |
JP7023853B2 (en) | 2016-03-04 | 2022-02-22 | アレクトル エルエルシー | Anti-TREM1 antibody and its usage |
JP7157981B2 (en) | 2016-03-07 | 2022-10-21 | チャールストンファーマ, エルエルシー | anti-nucleolin antibody |
WO2017156192A1 (en) | 2016-03-08 | 2017-09-14 | Academia Sinica | Methods for modular synthesis of n-glycans and arrays thereof |
TW202214700A (en) | 2016-03-14 | 2022-04-16 | 日商中外製藥股份有限公司 | Cell injury inducing therapeutic drug for use in cancer therapy |
CA3017776A1 (en) | 2016-03-15 | 2017-09-21 | Generon (Shanghai) Corporation Ltd. | Multispecific fab fusion proteins and use thereof |
CA3016552A1 (en) | 2016-03-15 | 2017-09-21 | Genentech, Inc. | Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies |
EP3429693B1 (en) | 2016-03-15 | 2023-08-23 | Mersana Therapeutics, Inc. | Napi2b-targeted antibody-drug conjugates and methods of use thereof |
PL3219726T3 (en) | 2016-03-17 | 2021-07-19 | Tillotts Pharma Ag | Anti-tnf alpha-antibodies and functional fragments thereof |
CN109153718B (en) | 2016-03-17 | 2022-02-08 | 努玛治疗有限公司 | anti-TNF alpha antibodies and functional fragments thereof |
LT3219727T (en) | 2016-03-17 | 2021-02-10 | Tillotts Pharma Ag | Anti-tnf alpha-antibodies and functional fragments thereof |
WO2017158084A1 (en) | 2016-03-17 | 2017-09-21 | Numab Innovation Ag | ANTI-TNFα-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF |
IL261261B2 (en) | 2016-03-17 | 2024-04-01 | Numab Therapeutics AG | Anti-tnfalpha-antibodies and functional fragments thereof |
US10745487B2 (en) | 2016-03-22 | 2020-08-18 | Bionomics Limited | Method of treating cancer by administering an anti-LGR5 monoclonal antibody |
EP3432924A1 (en) | 2016-03-23 | 2019-01-30 | Novartis AG | Cell secreted minibodies and uses thereof |
CA3019560A1 (en) | 2016-03-29 | 2017-10-05 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
KR20180128471A (en) | 2016-03-29 | 2018-12-03 | 얀센 바이오테크 인코포레이티드 | Treatment of psoriasis with increased dosing intervals of anti-IL12 and / or anti-IL23 antibodies |
US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
WO2017175058A1 (en) | 2016-04-07 | 2017-10-12 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
EP3443120A2 (en) | 2016-04-15 | 2019-02-20 | H. Hoffnabb-La Roche Ag | Methods for monitoring and treating cancer |
KR20190003958A (en) | 2016-04-15 | 2019-01-10 | 제넨테크, 인크. | Treatment and monitoring of cancer |
JOP20170091B1 (en) | 2016-04-19 | 2021-08-17 | Amgen Res Munich Gmbh | Administration of a bispecific construct binding to CD33 and CD3 for use in a method for the treatment of myeloid leukemia |
CN109379889A (en) | 2016-04-22 | 2019-02-22 | 台湾浩鼎生技股份有限公司 | Pass through the immune activation or immunoregulatory immunotherapy for cancer via GLOBO series antigen |
KR20230124093A (en) | 2016-05-10 | 2023-08-24 | 제넨테크, 인크. | Methods of decreasing trisulfide bonds during recombinant production of polypeptides |
TWI794171B (en) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-l1 inhibitors |
WO2017194568A1 (en) | 2016-05-11 | 2017-11-16 | Sanofi | Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors |
TWI808055B (en) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-1 inhibitors |
ES2864150T3 (en) | 2016-05-17 | 2021-10-13 | Abbvie Biotherapeutics Inc | Anti-cMet Antibody Drug Conjugates and Methods for Their Use |
CN109415441B (en) | 2016-05-24 | 2023-04-07 | 英斯梅德股份有限公司 | Antibodies and methods of making same |
JP2019516748A (en) | 2016-05-26 | 2019-06-20 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | PD-1 / PD-L1 inhibitor for treating cancer |
CA3024508A1 (en) | 2016-05-27 | 2017-11-30 | Agenus Inc. | Anti-tim-3 antibodies and methods of use thereof |
KR20220028143A (en) | 2016-05-27 | 2022-03-08 | 애브비 바이오테라퓨틱스 인크. | Anti-cd40 antibodies and their uses |
US10875921B2 (en) | 2016-05-27 | 2020-12-29 | Abbvie Biotherapeutics Inc. | Anti-4-1BB antibodies and their uses |
KR20190079713A (en) | 2016-06-13 | 2019-07-05 | 아이-맵 | Anti-pd-l1 antibodies and uses thereof |
EP3471767A4 (en) | 2016-06-15 | 2020-01-15 | Icahn School of Medicine at Mount Sinai | Influenza virus hemagglutinin proteins and uses thereof |
CA3030099A1 (en) | 2016-07-08 | 2018-01-11 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
JP2018035137A (en) | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag | Novel anti-fibroblast activated protein (FAP) binding agent and use thereof |
WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
CN116082506A (en) | 2016-07-22 | 2023-05-09 | 丹娜法伯癌症研究所公司 | Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof |
EP3487880A1 (en) | 2016-07-25 | 2019-05-29 | Biogen MA Inc. | Anti-hspa5 (grp78) antibodies and uses thereof |
US11642400B2 (en) | 2016-07-27 | 2023-05-09 | Obi Pharma, Inc. | Immunogenic/therapeutic glycan compositions and uses thereof |
KR102528998B1 (en) | 2016-07-29 | 2023-05-03 | 오비아이 파머 인코퍼레이티드 | Human Antibodies, Pharmaceutical Compositions and Methods |
NL2017267B1 (en) | 2016-07-29 | 2018-02-01 | Aduro Biotech Holdings Europe B V | Anti-pd-1 antibodies |
EP3490600A1 (en) | 2016-08-01 | 2019-06-05 | Xoma (Us) Llc | Parathyroid hormone receptor 1 (pth1r) antibodies and uses thereof |
NL2017270B1 (en) | 2016-08-02 | 2018-02-09 | Aduro Biotech Holdings Europe B V | New anti-hCTLA-4 antibodies |
CN109476748B (en) | 2016-08-08 | 2023-05-23 | 豪夫迈·罗氏有限公司 | Methods for treatment and diagnosis of cancer |
EP3496752B1 (en) | 2016-08-12 | 2022-05-18 | Genentech, Inc. | Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a vegf inhibitor |
US10538592B2 (en) | 2016-08-22 | 2020-01-21 | Cho Pharma, Inc. | Antibodies, binding fragments, and methods of use |
AU2017321973A1 (en) | 2016-09-02 | 2019-03-07 | Dana-Farber Cancer Institute, Inc. | Composition and methods of treating B cell disorders |
US20190233505A1 (en) | 2016-09-06 | 2019-08-01 | Dana-Farber Cancer Institute, Inc. | Methods of treating or preventing zika virus infection |
EP3510046A4 (en) | 2016-09-07 | 2020-05-06 | The Regents of the University of California | Antibodies to oxidation-specific epitopes |
WO2018049248A1 (en) | 2016-09-09 | 2018-03-15 | Icellhealth Consulting Llc | Oncolytic virus equipped with bispecific engager molecules |
IL306104A (en) | 2016-09-14 | 2023-11-01 | Abbvie Biotherapeutics Inc | Anti-pd-1(cd279) antibodies |
PT3328887T (en) | 2016-09-19 | 2021-10-19 | I Mab Biopharma Hangzhou Co Ltd | Anti-gm-csf antibodies and uses thereof |
EP3515478B1 (en) | 2016-09-21 | 2024-02-28 | Nextcure, Inc. | Antibodies for siglec-15 and methods of use thereof |
JOP20190009A1 (en) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | Antibodies against signal-regulatory protein alpha and methods of use |
EP3518969A2 (en) | 2016-09-28 | 2019-08-07 | Xoma (Us) Llc | Antibodies that bind interleukin-2 and uses thereof |
WO2018064299A1 (en) | 2016-09-29 | 2018-04-05 | Genentech, Inc. | Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a taxane |
MA46366A (en) | 2016-09-30 | 2019-08-07 | Janssen Biotech Inc | SAFE AND EFFECTIVE PROCESS FOR TREATING PSORIASIS WITH A SPECIFIC ANTIBODY AGAINST IL-23 |
US20180106818A1 (en) | 2016-10-03 | 2018-04-19 | Abbott Laboratories | Methods of assessing gfap status in patient samples |
CN109843324A (en) | 2016-10-06 | 2019-06-04 | 辉瑞公司 | AVELUMAB therapeutic regimen for treating cancer |
TWI775781B (en) | 2016-10-06 | 2022-09-01 | 美商建南德克公司 | Therapeutic and diagnostic methods for cancer |
EP3526256A1 (en) | 2016-10-11 | 2019-08-21 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
WO2018081531A2 (en) | 2016-10-28 | 2018-05-03 | Ariad Pharmaceuticals, Inc. | Methods for human t-cell activation |
JP7100030B2 (en) | 2016-10-28 | 2022-07-12 | アスチュート メディカル,インコーポレイテッド | Use of antibody against TIMP-2 to improve renal function |
AU2017355402A1 (en) | 2016-11-02 | 2019-05-30 | Health Research, Inc. | Combination treatment with antibody-drug conjugates and PARP inhibitors |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
AU2017353936A1 (en) | 2016-11-04 | 2019-05-02 | Novimmune Sa | Anti-CD19 antibodies and methods of use thereof |
KR102539159B1 (en) | 2016-11-07 | 2023-06-02 | 주식회사 뉴라클사이언스 | Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof |
MA46861A (en) | 2016-11-16 | 2019-09-25 | Janssen Biotech Inc | METHOD OF TREATING PSORIASIS WITH A SPECIFIC ANTI-IL-23 ANTIBODY |
US11401330B2 (en) | 2016-11-17 | 2022-08-02 | Seagen Inc. | Glycan-interacting compounds and methods of use |
WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
TWI822055B (en) | 2016-11-21 | 2023-11-11 | 台灣浩鼎生技股份有限公司 | Conjugated biological molecules, pharmaceutical compositions and methods |
CN110234319B (en) | 2016-11-23 | 2022-09-27 | 转化药物开发有限责任公司 | Compositions of benzamide and active compound and methods of use thereof |
BR112019008265A2 (en) | 2016-11-28 | 2019-07-09 | Chugai Pharmaceutical Co Ltd | ligand-binding molecule whose ligand-binding activity is adjustable |
BR112019011582A2 (en) | 2016-12-07 | 2019-10-22 | Agenus Inc. | antibodies and their methods of use |
KR20230037664A (en) | 2016-12-07 | 2023-03-16 | 아게누스 인코포레이티드 | Anti-ctla-4 antibodies and methods of use thereof |
ES2813057T3 (en) | 2016-12-15 | 2021-03-22 | Abbvie Biotherapeutics Inc | Anti-ox40 antibodies and their uses |
CN110234659A (en) | 2016-12-19 | 2019-09-13 | 特雷罗药物股份有限公司 | Analytical peptide and method for sensitivity analysis |
WO2018122043A1 (en) | 2016-12-27 | 2018-07-05 | F. Hoffmann-La Roche Ag | Novel biotin-specific monoclonal antibody and use thereof |
KR20210126136A (en) | 2016-12-27 | 2021-10-19 | 에프. 호프만-라 로슈 아게 | Novel biotin-specific monoclonal antibody and use thereof |
WO2018122204A1 (en) | 2016-12-27 | 2018-07-05 | F. Hoffmann-La Roche Ag | Novel biotin-specific monoclonal antibody and use thereof |
WO2018129284A1 (en) | 2017-01-05 | 2018-07-12 | The Johns Hopkins University | Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (psma) |
US20190315852A1 (en) | 2017-01-05 | 2019-10-17 | Netris Pharma | Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs |
MX2019007848A (en) | 2017-01-20 | 2019-09-09 | Tayu Huaxia Biotech Medical Group Co Ltd | Anti-pd-1 antibodies and uses thereof. |
MY188386A (en) | 2017-01-24 | 2021-12-07 | I Mab Biopharma Us Ltd | Anti-cd73 antibodies and uses thereof |
WO2018140510A1 (en) | 2017-01-25 | 2018-08-02 | Biogen Ma Inc. | Compositions and methods for treatment of stroke and other cns disorders |
JP2020506916A (en) | 2017-01-30 | 2020-03-05 | ヤンセン バイオテツク,インコーポレーテツド | Anti-TNF antibodies, compositions and methods for the treatment of active psoriatic arthritis |
JOP20190189A1 (en) | 2017-02-02 | 2019-08-01 | Amgen Res Munich Gmbh | Low ph pharmaceutical composition comprising t cell engaging antibody constructs |
CN110234995A (en) | 2017-02-02 | 2019-09-13 | 豪夫迈·罗氏有限公司 | Use the immunoassays of the analyte specificity combinating reagent of at least two Pegylations |
MA47442A (en) | 2017-02-07 | 2019-12-18 | Janssen Biotech Inc | ANTI-TNF ANTIBODIES, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLARTHRITIS |
CN108456251A (en) | 2017-02-21 | 2018-08-28 | 上海君实生物医药科技股份有限公司 | Anti- PD-L1 antibody and its application |
CN110546277A (en) | 2017-03-01 | 2019-12-06 | 豪夫迈·罗氏有限公司 | Methods for diagnosis and treatment of cancer |
WO2018160909A1 (en) | 2017-03-03 | 2018-09-07 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
TWI808963B (en) | 2017-03-22 | 2023-07-21 | 法商賽諾菲公司 | Treatment of lupus using humanized anti-cxcr5 antibodies |
US11016092B2 (en) | 2017-03-23 | 2021-05-25 | Abbott Laboratories | Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase L1 |
WO2018174274A1 (en) | 2017-03-24 | 2018-09-27 | 全薬工業株式会社 | ANTI-IgM/B CELL SURFACE ANTIGEN BISPECIFIC ANTIBODY |
KR102644408B1 (en) | 2017-03-30 | 2024-03-07 | 메르크 파텐트 게엠베하 | Combination of anti-PD-L1 antibody and DNA-PK inhibitor for treatment of cancer |
WO2018178363A1 (en) | 2017-03-30 | 2018-10-04 | Progastrine Et Cancers S.À R.L. | Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule |
ES2925227T3 (en) | 2017-03-30 | 2022-10-14 | Ecs Progastrin Sa | Compositions and methods for detecting lung cancer |
JP7209298B2 (en) | 2017-03-31 | 2023-01-20 | 公立大学法人奈良県立医科大学 | A pharmaceutical composition used for the prevention and/or treatment of blood coagulation factor IX disorders, containing a multispecific antigen-binding molecule that substitutes for the function of blood coagulation factor VIII |
US10722589B2 (en) | 2017-04-03 | 2020-07-28 | Covagen Ag | FGFR3 binding molecules |
JP7315466B2 (en) | 2017-04-05 | 2023-07-26 | アスチュート メディカル,インコーポレイテッド | Assays for TIMP2 with improved performance in biological samples |
CA3058652A1 (en) | 2017-04-07 | 2018-10-11 | Icahn School Of Medicine At Mount Sinai | Anti-influenza b virus neuraminidase antibodies and uses thereof |
CA3059366A1 (en) | 2017-04-13 | 2018-10-18 | Agenus Inc. | Anti-cd137 antibodies and methods of use thereof |
EP3610268A1 (en) | 2017-04-15 | 2020-02-19 | Abbott Laboratories | Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers |
CA3059133A1 (en) | 2017-04-21 | 2018-10-25 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
BR112019022108A2 (en) | 2017-04-22 | 2020-05-12 | Immunomic Therapeutics, Inc. | ENHANCED LAMP CONSTRUCTIONS |
US20230140818A1 (en) | 2017-04-27 | 2023-05-04 | The University Of Hong Kong | Use of hcn inhibitors for treatment of cancer |
JP7261739B2 (en) | 2017-04-27 | 2023-04-20 | 中外製薬株式会社 | Blood Coagulation Factor IX with Improved Pharmacokinetics |
WO2018200823A1 (en) | 2017-04-28 | 2018-11-01 | Abbott Laboratories | Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject |
ES2952961T3 (en) | 2017-05-01 | 2023-11-07 | Agenus Inc | Anti-TIGIT antibodies and methods of their use |
EP3618854A1 (en) | 2017-05-02 | 2020-03-11 | Immunomic Therapeutics, Inc. | Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens |
EP3620531A4 (en) | 2017-05-02 | 2021-03-17 | National Center of Neurology and Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to il-6 and neutrophils |
EP3618864A1 (en) | 2017-05-05 | 2020-03-11 | Amgen Inc. | Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration |
US10865238B1 (en) | 2017-05-05 | 2020-12-15 | Duke University | Complement factor H antibodies |
JOP20190256A1 (en) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | Newcastle disease viruses and uses thereof |
WO2018213316A1 (en) | 2017-05-16 | 2018-11-22 | Alector Llc | Anti-siglec-5 antibodies and methods of use thereof |
US10914729B2 (en) | 2017-05-22 | 2021-02-09 | The Trustees Of Princeton University | Methods for detecting protein binding sequences and tagging nucleic acids |
EP3630830A1 (en) | 2017-05-23 | 2020-04-08 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Novel cd73 antibody, preparation and uses thereof |
CN110651190A (en) | 2017-05-25 | 2020-01-03 | 雅培实验室 | Method for using early biomarkers to help determine whether to perform imaging on a human subject who has suffered or may have suffered a head injury |
EP3630167A1 (en) | 2017-05-26 | 2020-04-08 | NovImmune SA | Anti-cd47 x anti-mesothelin antibodies and methods of use thereof |
EP3631467A1 (en) | 2017-05-30 | 2020-04-08 | Abbott Laboratories | Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin i |
AU2018277545A1 (en) | 2017-05-31 | 2019-12-19 | Stcube & Co., Inc. | Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1 |
US20200148768A1 (en) | 2017-05-31 | 2020-05-14 | Stcube & Co., Inc. | Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof |
EP3635007A1 (en) | 2017-06-06 | 2020-04-15 | STCube & Co., Inc. | Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands |
WO2019000223A1 (en) | 2017-06-27 | 2019-01-03 | Nanjing Legend Biotech Co., Ltd. | Chimeric antibody immune effctor cell engagers and methods of use thereof |
TW201920266A (en) | 2017-07-14 | 2019-06-01 | 美商輝瑞大藥廠 | Antibodies to MAdCAM |
JP2020527351A (en) | 2017-07-21 | 2020-09-10 | ジェネンテック, インコーポレイテッド | Cancer treatment and diagnosis |
CN111491661A (en) | 2017-07-27 | 2020-08-04 | 诺莫坎制药有限责任公司 | M (H) DM2/4 antibodies and their use in the diagnosis and treatment of cancer |
EP4248996A3 (en) | 2017-08-03 | 2023-11-08 | Alector LLC | Anti-trem2 antibodies and methods of use thereof |
KR20200033798A (en) | 2017-08-03 | 2020-03-30 | 알렉터 엘엘씨 | Anti-CD33 antibodies and methods of use |
KR20200054209A (en) | 2017-08-21 | 2020-05-19 | 아다진 인크. | Dynamic human antibody light chain library |
WO2019036842A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | Dynamic human heavy chain antibody libraries |
MX2020002612A (en) | 2017-09-07 | 2020-07-13 | Univ Res Inst Inc Augusta | Antibodies to programmed cell death protein 1. |
US11497756B2 (en) | 2017-09-12 | 2022-11-15 | Sumitomo Pharma Oncology, Inc. | Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib |
WO2019059411A1 (en) | 2017-09-20 | 2019-03-28 | Chugai Seiyaku Kabushiki Kaisha | Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent |
BR112020005737A2 (en) | 2017-09-22 | 2020-11-17 | F. Hoffmann-La Roche Ag | multivalent recombinant antibody and its use, kit and method to detect an antigen |
TW201922780A (en) | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | Safe and effective method of treating Lupus with anti-IL12/IL23 antibody |
US11230601B2 (en) | 2017-10-10 | 2022-01-25 | Tilos Therapeutics, Inc. | Methods of using anti-lap antibodies |
EP3694890A4 (en) | 2017-10-12 | 2021-11-03 | Immunowake Inc. | Vegfr-antibody light chain fusion protein |
US11692037B2 (en) | 2017-10-20 | 2023-07-04 | Hyogo College Of Medicine | Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion |
US11826414B2 (en) | 2017-10-23 | 2023-11-28 | Cz Biohub Sf, Llc | Measurement of afucosylated IgG Fc glycans and related vaccination methods |
WO2019084460A1 (en) | 2017-10-26 | 2019-05-02 | The Regents Of The University Of California | Inhibition of oxidation-specific epitopes to treat ischemic reperfusion injury |
AU2018361957B2 (en) | 2017-10-31 | 2023-05-25 | Staten Biotechnology B.V. | Anti-ApoC3 antibodies and methods of use thereof |
US20190160089A1 (en) | 2017-10-31 | 2019-05-30 | Immunogen, Inc. | Combination treatment with antibody-drug conjugates and cytarabine |
TW201923089A (en) | 2017-11-06 | 2019-06-16 | 美商建南德克公司 | Diagnostic and therapeutic methods for cancer |
EP3717069A1 (en) | 2017-11-27 | 2020-10-07 | Purdue Pharma L.P. | Humanized antibodies targeting human tissue factor |
EP3719036A4 (en) | 2017-11-28 | 2021-09-08 | Chugai Seiyaku Kabushiki Kaisha | Ligand-binding molecule having adjustable ligand-binding activity |
ES2920283T3 (en) | 2017-12-05 | 2022-08-02 | Progastrine Et Cancers S A R L | Combination therapy between an antiprogastrin antibody and immunotherapy to treat cancer |
WO2019113375A2 (en) | 2017-12-06 | 2019-06-13 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem and progenitor cells |
WO2019113525A2 (en) | 2017-12-09 | 2019-06-13 | Abbott Laboratories | Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1) |
EP3721234A1 (en) | 2017-12-09 | 2020-10-14 | Abbott Laboratories | Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1 |
SG11202004273YA (en) | 2017-12-11 | 2020-06-29 | Amgen Inc | Continuous manufacturing process for bispecific antibody products |
EP3710484B1 (en) | 2017-12-20 | 2023-10-25 | Harbour Biomed (Shanghai) Co., Ltd | Antibodies binding ctla-4 and uses thereof |
US11667713B2 (en) | 2017-12-28 | 2023-06-06 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
WO2019133902A2 (en) | 2017-12-28 | 2019-07-04 | Astute Medical, Inc. | Antibodies and assays for ccl14 |
EP3732202A4 (en) | 2017-12-28 | 2022-06-15 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against tigit |
US20220135687A1 (en) | 2017-12-28 | 2022-05-05 | Nanjing Legend Biotech Co., Ltd. | Antibodies and variants thereof against pd-l1 |
TW201940518A (en) | 2017-12-29 | 2019-10-16 | 美商安進公司 | Bispecific antibody construct directed to MUC17 and CD3 |
CA3084518A1 (en) | 2018-01-15 | 2019-07-18 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against pd-1 |
US20210251899A1 (en) | 2018-01-25 | 2021-08-19 | Acm Biolabs Pte Ltd | Polymersomes comprising a soluble encapsulated antigen as well as methods of making and uses thereof |
WO2019145537A1 (en) | 2018-01-26 | 2019-08-01 | Ecs-Progastrin Sa | Combination of progastrin detection with other cancer biomarkers in cancer diagnosis |
WO2019151418A1 (en) | 2018-01-31 | 2019-08-08 | 元一 加藤 | Therapeutic agent for asthma containing il-6 inhibitor |
TW202000702A (en) | 2018-02-26 | 2020-01-01 | 美商建南德克公司 | Dosing for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies |
US20200400675A1 (en) | 2018-02-27 | 2020-12-24 | Ecs-Progastrin Sa | Progastrin as a biomarker for immunotherapy |
WO2019169229A1 (en) | 2018-03-01 | 2019-09-06 | Nextcure, Inc. | Klrg1 binding compositions and methods of use thereof |
NL2020520B1 (en) | 2018-03-02 | 2019-09-12 | Labo Bio Medical Invest B V | Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders |
JP2021515770A (en) | 2018-03-05 | 2021-06-24 | ヤンセン バイオテツク,インコーポレーテツド | Treatment of Crohn's disease using anti-IL-23 specific antibody |
BR112020017701A2 (en) | 2018-03-12 | 2020-12-29 | Zoetis Services Llc | ANTI-NGF ANTIBODIES AND METHODS OF THE SAME |
AU2019235033A1 (en) | 2018-03-14 | 2020-07-30 | Beijing Xuanyi Pharmasciences Co., Ltd. | Anti-claudin 18.2 antibodies |
US11203646B2 (en) | 2018-03-14 | 2021-12-21 | Novimmune Sa | Anti-CD3 epsilon antibodies and methods of use thereof |
CN112040979A (en) | 2018-03-21 | 2020-12-04 | Alx肿瘤生物技术公司 | Antibodies to signal-modulating protein alpha and methods of use |
WO2019180272A1 (en) | 2018-03-23 | 2019-09-26 | Fundación Instituto De Investigación Sanitaria De Santiago De Compostela | Anti-leptin affinity reagents for use in the treatment of obesity and other leptin-resistance associated diseases |
PL3775909T3 (en) | 2018-03-26 | 2023-09-18 | Glycanostics S.R.O. | Means and methods for glycoprofiling of a protein |
PE20201343A1 (en) | 2018-04-02 | 2020-11-25 | Bristol Myers Squibb Co | ANTI-TREM-1 ANTIBODIES AND USES OF THEM |
WO2019197651A1 (en) | 2018-04-12 | 2019-10-17 | Mediapharma S.R.L. | Lgals3bp antibody-drug-conjugate and its use for the treatment of cancer |
AU2019256383A1 (en) | 2018-04-17 | 2020-11-26 | Celldex Therapeutics, Inc. | Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs |
EP3784274A1 (en) | 2018-04-27 | 2021-03-03 | Fondazione Ebri Rita Levi-Montalcini | Antibody directed against a tau-derived neurotoxic peptide and uses thereof |
JP2021522298A (en) | 2018-05-04 | 2021-08-30 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Simultaneous inhibition of PD-1 / PD-L1, TGFβ and DNA-PK for cancer treatment |
US20190345245A1 (en) | 2018-05-11 | 2019-11-14 | Janssen Biotech, Inc. | Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody |
TW202003048A (en) | 2018-05-15 | 2020-01-16 | 美商伊繆諾金公司 | Combination treatment with antibody-drug conjugates and FLT3 inhibitors |
CA3100004A1 (en) | 2018-05-15 | 2019-11-21 | Immunomic Therapeutics, Inc. | Improved lamp constructs comprising allergens |
JPWO2019225568A1 (en) | 2018-05-21 | 2021-07-01 | 中外製薬株式会社 | Lyophilized preparation enclosed in a glass container |
US11319373B2 (en) | 2018-05-25 | 2022-05-03 | Alector Llc | Anti-SIRPA antibodies and methods of use thereof |
WO2019232321A1 (en) | 2018-06-01 | 2019-12-05 | NanoView Biosciences, Inc. | Compositions, systems, and methods for enhanced label-free and fluorescence - based detection of nanoparticles |
EP3802610A1 (en) | 2018-06-05 | 2021-04-14 | Amgen Inc. | Modulating antibody dependent cellular phagocytosis |
AU2019282778A1 (en) | 2018-06-08 | 2020-12-10 | Alector Llc | Anti-Siglec-7 antibodies and methods of use thereof |
AU2019288677A1 (en) | 2018-06-21 | 2021-01-14 | Yumanity Therapeutics, Inc. | Compositions and methods for the treatment and prevention of neurological disorders |
WO2019246557A1 (en) | 2018-06-23 | 2019-12-26 | Genentech, Inc. | Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor |
WO2020006176A1 (en) | 2018-06-27 | 2020-01-02 | Obi Pharma, Inc. | Glycosynthase variants for glycoprotein engineering and methods of use |
WO2020003210A1 (en) | 2018-06-29 | 2020-01-02 | Kangwon National University University-Industry Cooperation Foundation | Anti-l1cam antibodies and uses thereof |
FI3618928T3 (en) | 2018-07-13 | 2023-04-21 | Alector Llc | Anti-sortilin antibodies and methods of use thereof |
KR20210034622A (en) | 2018-07-18 | 2021-03-30 | 제넨테크, 인크. | Lung cancer treatment method using PD-1 axis binding antagonist, anti-metabolite, and platinum agent |
US20200025776A1 (en) | 2018-07-18 | 2020-01-23 | Janssen Biotech, Inc. | Sustained Response Predictors After Treatment With Anti-IL23 Specific Antibody |
BR112021000934A2 (en) | 2018-07-20 | 2021-04-27 | Pierre Fabre Medicament | receiver for sight |
MX2021000933A (en) | 2018-07-27 | 2021-05-27 | Alector Llc | Anti-siglec-5 antibodies and methods of use thereof. |
CN112771075A (en) | 2018-07-30 | 2021-05-07 | 安进研发(慕尼黑)股份有限公司 | Prolonged administration of bispecific antibody constructs that bind to CD33 and CD3 |
EA202190435A1 (en) | 2018-08-03 | 2021-06-30 | Эмджен Рисерч (Мюник) Гмбх | ANTIBODY BASED CONSTRUCTIONS FOR CLDN18.2 AND CD3 BINDING |
AU2019319822A1 (en) | 2018-08-08 | 2021-03-18 | Genentech, Inc. | Use of tryptophan derivatives and L-methionine for protein formulation |
WO2020043670A1 (en) | 2018-08-27 | 2020-03-05 | Affimed Gmbh | Cryopreserved nk cells preloaded with an antibody construct |
CA3110530A1 (en) | 2018-09-11 | 2020-03-19 | Amgen Inc. | Methods of modulating antibody-dependent cell-mediated cytotoxicity |
WO2020053325A1 (en) | 2018-09-12 | 2020-03-19 | Acm Biolabs Pte Ltd | Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof |
AU2019342099A1 (en) | 2018-09-19 | 2021-04-08 | Genentech, Inc. | Therapeutic and diagnostic methods for bladder cancer |
EP4249917A3 (en) | 2018-09-21 | 2023-11-08 | F. Hoffmann-La Roche AG | Diagnostic methods for triple-negative breast cancer |
CN113164596A (en) | 2018-09-24 | 2021-07-23 | 詹森生物科技公司 | Safe and effective methods of treating ulcerative colitis with anti-IL 12/IL23 antibodies |
CA3114024A1 (en) | 2018-09-26 | 2020-04-02 | Merck Patent Gmbh | Combination of a pd-1 antagonist, an atr inhibitor and a platinating agent for the treatment of cancer |
KR20210068408A (en) | 2018-09-28 | 2021-06-09 | 암젠 인크 | Antibodies to Soluble BCMA |
AU2019352017A1 (en) | 2018-10-03 | 2021-05-06 | Staten Biotechnology B.V. | Antibodies specific for human and cynomolgus ApoC3 and methods of use thereof |
US11130802B2 (en) | 2018-10-10 | 2021-09-28 | Tilos Therapeutics, Inc. | Anti-lap antibody variants |
WO2020077212A1 (en) | 2018-10-11 | 2020-04-16 | Amgen Inc. | Downstream processing of bispecific antibody constructs |
CA3116234A1 (en) | 2018-10-15 | 2020-04-23 | Merck Patent Gmbh | Combination therapy utilizing dna alkylating agents and atr inhibitors |
CN113196061A (en) | 2018-10-18 | 2021-07-30 | 豪夫迈·罗氏有限公司 | Methods of diagnosis and treatment of sarcoma-like renal cancer |
WO2020086408A1 (en) | 2018-10-26 | 2020-04-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A high-yield perfusion-based transient gene expression bioprocess |
WO2020092455A2 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Car t cell transcriptional atlas |
CA3118453A1 (en) | 2018-11-02 | 2020-05-07 | The Regents Of The University Of California | Compositions and methods for treating brain injury |
EP3877407A1 (en) | 2018-11-05 | 2021-09-15 | F. Hoffmann-La Roche AG | Methods of producing two chain proteins in prokaryotic host cells |
US20220011301A1 (en) | 2018-11-16 | 2022-01-13 | Roche Diagnostics Operations, Inc. | Streptavidin-coated solid phases with a member of a binding pair |
EP3883607A4 (en) | 2018-11-20 | 2022-08-17 | Janssen Biotech, Inc. | Safe and effective method of treating psoriasis with anti-il-23 specific antibody |
CA3119807A1 (en) | 2018-12-04 | 2020-06-11 | Sumitomo Dainippon Pharma Oncology, Inc. | Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
US20220098310A1 (en) | 2018-12-06 | 2022-03-31 | Alexion Pharmaceuticals, Inc. | Anti-alk2 antibodies and uses thereof |
US20220026445A1 (en) | 2018-12-07 | 2022-01-27 | Georgia Tech Research Corporation | Antibodies that bind to natively folded myocilin |
MA54562A (en) | 2018-12-18 | 2021-10-27 | Janssen Biotech Inc | SAFE AND EFFECTIVE METHOD OF TREATING LUPUS WITH AN ANTI-IL12/IL23 ANTIBODY |
CN115120716A (en) | 2019-01-14 | 2022-09-30 | 健泰科生物技术公司 | Methods of treating cancer with PD-1 axis binding antagonists and RNA vaccines |
JP2022518208A (en) | 2019-01-15 | 2022-03-14 | ヤンセン バイオテツク,インコーポレーテツド | Anti-TNF Antibodies, Compositions, and Methods for the Treatment of Juvenile Idiopathic Arthritis |
BR112021014267A2 (en) | 2019-01-23 | 2022-02-15 | Janssen Biotech Inc | Anti-tnf antibody compositions and methods for the treatment of psoriatic arthritis |
AU2020211976A1 (en) | 2019-01-23 | 2021-07-15 | Genentech, Inc. | Methods of producing multimeric proteins in eukaryotic host cells |
CN113329770A (en) | 2019-01-24 | 2021-08-31 | 中外制药株式会社 | Novel cancer antigen and antibody against said antigen |
WO2020157122A1 (en) | 2019-01-29 | 2020-08-06 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Treating the causative agent in adhesiogenesis |
AU2019427766A1 (en) | 2019-01-30 | 2021-09-16 | Nomocan Pharmaceuticals Llc | Antibodies to M(H)DM2/4 and their use in diagnosing and treating cancer |
WO2020163589A1 (en) | 2019-02-08 | 2020-08-13 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
US11028176B2 (en) | 2019-02-13 | 2021-06-08 | The Brigham And Women's Hospital, Inc. | Anti-peripheral lymph node addressin antibodies and uses thereof |
CN112703013B (en) | 2019-02-22 | 2022-09-30 | 武汉友芝友生物制药股份有限公司 | CD3 antigen binding fragment and application thereof |
US11242407B2 (en) | 2019-02-26 | 2022-02-08 | Inspirna, Inc. | High-affinity anti-MERTK antibodies and uses thereof |
CA3130695A1 (en) | 2019-02-27 | 2020-09-03 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies |
CN113508140A (en) | 2019-02-28 | 2021-10-15 | 学校法人顺天堂 | Antibody binding to cleaved mutant Calreticulin and bone marrow proliferative tumor diagnostic, prophylactic or therapeutic agent |
CN113825765A (en) | 2019-03-14 | 2021-12-21 | 詹森生物科技公司 | Method for producing anti-IL 12/IL23 antibody composition |
JP2022526881A (en) | 2019-03-14 | 2022-05-27 | ヤンセン バイオテツク,インコーポレーテツド | Methods for Producing Anti-TNF Antibody Compositions |
CA3133388A1 (en) | 2019-03-14 | 2020-09-17 | Janssen Biotech, Inc. | Methods for producing anti-tnf antibody compositions |
WO2020183269A1 (en) | 2019-03-14 | 2020-09-17 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-tnf antibody compositions |
KR20230146132A (en) | 2019-03-15 | 2023-10-18 | 카티전 테라퓨틱스, 인코포레이티드 | Anti-bcma chimeric antigen receptors |
AU2020243588A1 (en) | 2019-03-18 | 2021-10-07 | Janssen Biotech, Inc. | Method of treating psoriasis in pediatric subjects with anti-IL12/IL23 antibody |
US20220153875A1 (en) | 2019-03-19 | 2022-05-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain |
JP2022525149A (en) | 2019-03-20 | 2022-05-11 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | Treatment of Acute Myeloid Leukemia (AML) with Venetoclax Failure |
US11090336B2 (en) | 2019-03-27 | 2021-08-17 | The Trustees Of The University Of Pennsylvania | Tn-MUC1 chimeric antigen receptor (CAR) T cell therapy |
CN113874392A (en) | 2019-03-28 | 2021-12-31 | 丹尼斯科美国公司 | Engineered antibodies |
JPWO2020209318A1 (en) | 2019-04-10 | 2020-10-15 | ||
CA3135694A1 (en) | 2019-04-17 | 2020-10-22 | Hiroshima University | Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination |
US20230135930A1 (en) | 2019-04-24 | 2023-05-04 | Heidelberg Pharma Research Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
CN114269376A (en) | 2019-05-03 | 2022-04-01 | 豪夫迈·罗氏有限公司 | Methods of treating cancer with anti-PD-L1 antibodies |
US20200369759A1 (en) | 2019-05-23 | 2020-11-26 | Fibrogen, Inc. | Methods of treatment of muscular dystrophies |
US11780911B2 (en) | 2019-05-23 | 2023-10-10 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha |
EP3976648A1 (en) | 2019-06-03 | 2022-04-06 | Janssen Biotech, Inc. | Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis |
AU2020288404A1 (en) | 2019-06-03 | 2022-02-03 | Janssen Biotech, Inc. | Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis |
BR112021023735A2 (en) | 2019-06-05 | 2022-01-04 | Chugai Pharmaceutical Co Ltd | Antibody cleavage site binding molecule |
EP3983520A1 (en) | 2019-06-13 | 2022-04-20 | Amgen, Inc | Automated biomass-based perfusion control in the manufacturing of biologics |
WO2021021676A1 (en) | 2019-07-26 | 2021-02-04 | Amgen Inc. | Anti-il13 antigen binding proteins |
WO2021028752A1 (en) | 2019-08-15 | 2021-02-18 | Janssen Biotech, Inc. | Anti-tfn antibodies for treating type i diabetes |
CN114585644A (en) | 2019-08-30 | 2022-06-03 | 艾吉纳斯公司 | anti-CD 96 antibodies and methods of use thereof |
US20220348650A1 (en) | 2019-09-03 | 2022-11-03 | Bio-Thera Solutions, Ltd. | Anti-tigit immunosuppressant and application thereof |
CR20220095A (en) | 2019-09-04 | 2022-06-06 | Genentech Inc | Cd8 binding agents and uses thereof |
EP4028416A1 (en) | 2019-09-10 | 2022-07-20 | Amgen Inc. | Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity |
CN114340675A (en) | 2019-09-12 | 2022-04-12 | 豪夫迈·罗氏有限公司 | Compositions and methods for treating lupus nephritis |
WO2021062323A1 (en) | 2019-09-26 | 2021-04-01 | Stcube & Co. | Antibodies specific to glycosylated ctla-4 and methods of use thereof |
MX2022003610A (en) | 2019-09-27 | 2022-04-20 | Genentech Inc | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies. |
CN114829404A (en) | 2019-10-09 | 2022-07-29 | 斯特库比公司 | Antibodies specific for glycosylated LAG3 and methods of use thereof |
JP2022551732A (en) | 2019-10-18 | 2022-12-13 | イミュノミック セラピューティックス, インコーポレイテッド | Improved LAMP constructs containing cancer antigens |
US20220401481A1 (en) | 2019-11-01 | 2022-12-22 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem and progenitor cells |
KR20220095205A (en) | 2019-11-01 | 2022-07-06 | 아레스 트레이딩 에스.아. | Combination inhibition of PD-1, TGFβ and ATM with radiotherapy for the treatment of cancer |
AU2020379201A1 (en) | 2019-11-05 | 2022-05-26 | Glaxosmithkline Intellectual Property (No. 4) Ltd. | Combined inhibition of PD-1, TGFβ and TIGIT for the treatment of cancer |
KR20220092580A (en) | 2019-11-06 | 2022-07-01 | 제넨테크, 인크. | Diagnosis and treatment methods for the treatment of blood cancer |
EP4058485A1 (en) | 2019-11-13 | 2022-09-21 | Amgen Inc. | Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules |
EP3825330A1 (en) | 2019-11-19 | 2021-05-26 | International-Drug-Development-Biotech | Anti-cd117 antibodies and methods of use thereof |
WO2021113655A1 (en) | 2019-12-05 | 2021-06-10 | Alector Llc | Methods of use of anti-trem2 antibodies |
US11897950B2 (en) | 2019-12-06 | 2024-02-13 | Augusta University Research Institute, Inc. | Osteopontin monoclonal antibodies |
CR20220322A (en) | 2019-12-09 | 2022-07-28 | Genentech Inc | Anti-pd-l1 antibody formulations |
BR112022011337A2 (en) | 2019-12-12 | 2022-08-23 | Alector Llc | METHOD TO TREAT AND/OR DELAY THE PROGRESSION OF A DISEASE OR INJURY IN AN INDIVIDUAL |
WO2021127528A1 (en) | 2019-12-20 | 2021-06-24 | Amgen Inc. | Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumors |
WO2021130383A1 (en) | 2019-12-27 | 2021-07-01 | Affimed Gmbh | Method for the production of bispecific fcyriii x cd30 antibody construct |
CN115052663A (en) | 2020-01-08 | 2022-09-13 | 辛瑟斯治疗股份有限公司 | ALK5 inhibitor conjugates and uses thereof |
EP4093771A1 (en) | 2020-01-22 | 2022-11-30 | Amgen Research (Munich) GmbH | Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof |
WO2021194481A1 (en) | 2020-03-24 | 2021-09-30 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
WO2022050954A1 (en) | 2020-09-04 | 2022-03-10 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
JP2023512654A (en) | 2020-01-31 | 2023-03-28 | ジェネンテック, インコーポレイテッド | Methods for Inducing Neoepitope-Specific T Cells Using PD-1 Axis Binding Antagonists and RNA Vaccines |
CN113248611A (en) | 2020-02-13 | 2021-08-13 | 湖南华康恒健生物技术有限公司 | anti-BCMA antibody, pharmaceutical composition and application thereof |
US20230159637A1 (en) | 2020-02-24 | 2023-05-25 | Alector Llc | Methods of use of anti-trem2 antibodies |
CA3174103A1 (en) | 2020-03-06 | 2021-09-10 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
WO2021177980A1 (en) | 2020-03-06 | 2021-09-10 | Genentech, Inc. | Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist |
US11896619B2 (en) | 2020-03-10 | 2024-02-13 | Massachusetts Institute Of Technology | Compositions and methods for immunotherapy of NPM1c-positive cancer |
WO2021183861A1 (en) | 2020-03-12 | 2021-09-16 | Amgen Inc. | Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor |
EP4121459A1 (en) | 2020-03-19 | 2023-01-25 | Amgen Inc. | Antibodies against mucin 17 and uses thereof |
WO2021193928A1 (en) | 2020-03-27 | 2021-09-30 | 株式会社PhotoQ3 | Pharmaceutical drug for destroying tumor cells |
US20230203191A1 (en) | 2020-03-30 | 2023-06-29 | Danisco Us Inc | Engineered antibodies |
EP4130035A1 (en) | 2020-03-31 | 2023-02-08 | Bio-Thera Solutions, Ltd. | Antibody and fusion protein for treating coronaviruses and use thereof |
CA3172451A1 (en) | 2020-04-03 | 2021-10-07 | Robert Paul | Methods of use of anti-trem2 antibodies |
WO2021202959A1 (en) | 2020-04-03 | 2021-10-07 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
CN115379858A (en) | 2020-04-06 | 2022-11-22 | 光爱科技公司 | Medicinal product for killing tumor cells |
EP4132971A1 (en) | 2020-04-09 | 2023-02-15 | Merck Sharp & Dohme LLC | Affinity matured anti-lap antibodies and uses thereof |
WO2021211331A1 (en) | 2020-04-13 | 2021-10-21 | Abbott Point Of Care Inc. | METHODS, COMPLEXES AND KITS FOR DETECTING OR DETERMINING AN AMOUNT OF A ß-CORONAVIRUS ANTIBODY IN A SAMPLE |
WO2021209458A1 (en) | 2020-04-14 | 2021-10-21 | Ares Trading S.A. | Combination treatment of cancer |
JP2023106635A (en) | 2020-04-17 | 2023-08-02 | 中外製薬株式会社 | Bispecific antigen binding molecules and compositions related thereto, uses, kits and methods for producing compositions |
JP2023523145A (en) | 2020-04-27 | 2023-06-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Isotype-independent antibody against lipoprotein (a) |
CN115997009A (en) | 2020-04-27 | 2023-04-21 | 美真达治疗公司 | Methods and compositions for in vivo transduction of hematopoietic stem and progenitor cells |
EP4143345A1 (en) | 2020-04-28 | 2023-03-08 | Genentech, Inc. | Methods and compositions for non-small cell lung cancer immunotherapy |
JP2023527293A (en) | 2020-05-19 | 2023-06-28 | アムジエン・インコーポレーテツド | MAGEB2 binding construct |
CN115667515A (en) | 2020-05-22 | 2023-01-31 | 中外制药株式会社 | Antibody neutralizing substance having coagulation factor VIII (F.VIII) function-replacing activity |
EP3915641A1 (en) | 2020-05-27 | 2021-12-01 | International-Drug-Development-Biotech | Anti-cd5 antibodies and methods of use thereof |
EP4157874A2 (en) | 2020-05-29 | 2023-04-05 | Amgen Inc. | Adverse effects-mitigating administration of a bispecific antibody construct binding to cd33 and cd3 |
US20230235080A1 (en) | 2020-06-03 | 2023-07-27 | Bionecure Therapeutics, Inc. | Trophoblast cell-surface antigen-2 (trop-2) antibodies |
WO2021249969A1 (en) | 2020-06-10 | 2021-12-16 | Merck Patent Gmbh | Combination product for the treatment of cancer diseases |
WO2021257503A1 (en) | 2020-06-16 | 2021-12-23 | Genentech, Inc. | Methods and compositions for treating triple-negative breast cancer |
MX2022015881A (en) | 2020-06-18 | 2023-01-24 | Genentech Inc | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists. |
WO2021261546A1 (en) | 2020-06-24 | 2021-12-30 | 国立大学法人 東京大学 | Photosensitizing dye |
WO2022006562A1 (en) | 2020-07-03 | 2022-01-06 | Dana-Farber Cancer Institute, Inc. | Multispecific coronavirus antibodies |
US20230322867A1 (en) | 2020-07-24 | 2023-10-12 | Amgen Inc. | Immunogens derived from sars-cov2 spike protein |
WO2022025030A1 (en) | 2020-07-28 | 2022-02-03 | 中外製薬株式会社 | Prefilled syringe preparation with needle, provided with needle shield and including novel modified antibody |
AU2021317974A1 (en) | 2020-07-31 | 2023-03-16 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical Composition comprising Cell Expressing Chimeric Receptor |
CA3190109A1 (en) | 2020-07-31 | 2022-02-03 | Genentech, Inc. | Anti-integrin beta7 antibody formulations and devices |
WO2022031749A1 (en) | 2020-08-03 | 2022-02-10 | Genentech, Inc. | Diagnostic and therapeutic methods for lymphoma |
EP4193149A1 (en) | 2020-08-04 | 2023-06-14 | Abbott Laboratories | Improved methods and kits for detecting sars-cov-2 protein in a sample |
CN114057877A (en) | 2020-08-07 | 2022-02-18 | 百奥泰生物制药股份有限公司 | anti-PD-L1 antibody and application thereof |
EP4196612A1 (en) | 2020-08-12 | 2023-06-21 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
CN114106173A (en) | 2020-08-26 | 2022-03-01 | 上海泰槿生物技术有限公司 | anti-OX 40 antibodies, pharmaceutical compositions and uses thereof |
US20240092890A1 (en) | 2020-08-27 | 2024-03-21 | Juntendo Educational Foundation | Anti-cleaved mutant calr-cd3 bispecific antibody and pharmaceutical composition |
WO2022047381A1 (en) | 2020-08-31 | 2022-03-03 | Genentech, Inc. | Methods for producing antibodies |
CN116390750A (en) | 2020-09-04 | 2023-07-04 | 罗格斯新泽西州立大学 | SARS-CoV-2 vaccine and antibody |
JP2023541456A (en) | 2020-09-14 | 2023-10-02 | ブイオーアール バイオファーマ インコーポレーテッド | Chimeric antigen receptor for cancer treatment |
CA3187272A1 (en) | 2020-10-08 | 2022-04-14 | Thorsten Ross | Trispecific binders |
US20230382978A1 (en) | 2020-10-15 | 2023-11-30 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods |
WO2022087274A1 (en) | 2020-10-21 | 2022-04-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibodies that neutralize type-i interferon (ifn) activity |
WO2022093981A1 (en) | 2020-10-28 | 2022-05-05 | Genentech, Inc. | Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists |
WO2022090455A1 (en) | 2020-11-02 | 2022-05-05 | F. Hoffmann-La Roche Ag | Sars-cov-2 nucleocapsid antibodies |
JP2023550900A (en) | 2020-11-02 | 2023-12-06 | アレス トレーディング ソシエテ アノニム | combination therapy for cancer |
AU2021372815A1 (en) | 2020-11-02 | 2023-06-22 | Ares Trading S.A. | Combination treatment of cancer |
WO2022096700A1 (en) | 2020-11-06 | 2022-05-12 | Amgen Research (Munich) Gmbh | Polypeptide constructs selectively binding to cldn6 and cd3 |
AU2021375733A1 (en) | 2020-11-06 | 2023-06-08 | Amgen Inc. | Polypeptide constructs binding to cd3 |
MX2023005197A (en) | 2020-11-06 | 2023-05-16 | Amgen Inc | Antigen binding domain with reduced clipping rate. |
WO2022095970A1 (en) | 2020-11-06 | 2022-05-12 | 百奥泰生物制药股份有限公司 | Bispecific antibody and use thereof |
CN116323671A (en) | 2020-11-06 | 2023-06-23 | 安进公司 | Multi-targeting bispecific antigen binding molecules with increased selectivity |
WO2022100694A1 (en) | 2020-11-12 | 2022-05-19 | 迈威(上海)生物科技股份有限公司 | Antibody and preparation method therefor |
CA3198161A1 (en) | 2020-12-01 | 2022-06-09 | Beth MCQUISTON | Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi |
WO2023102384A1 (en) | 2021-11-30 | 2023-06-08 | Abbott Laboratories | Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi |
WO2022140797A1 (en) | 2020-12-23 | 2022-06-30 | Immunowake Inc. | Immunocytokines and uses thereof |
WO2022147147A1 (en) | 2020-12-30 | 2022-07-07 | Abbott Laboratories | Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample |
JP2024512324A (en) | 2021-03-05 | 2024-03-19 | ジーオー セラピューティクス,インコーポレイテッド | Anti-glycoCD44 antibodies and their uses |
AU2022232951A1 (en) | 2021-03-10 | 2023-10-19 | Immunowake Inc. | Immunomodulatory molecules and uses thereof |
CA3211328A1 (en) | 2021-03-12 | 2022-09-15 | Takatoshi Ozawa | Pharmaceutical composition for treatment or prevention of myasthenia gravis |
CA3212729A1 (en) | 2021-03-12 | 2022-09-15 | Janssen Biotech, Inc. | Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody |
CA3213278A1 (en) | 2021-03-12 | 2022-09-15 | Janssen Biotech, Inc. | Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody |
CA3213599A1 (en) | 2021-03-15 | 2022-09-22 | Genentech, Inc. | Compositions and methods of treating lupus nephritis |
EP4308694A1 (en) | 2021-03-16 | 2024-01-24 | Magenta Therapeutics, Inc. | Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients |
AU2022241935A1 (en) | 2021-03-22 | 2023-09-28 | Novimmune S.A. | Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof |
JP2024511137A (en) | 2021-03-22 | 2024-03-12 | ノビミューン エスアー | Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereof |
JP2024514530A (en) | 2021-04-02 | 2024-04-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Antibodies against truncated CDCP1 and uses thereof |
AR125290A1 (en) | 2021-04-02 | 2023-07-05 | Amgen Inc | MAGEB2 JOINING CONSTRUCTIONS |
EP4319728A1 (en) | 2021-04-09 | 2024-02-14 | Genentech, Inc. | Combination therapy with a raf inhibitor and a pd-1 axis inhibitor |
WO2022218957A1 (en) | 2021-04-12 | 2022-10-20 | Acm Biolabs Pte Ltd | Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof |
CA3218697A1 (en) | 2021-05-03 | 2022-11-10 | Merck Patent Gmbh | Her2 targeting fc antigen binding fragment-drug conjugates |
EP4334353A1 (en) | 2021-05-04 | 2024-03-13 | Regeneron Pharmaceuticals, Inc. | Multispecific fgf21 receptor agonists and their uses |
EP4334354A1 (en) | 2021-05-06 | 2024-03-13 | Dana-Farber Cancer Institute, Inc. | Antibodies against alk and methods of use thereof |
WO2022234102A1 (en) | 2021-05-06 | 2022-11-10 | Amgen Research (Munich) Gmbh | Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases |
WO2022245920A1 (en) | 2021-05-18 | 2022-11-24 | Abbott Laboratories | Methods of evaluating brain injury in a pediatric subject |
EP4346905A1 (en) | 2021-05-25 | 2024-04-10 | Merck Patent GmbH | Egfr targeting fc antigen binding fragment-drug conjugates |
EP4351640A1 (en) | 2021-06-07 | 2024-04-17 | Ares Trading S.A. | Combination treatment of cancer |
CA3218481A1 (en) | 2021-06-14 | 2022-12-22 | argenx BV | Anti-il-9 antibodies and methods of use thereof |
CA3222291A1 (en) | 2021-06-14 | 2022-12-22 | Jaime MARINO | Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind |
AU2022306973A1 (en) | 2021-07-09 | 2024-02-22 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-il12/il23 antibody compositions |
KR20240032991A (en) | 2021-07-09 | 2024-03-12 | 얀센 바이오테크 인코포레이티드 | Manufacturing Methods for Producing Anti-TNF Antibody Compositions |
KR20240034218A (en) | 2021-07-09 | 2024-03-13 | 얀센 바이오테크 인코포레이티드 | Manufacturing Methods for Producing Anti-TNF Antibody Compositions |
WO2023010118A1 (en) | 2021-07-29 | 2023-02-02 | Vor Biopharma Inc. | Nfat-responsive reporter systems for assessing chimeric antigen receptor activation and methods of making and using the same |
IL308154A (en) | 2021-07-30 | 2023-12-01 | Affimed Gmbh | Duplexbodies |
WO2023014863A1 (en) | 2021-08-05 | 2023-02-09 | Go Therapeutics, Inc. | Anti-glyco-muc4 antibodies and their uses |
IL310535A (en) | 2021-08-10 | 2024-03-01 | Byomass Inc | Anti-gdf15 antibodies, compositions and uses thereof |
WO2023023491A1 (en) | 2021-08-16 | 2023-02-23 | Hemogenyx Pharmaceuticals Llc | Anti-flt3 antibodies, cars, car t cells and methods of use |
AU2022328625A1 (en) | 2021-08-17 | 2024-03-21 | Eli Lilly And Company | Bispecific anti-flt3/cd3 antibodies and methods of use |
CA3230038A1 (en) | 2021-08-31 | 2023-03-09 | Hongwei Zhang | Methods and systems of diagnosing brain injury |
TW202325733A (en) | 2021-09-03 | 2023-07-01 | 美商Go治療公司 | Anti-glyco-lamp1 antibodies and their uses |
WO2023034569A1 (en) | 2021-09-03 | 2023-03-09 | Go Therapeutics, Inc. | Anti-glyco-cmet antibodies and their uses |
WO2023056268A1 (en) | 2021-09-30 | 2023-04-06 | Abbott Laboratories | Methods and systems of diagnosing brain injury |
WO2023057871A1 (en) | 2021-10-04 | 2023-04-13 | Novartis Ag | Surfactant stabilizers |
WO2023058705A1 (en) | 2021-10-08 | 2023-04-13 | 中外製薬株式会社 | Drug formulation of anti-hla-dq2.5 antibody |
WO2023069421A1 (en) | 2021-10-18 | 2023-04-27 | Byomass Inc. | Anti-activin a antibodies, compositions and uses thereof |
WO2023072904A1 (en) | 2021-10-26 | 2023-05-04 | F. Hoffmann-La Roche Ag | Monoclonal antibodies specific for sars-cov-2 rbd |
WO2023073615A1 (en) | 2021-10-29 | 2023-05-04 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
WO2023078968A1 (en) | 2021-11-03 | 2023-05-11 | Affimed Gmbh | Bispecific cd16a binders |
WO2023079493A1 (en) | 2021-11-03 | 2023-05-11 | Affimed Gmbh | Bispecific cd16a binders |
WO2023081471A1 (en) | 2021-11-05 | 2023-05-11 | Dana-Farber Cancer Institute, Inc. | Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof |
WO2023081898A1 (en) | 2021-11-08 | 2023-05-11 | Alector Llc | Soluble cd33 as a biomarker for anti-cd33 efficacy |
WO2023084488A1 (en) | 2021-11-15 | 2023-05-19 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
WO2023095000A1 (en) | 2021-11-23 | 2023-06-01 | Janssen Biotech, Inc. | Method of treating ulcerative colitis with anti-il23 specific antibody |
WO2023097024A1 (en) | 2021-11-24 | 2023-06-01 | Dana-Farber Cancer Institute, Inc. | Antibodies against ctla-4 and methods of use thereof |
WO2023114544A1 (en) | 2021-12-17 | 2023-06-22 | Dana-Farber Cancer Institute, Inc. | Antibodies and uses thereof |
WO2023111168A1 (en) | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | A novel antibody for detection of amyloid beta 42 (aβ42) |
WO2023114543A2 (en) | 2021-12-17 | 2023-06-22 | Dana-Farber Cancer Institute, Inc. | Platform for antibody discovery |
WO2023114978A1 (en) | 2021-12-17 | 2023-06-22 | Abbott Laboratories | Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples |
WO2023122213A1 (en) | 2021-12-22 | 2023-06-29 | Byomass Inc. | Targeting gdf15-gfral pathway cross-reference to related applications |
US20230213536A1 (en) | 2021-12-28 | 2023-07-06 | Abbott Laboratories | Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan |
WO2023147107A1 (en) | 2022-01-31 | 2023-08-03 | Byomass Inc. | Myeloproliferative conditions |
WO2023150652A1 (en) | 2022-02-04 | 2023-08-10 | Abbott Laboratories | Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample |
WO2023164516A1 (en) | 2022-02-23 | 2023-08-31 | Alector Llc | Methods of use of anti-trem2 antibodies |
WO2023169896A1 (en) | 2022-03-09 | 2023-09-14 | Astrazeneca Ab | BINDING MOLECULES AGAINST FRα |
WO2023170216A1 (en) | 2022-03-11 | 2023-09-14 | Astrazeneca Ab | A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY |
EP4245772A1 (en) | 2022-03-18 | 2023-09-20 | Netris Pharma | Anti-netrin-1 antibody to treat liver inflammation |
WO2023178357A1 (en) | 2022-03-18 | 2023-09-21 | Evolveimmune Therapeutics, Inc. | Bispecific antibody fusion molecules and methods of use thereof |
EP4249509A1 (en) | 2022-03-22 | 2023-09-27 | Netris Pharma | Anti-netrin-1 antibody against arthritis-associated pain |
WO2023186968A1 (en) | 2022-03-29 | 2023-10-05 | Netris Pharma | Novel mcl-1 inhibitor and combination of mcl-1 and a bh3 mimetic, such as a bcl-2 inhibitor |
WO2023187707A1 (en) | 2022-03-30 | 2023-10-05 | Janssen Biotech, Inc. | Method of treating mild to moderate psoriasis with il-23 specific antibody |
US20230355792A1 (en) | 2022-04-07 | 2023-11-09 | Heidelberg Pharma Research Gmbh | Methods of improving the therapeutic index |
WO2023201201A1 (en) | 2022-04-10 | 2023-10-19 | Immunomic Therapeutics, Inc. | Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof |
WO2023215498A2 (en) | 2022-05-05 | 2023-11-09 | Modernatx, Inc. | Compositions and methods for cd28 antagonism |
TW202346368A (en) | 2022-05-12 | 2023-12-01 | 德商安美基研究(慕尼黑)公司 | Multichain multitargeting bispecific antigen-binding molecules of increased selectivity |
US20230374122A1 (en) | 2022-05-18 | 2023-11-23 | Janssen Biotech, Inc. | Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody |
WO2023235415A1 (en) | 2022-06-01 | 2023-12-07 | Genentech, Inc. | Method to identify a patient with an increased likelihood of chemotherapy-induced peripheral neuropathy |
WO2023240109A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Multispecific molecules for modulating t-cell activity, and uses thereof |
WO2023240058A2 (en) | 2022-06-07 | 2023-12-14 | Genentech, Inc. | Prognostic and therapeutic methods for cancer |
WO2023240124A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Pseudotyped viral particles for targeting tcr-expressing cells |
WO2024006876A1 (en) | 2022-06-29 | 2024-01-04 | Abbott Laboratories | Magnetic point-of-care systems and assays for determining gfap in biological samples |
WO2024015953A1 (en) | 2022-07-15 | 2024-01-18 | Danisco Us Inc. | Methods for producing monoclonal antibodies |
WO2024039670A1 (en) | 2022-08-15 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | Antibodies against cldn4 and methods of use thereof |
WO2024039672A2 (en) | 2022-08-15 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | Antibodies against msln and methods of use thereof |
WO2024038165A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Ltd | T cell receptor fusion proteins specific for mage a4 |
WO2024059675A2 (en) | 2022-09-14 | 2024-03-21 | Amgen Inc. | Bispecific molecule stabilizing composition |
WO2024059708A1 (en) | 2022-09-15 | 2024-03-21 | Abbott Laboratories | Biomarkers and methods for differentiating between mild and supermild traumatic brain injury |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5204244A (en) * | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
WO1991000906A1 (en) * | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
NZ255101A (en) * | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
EP0754225A4 (en) * | 1993-04-26 | 2001-01-31 | Genpharm Int | Transgenic non-human animals capable of producing heterologous antibodies |
ATE390933T1 (en) * | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | HUMAN ANTIBODIES AGAINST IL-8 DERIVED FROM IMMUNIZED XENOMICES |
-
1995
- 1995-04-28 EP EP95918935A patent/EP0823941A4/en not_active Withdrawn
- 1995-04-28 AU AU24668/95A patent/AU2466895A/en not_active Abandoned
- 1995-04-28 WO PCT/US1995/005500 patent/WO1996034096A1/en not_active Application Discontinuation
- 1995-04-28 CA CA002219486A patent/CA2219486A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2466895A (en) | 1996-11-18 |
EP0823941A1 (en) | 1998-02-18 |
WO1996034096A1 (en) | 1996-10-31 |
EP0823941A4 (en) | 2001-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2219486A1 (en) | Human antibodies derived from immunized xenomice | |
US6075181A (en) | Human antibodies derived from immunized xenomice | |
CA2219361C (en) | Human antibodies derived from immunized xenomice | |
US6657103B1 (en) | Human antibodies derived from immunized xenomice | |
US20050054055A1 (en) | Human antibodies derived from immunized xenomice | |
US6150584A (en) | Human antibodies derived from immunized xenomice | |
KR19990008197A (en) | Human Antibodies from Immunized Genomous | |
US20050287630A1 (en) | Human antibodies derived from immunized xenomice | |
US20050241006A1 (en) | Human antibodies derived from immunized xenomice | |
AU2006200868B2 (en) | Human Antibodies Derived From Immunized Xenomice | |
AU2008202860B2 (en) | Human Antibodies Derived From Immunized Xenomice | |
AU5336100A (en) | Human antibodies derived from immunized xenomice | |
AU2003227322B2 (en) | Human Antibodies Derived From Immunized Xenomice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |